WO2022076606A1 - Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs - Google Patents

Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs Download PDF

Info

Publication number
WO2022076606A1
WO2022076606A1 PCT/US2021/053841 US2021053841W WO2022076606A1 WO 2022076606 A1 WO2022076606 A1 WO 2022076606A1 US 2021053841 W US2021053841 W US 2021053841W WO 2022076606 A1 WO2022076606 A1 WO 2022076606A1
Authority
WO
WIPO (PCT)
Prior art keywords
tils
inhibitor
population
expansion
days
Prior art date
Application number
PCT/US2021/053841
Other languages
English (en)
Inventor
Maria Fardis
Friedrich Graf FINCKENSTEIN
Original Assignee
Iovance Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics, Inc. filed Critical Iovance Biotherapeutics, Inc.
Priority to JP2023521133A priority Critical patent/JP2023546359A/ja
Priority to CA3195019A priority patent/CA3195019A1/fr
Priority to EP21802087.3A priority patent/EP4225330A1/fr
Priority to US18/247,877 priority patent/US20230372397A1/en
Priority to JP2023521067A priority patent/JP2023544199A/ja
Priority to US18/247,878 priority patent/US20230374453A1/en
Priority to CA3195023A priority patent/CA3195023A1/fr
Priority to PCT/US2021/055304 priority patent/WO2022076952A1/fr
Priority to EP21805781.8A priority patent/EP4225331A1/fr
Publication of WO2022076606A1 publication Critical patent/WO2022076606A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Definitions

  • NSCLC non-small-cell lung cancer
  • the preferred option is treatment with targeted TKIs directed against the relevant mutation (e.g., osimertinib for epidermal growth factor receptor [EGFR] mutations, ceritinib for ALK mutations or crizotinib for ROS-1 mutations).
  • TKIs directed against the relevant mutation
  • the available treatment options include pembrolizumab monotherapy (commonly used only for patients with tumor proportion score (TPS) for PD-L1 expression of at least 50%) or pembrolizumab in combination with chemotherapy.
  • the preferred option is the combination of pemetrexed, carboplatin or cisplatin, and pembrolizumab.
  • Patients with TPS for PD- L1 ⁇ 1% and no actionable mutations have no viable treatment options and are not candidates for PD- 1 or PD-L1 CPIs.
  • the combination of platinum-based doublet chemotherapy, bevacizumab, and atezolizumab is another potential therapeutic alternative in patients with NSCLC, as is a combination of nivolumab, ipilimumab and cytotoxic therapy (Hellmann et al.2019 New Engl J Med 381:2020- 31).
  • TIL manufacturing and treatment processes are limited by length, cost, sterility concerns, and other factors described herein such that the potential to treat patients which are refractory to anti-PD-1 and/or anit-PD-L1 and/or VEGF inhibitor treatments and as such have been severly limited.
  • TIL manufacturing processes and therapies based on such processes that are appropriate for use in treating patients for whom very few or no viable treatment options remain.
  • the present invention meets this need by providing a shortened manufacturing process for use in generating TILs which can then be employed in the treatment of non-small cell lung carcinoma (NSCLC) patients whom are refractory to anti-PD-1, anti-PD-Ll, and/or VEGF inhibitor (including VEGF-A inhibitor) treatment.
  • NSCLC non-small cell lung carcinoma
  • the present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs for use in treatment of non-small cell lung carcinoma (NSCLC) patients whom are refractory to anti-PD-1 treatment.
  • NSCLC non-small cell lung carcinoma
  • the present invention provides a method of treating non-small cell lung carcinoma (NSCLC) by administering a population of tumor infdtrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations.
  • TPS tumor proportion score
  • the present invention provides a method of treating non-small cell lung carcinoma (NSCLC) by administering a population of tumor infdtrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations; wherein the method comprises:
  • step (c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-14 days to obtain the second population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
  • step (d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-14 days to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
  • APCs antigen presenting cells
  • step (e) harvesting therapeutic population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system;
  • step (f) transferring the harvested TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system;
  • step (g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process
  • step (h) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (g) to the subject or patient.
  • the present invention provides a method of treating non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory or resistant to treatment with an anti-PD-1 and/or anti-PD-Ll antibody, by administering a population of tumor infiltrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations; wherein the method comprises:
  • step (c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-11 days to obtain the second population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
  • step (d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-11 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
  • APCs antigen presenting cells
  • step (e) harvesting the third population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system;
  • step (f) transferring the harvested third TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system;
  • step (g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process
  • step (h) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (g) to the subject.
  • the present invention provides a method of treating non-small cell lung carcinoma (NSCLC) by administering a population of tumor infdtrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations; wherein the method comprises:
  • step (c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-11 days to obtain the second population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
  • step (d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-11 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
  • APCs antigen presenting cells
  • step (e) harvesting the third population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system;
  • step (f) transferring the harvested third TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system;
  • step (g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process
  • step (h) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (g) to the subject or patient.
  • the present invention provides a method of treating non-small cell lung carcinoma (NSCLC) by administering a population of tumor infdtrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations; wherein the method comprises:
  • a NSCLC tumor comprising a first population of TILs, optionally from surgical resection, needle biopsy, core biopsy, small biopsy, or other means for obtaining a sample that contains a mixture of tumor and TIL cells from a NSCLC tumor;
  • step (c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-11 days to obtain the second population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system;
  • step (d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-11 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
  • APCs antigen presenting cells
  • step (e) harvesting the third population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system;
  • step (f) transferring the harvested third TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system;
  • step (g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process
  • step (h) administering a therapeutically effective dosage of the third population of TILs from the infusion bag in step (g) to the subject.
  • the second population of TILs is at least 50-fold greater in number than the first population of TILs.
  • the present invention provides a method of treating non-small cell lung carcinoma (NSCLC) by administering a population of tumor infiltrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations; wherein the method comprises:
  • the second cell culture medium comprises IL-2, OKT-3 (anti-CD3 antibody), and optionally irradiated allogeneic peripheral blood mononuclear cells (PBMCs); and wherein the rapid expansion is performed over a period of 14 days or less, optionally the rapid expansion can proceed for 1 day, 2 days, 3 days, 4, days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days after initiation of the rapid expansion;
  • the present invention provides a method of treating non-small cell lung carcinoma (NSCLC) by administering a population of tumor infdtrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations; wherein the method comprises:
  • a NSCLC tumor comprising a first population of TILs, optionally from surgical resection, needle biopsy, core biopsy, small biopsy, or other means for obtaining a sample that contains a mixture of tumor and TIL cells from a NSCLC tumor;
  • the second cell culture medium comprises IL-2, OKT-3 (anti-CD3 antibody), and optionally irradiated allogeneic peripheral blood mononuclear cells (PBMCs); and wherein the rapid expansion is performed over a period of 14 days or less, optionally the rapid expansion can proceed for 1 day, 2 days, 3 days, 4, days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days after initiation of the rapid expansion;
  • a method of treating non-small cell lung carcinoma wherein the NSCLC is refractory or resistant to treatment with an anti-PD-1 and/or anti-PD-Ll antibody, by administering a population of tumor infiltrating lymphocytes (TILs) to a subject or patient in need thereof, wherein the subject or patient has at least one of: i. a predetermined tumor proportion score (TPS) of PD-L1 of ⁇ 1%, ii. a TPS score of PD-L1 of 1%-49%, or iii. a predetermined absence of one or more driver mutations; wherein the method comprises:
  • the second cell culture medium comprises IL-2, OKT-3 (anti-CD3 antibody), and optionally irradiated allogeneic peripheral blood mononuclear cells (PBMCs); and wherein the rapid expansion is performed over a period of 14 days or less, optionally the rapid expansion can proceed for 1 day, 2 days, 3 days, 4, days, 5 days, 6 days, 7 days, 8 days, 9 days or 10 days after initiation of the rapid expansion;
  • PBMCs peripheral blood mononuclear cells
  • the third population of TILs is at least 50-fold greater in number than the second population of TILs after 7-8 days from the start of the rapid expansion.
  • the patient or subject has a TPS of PD-L1 of ⁇ 1%.
  • the patient or subject has a TPS of PD-L1 of 1%-49%.
  • the patient or subject has a NSCLC that is not indicated for treatment by an EGFR inhibitor, a BRAF inhibitor, an ALK inhibitor, a c-Ros inhibitor, a RET inhibitor, an ERBB2 inhibitor, BRCA inhibitor, a MAP2K1 inhibitor, PIK3CA inhibitor, CDKN2A inhibitor, a PTEN inhibitor, an UMD inhibitor, an NRAS inhibitor, a KRAS inhibitor, an NF1 inhibitor, MET inhibitor a TP53 inhibitor, a CREBBP inhibitor, a KMT2C inhibitor, a KMT2D mutation, an ARID 1 A mutation, a RBI inhibitor, an ATM inhibitor, a SETD2 inhibitor, a FLT3 inhibitor, a PTPN11 inhibitor, a FGFR1 inhibitor, an EP300 inhibitor, a MYC inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a FBXW7 inhibitor, a CCND3 inhibitor, and a GNA11 inhibitor.
  • the patient or subject has a predetermined absence of one or more driver mutations.
  • the patient or subject has a TPS of PD-L1 of ⁇ 1% and has a predetermined absence of one or more driver mutations.
  • the one or more driver is selected from the group consisting of an EGFR mutation, an EGFR insertion, EGFR exon20, a KRAS mutation, a BRAF -mutation, a BRAF V600 mutation, an ALK-mutation, a c-ROS-mutation (ROS 1 -mutation), a ROS1 fusion, a RET mutation, a RET fusion, an ERBB2 mutation, an ERBB2 amplification, a BRCA mutation, a MAP2K1 mutation, PIK3CA, CDKN2A, a PTEN mutation, an UMD mutation, an NRAS mutation, a KRAS mutation, an NF1 mutation, a MET mutation, a MET splice and/or altered MET signaling, a TP53 mutation, a CREBBP mutation, a KMT2C mutation, a KMT2D mutation, an ARID 1 A mutation, a RB 1 mutation, an
  • the patient or subject has a TPS of ⁇ 1% and has a NSCLC that is not indicated for treatment by an EGFR inhibitor, a BRAF inhibitor, an ALK inhibitor, a c-Ros inhibitor, a RET inhibitor, an ERBB2 inhibitor, BRCA inhibitor, a MAP2K1 inhibitor, PIK3CA inhibitor, CDKN2A inhibitor, a PTEN inhibitor, an UMD inhibitor, an NRAS inhibitor, a KRAS inhibitor, an NF1 inhibitor, MET inhibitor a TP53 inhibitor, a CREBBP inhibitor, a KMT2C inhibitor, a KMT2D mutation, an ARID 1 A mutation, a RBI inhibitor, an ATM inhibitor, a SETD2 inhibitor, a FLT3 inhibitor, a PTPN 11 inhibitor, a FGFR1 inhibitor, an EP300 inhibitor, a MYC inhibitor, an EZH2 inhibitor, a IAK2 inhibitor, a FBXW7 inhibitor, a CCND3
  • the NSCLC has low or no expression of PD-L1.
  • the NSCLC is refractory or resistant to treatment with a chemotherapeutic agent.
  • the NSCLC is refractory or resistant to treatment with a VEGF-A inhibitor.
  • the NSCLC has been treated with a chemotherapeutic agent but is not being currently treated with a chemotherapeutic agent.
  • the NSCLC has been treated with a chemotherapeutic agent but is not being currently treated with a chemotherapeutic agent and has a TPS of ⁇ 1%.
  • the NSCLC has been treated with a VEGF-A inhibitor but is not being currently treated with a VEGF-A inhibitor.
  • the NSCLC has been treated with a VEGF-A inhibitor but is not being currently treated with a VEGF-A inhibitor and has a TPS of ⁇ 1%.
  • the NSCLC has been treated with a chemotherapeutic agent and/or a VEGF-A inhibitor, but is not being currently treated with a chemotherapeutic agent and/or a VEGF-A inhibitor.
  • the NSCLC has been treated with a chemotherapeutic agent and/or a VEGF-A inhibitor but is not being currently treated with a chemotherapeutic agent and/or a VEGF-A inhibitor and has a TPS of ⁇ 1%.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody and has been previously treated a chemotherapeutic agent and/or a VEGF-A inhibitor.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody and has been previously treated a chemotherapeutic agent and/or a VEGF-A inhibitor but is not being currently treated with a chemotherapeutic agent and/or a VEGF-A inhibitor.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody and has been previously treated a VEGF-A inhibitor but is not being currently treated with a VEGF-A inhibitor.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody and has been previously treated a chemotherapeutic agent and/or a VEGF-A inhibitor but is not being currently treated with a chemotherapeutic agent and/or a VEGF-A inhibitor.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody and has low or no expression of PD-L1.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody and has been previously treated a chemotherapeutic agent and/or a VEGF-A inhibitor but is not being currently treated with a chemotherapeutic agent and/or a VEGF-A inhibitor and has a TPS of ⁇ 1%.
  • the NSCLC has been previously treated with an anti-PD-1 and/or anti- PD-Ll and/or anti-PD-L2 antibody.
  • the NSCLC has been previously treated with an anti-PD-1 and/or anti- PD-Ll antibody and has been previously treated a chemotherapeutic agent and/or a VEGF-A inhibitor.
  • the NSCLC is refractory or resistant to treatment with an anti-PD-1 and/or anti-PD-Ll antibody.
  • the NSCLC has been previously treated with an anti-PD-1 and/or anti- PD-Ll antibody and the tumor proportion score was determined prior to the anti-PD-1 and/or anti- PD-Ll antibody treatment.
  • the NSCLC has been previously treated with an anti-PD-Ll antibody and the tumor proportion score was determined prior to the anti-PD-Ll antibody treatment, or the NSCLC has been previously treated with an anti-PD-1 antibody and the tumor proportion score was determined prior to the anti-PD-1 antibody treatment.
  • the NSCLC has been treated with a chemotherapeutic agent and/or a VEGF-A inhibitor.
  • the NSCLC has not been previously treated with an anti-PD-1 and/or anti-PD-Ll antibody and has bulky disease at baseline.
  • the NSCLC has been previously treated with an anti-PD-1 and/or anti- PD-Ll antibody and has bulky disease at baseline.
  • the NSCLC has been treated with a chemotherapeutic agent and has bulky disease at baseline.
  • the NSCLC has been treated with a chemotherapeutic agent and/or VEGF-A inhibitor but is not being currently treated with a chemotherapeutic agent and/or VEGF-A inhibitor and has bulky disease at baseline.
  • bulky disease is indicated where the maximal tumor diameter is greater than 7 cm measured in either the transverse or coronal plane or swollen lymph nodes with a short-axis diameter of 20 mm or greater.
  • the NSCLC is refractory or resistant to at least two prior systemic treatment courses, not including neo-adjuvant or adjuvant therapies.
  • the NSCLC is refractory or resistant to an anti-PD-1 or an anti-PD-Ll antibody selected from the group consisting of nivolumab, pembrolizumab, JS001, TSR-042, pidilizumab, BGB-A317, SHR-1210, REGN2810, MDX-1106, PDR001, anti-PD-1 from clone: RMP1-14, anti-PD-1 antibodies disclosed in U.S. Patent No. 8,008,449, durvalumab, atezolizumab, avelumab, and fragments, derivatives, variants, as well as biosimilars thereof.
  • an anti-PD-1 or an anti-PD-Ll antibody selected from the group consisting of nivolumab, pembrolizumab, JS001, TSR-042, pidilizumab, BGB-A317, SHR-1210, REGN2810, MDX-1106, PDR001, anti-PD-1 from clone: R
  • the NSCLC is refractory or resistant to pembrolizumab or a biosimilar thereof.
  • the NSCLC is refractory or resistant to nivolumab or a biosimilar thereof.
  • the NSCLC is refractory or resistant to an anti-CTLA-4 antibody.
  • the NSCLC is refractory or resistant to an anti-CTLA-4 antibody and pembrolizumab or a biosimilar thereof.
  • the NSCLC is refractory or resistant to an anti-CTLA-4 antibody, and nivolumab or a biosimilar thereof.
  • the anti- CTLA-4 antibody is ipilimumab or a biosimilar thereof.
  • the NSCLC is refractory or resistant to durvalumab or a biosimilar thereof.
  • the NSCLC is refractory or resistant to atezolizumab or a biosimilar thereof.
  • the NSCLC is refractory or resistant to avelumab or a biosimilar thereof.
  • the chemotherapeutic agent is a platinum doublet chemotherapeutic agent(s).
  • the platinum doublet chemotherapeutic agent therapy comprises: i) a first chemotherapeutic agent selected from the group consisting of cisplatin and carboplatin, ii) and a second chemotherapeutic agent selected from the group consisting of vinorelbine, gemcitabine and a taxane (including for example, paclitaxel, docetaxel or nab-paclitaxel).
  • the chemotherapeutic agent including the first and/or second chemotherapeutic agent, is in combination with pemetrexed.
  • the NSCLC is refractory or resistant to a combination therapy comprising carboplatin, paclitaxel, pemetrexed, and cisplatin.
  • the NSCLC is refractory or resistant to a combination therapy comprising carboplatin, paclitaxel, pemetrexed, cisplatin, nivolumab, and ipilimumab.
  • the NSCLC is refractory or resistant to a VEGF-A inhibitor.
  • the NSCLC is refractory or resistant to a VEGF-A inhibitor selected from the group consisting of bevacizumab, ranibizumab, and icrucumab.
  • the NSCLC is refractory or resistant to bevacizumab.
  • the NSCLC has been analyzed for the absence or presence of one or more driver mutations.
  • one or more driver mutations are not present.
  • the NSCLC treatment is independent of the presence or absence of one or more driver mutations.
  • the one or more driver mutations is selected from the group consisting of an EGFR mutation, an EGFR insertion, a KRAS mutation, a BRAF -mutation, an ALK-mutation, a c-ROS-mutation a c-ROS-mutation, EML4-ALK, and MET mutation.
  • the EGFR mutation results in tumor transformation from NSCLC to small cell lung cancer (SCLC).
  • the NSCLC treatment is independent of the presence or absence of high-tumor mutational burden (high-TMB) and/or microsatellite instability-high (MSI-high) status.
  • high-TMB high-tumor mutational burden
  • MSI-high microsatellite instability-high
  • the NSCLC exhibits high-TMB and/or MSI-high status.
  • the IL-2 is present at an initial concentration of between 1000 lU/mL and 6000 lU/mL in the first cell culture medium, when present. [0080] In some embodiments, the IL-2 is present at an initial concentration of between 1000 lU/mL and 6000 lU/mL and the OKT-3 antibody is present at an initial concentration of about 30 ng/mL in the second cell culture medium, when present.
  • the initial expansion when present, is performed using a gas permeable container.
  • the rapid expansion when present, is performed using a gas permeable container.
  • the first cell culture medium when present, further comprises a cytokine selected from the group consisting of IL-4, IL-7, IL- 15, IL-21, and combinations thereof.
  • the second cell culture medium when present, further comprises a cytokine selected from the group consisting of IL-4, IL-7, IL- 15, IL-21, and combinations thereof.
  • the method further comprises the step of treating the patient with a non-myeloablative lymphodepletion regimen prior to administering the third population of TILs to the patient.
  • the non-myeloablative lymphodepletion regimen comprises the steps of administration of cyclophosphamide at a dose of 60 mg/m 2 /day for two days followed by administration of fludarabine at a dose of 25 mg/m 2 /day for five days.
  • the non-myeloablative lymphodepletion regimen comprises the steps of administration of cyclophosphamide at a dose of 60 mg/m 2 /day and fludarabine at a dose of 25 mg/m 2 /day for two days followed by administration of fludarabine at a dose of 25 mg/m 2 /day for three days.
  • the cyclophosphamide is administered with mesna.
  • the method further comprises the step of treating the patient with an IL-2 regimen starting on the day after administration of the third population of TILs to the patient.
  • the method further comprises the step of treating the patient with an IL-2 regimen starting on the same day as administration of the third population of TILs to the patient.
  • the IL-2 regimen is a high-dose IL-2 regimen comprising 600,000 or 720,000 lU/kg of aldesleukin, or a biosimilar or variant thereof, administered as a 15 -minute bolus intravenous infusion every eight hours until tolerance.
  • a therapeutically effective population of TILs is administered and comprises from about 2.3 x10 10 to about 13.7x10 10 TILs.
  • the initial expansion is performed over a period of 21 days or less.
  • the initial expansion is performed over a period of 7 days or less.
  • the rapid expansion is performed over a period of 7 days or less.
  • the first expansion in step (c) and the second expansion in step (d) are each individually performed within a period of 11 days.
  • the steps (a) through (f) are performed in about 10 days to about 24 days.
  • the steps (a) through (f) are performed in about 10 days to about 22 days.
  • Figure 1 Exemplary Gen 2 (Process 2A) type chart providing an overview of Steps A through F.
  • Figure 2 Exemplary process flow chart of Gen 2 (Process 2A) type process.
  • Figure 3 Shows a diagram of an embodiment of a cryopreserved TIL exemplary manufacturing process ( ⁇ 22 days).
  • Figure 4 Shows a diagram of an embodiment of Gen 2, a 22-day process for TIL manufacturing.
  • Figure 5 Comparison table of Steps A through F from exemplary embodiments of process 1C and Gen 2.
  • Figure 6 Detailed comparison of an embodiment of process 1C and an embodiment of Gen 2.
  • Figure 7 Exemplary Gen 3 type process for NSCLC tumors.
  • Figure 8A-8D A) Shows a comparison between the 2A process (approximately 22-day process) and an embodiment of the Gen 3 process for TIL manufacturing (approximately 14-days to 16-days process).
  • Figure 9 Provides an experimental flow chart for comparability between Gen 2 (Gen 2) versus Gen 3.
  • Figure 10 Shows a comparison between various Gen 2 (2A process) and the Gen 3.1 process embodiment.
  • Figure 11 Table describing various features of embodiments of the Gen 2, Gen 2.1 and Gen 3.0 process.
  • Figure 12 Overview of the media conditions for an embodiment of the Gen 3 process, referred to as Gen 3.1.
  • Figure 13 Table describing various features of embodiments of the Gen 2, Gen 2.1 and Gen 3.0 process.
  • Figure 14 Table comparing various features of embodiments of the Gen 2 and Gen 3.0 processes.
  • Figure 15 Table providing media uses in the various embodiments of the described expansion processes.
  • Figure 16 Schematic of an exemplary embodiment of the Gen 3 process (a 16-day process).
  • Figure 17 Schematic of an exemplary embodiment of a method for expanding T cells from hematopoietic malignancies using Gen 3 expansion platform.
  • Figure 18 Provides the structures I-A and I-B, the cylinders refer to individual polypeptide binding domains.
  • Structures I-A and I-B comprise three linearly-linked TNFRSF binding domains derived from e.g., 4-1BBL or an antibody that binds 4-1BB, which fold to form atrivalent protein, which is then linked to a second trivalent protein through IgGl-Fc (including CH3 and CH2 domains) is then used to link two of the trivalent proteins together through disulfide bonds (small elongated ovals), stabilizing the structure and providing an agonists capable of bringing together the intracellular signaling domains of the six receptors and signaling proteins to form a signaling complex.
  • IgGl-Fc including CH3 and CH2 domains
  • the TNFRSF binding domains denoted as cylinders may be scFv domains comprising, e.g., a VH and a VL chain connected by a linker that may comprise hydrophilic residues and Gly and Ser sequences for flexibility, as well as Glu and Lys for solubility.
  • Figure 19 Schematic of an exemplary embodiment of the Gen 3 process (a 16-day process).
  • Figure 20 Provides a process overview for an exemplary embodiment of the Gen 3.1 process (a 16 day process).
  • Figure 21 Schematic of an exemplary embodiment of the Gen 3.1 Test process (a 16-17 day process).
  • Figure 22 Schematic of an exemplary embodiment of the Gen 3 process (a 16-day process).
  • Figure 23A-23B Comparison table for exemplary Gen 2 and exemplary Gen 3 processes.
  • Figure 24 Schematic of an exemplary embodiment of the Gen 3 process (a 16/17 day process) preparation timeline.
  • Figure 25 Schematic of an exemplary embodiment of the Gen 3 process (a 14-16 day process).
  • Figure 26A-26B Schematic of an exemplary embodiment of the Gen 3 process (a 16 day process).
  • Figure 27 Schematic of an exemplary embodiment of the Gen 3 process (a 16 day process).
  • Figure 28 Comparison of Gen 2, Gen 2. 1 and an embodiment of the Gen 3 process (a 16 day process).
  • Figure 29 Comparison of Gen 2, Gen 2. 1 and an embodiment of the Gen 3 process (a 16 day process).
  • Figure 30 Gen 3 embodiment components.
  • Figure 31 Gen 3 embodiment flow chart comparison (Gen 3.0, Gen 3.1 control, Gen 3.1 Test).
  • Figure 32 Shown are the components of an exemplary embodiment of the Gen 3 process (a 16-17 day process).
  • Figure 33 Acceptance criteria table.
  • Figure 34 Diagram of Study Design related to study described in Example 19.
  • FIG 35 Schematic of TIL-based immunotherapy banufacturing process related to the study described in Example 19.
  • CMO contract manufacturing organization
  • GMP Good Manufacturing Practices
  • IL-2 interleukin-2
  • OKT3 monoclonal antibody to CD3
  • TIL tumor infdtrating lymphocytes.
  • Figure 36 Study Flowchart (all four cohorts).
  • Figure 37 Chart providing infomraiton regarding various FDA approved PD-L1 assays.
  • SEQ ID NO: 1 is the amino acid sequence of the heavy chain of muromonab.
  • SEQ ID NO:2 is the amino acid sequence of the light chain of muromonab.
  • SEQ ID NO:3 is the amino acid sequence of a recombinant human IL-2 protein.
  • SEQ ID NO:4 is the amino acid sequence of aldesleukin.
  • SEQ ID NO:5 is an IL-2 form.
  • SEQ ID NO:6 is the amino acid sequence of nemvaleukin alfa.
  • SEQ ID NO: 7 is an IL-2 form.
  • SEQ ID NO: 8 is a mucin domain polypeptide.
  • SEQ ID NO:9 is the amino acid sequence of a recombinant human IL-4 protein.
  • SEQ ID NO: 10 is the amino acid sequence of a recombinant human IL-7 protein.
  • SEQ ID NO: 11 is the amino acid sequence of a recombinant human IL-15 protein.
  • SEQ ID NO: 12 is the amino acid sequence of a recombinant human IL-21 protein.
  • SEQ ID NO: 13 is an IL-2 sequence.
  • SEQ ID NO: 14 is an IL-2 mutein sequence.
  • SEQ ID NO: 15 is an IL-2 mutein sequence.
  • SEQ ID NO: 16 is the HCDR1 IL-2 for IgG.IL2R67A.Hl.
  • SEQ ID NO: 17 is the HCDR2 for IgG.IL2R67A.Hl.
  • SEQ ID NO: 18 is the HCDR3 for IgG.IL2R67A.Hl.
  • SEQ ID NO: 19 is the HCDR1 IL-2 kabat for IgG.IL2R67A.Hl .
  • SEQ ID NO:20 is the HCDR2 kabat for IgG.IL2R67A.Hl .
  • SEQ ID NO:21 is the HCDR3 kabat for IgG.IL2R67A.Hl.
  • SEQ ID NO:22 is the HCDR1 IL-2 clothia for IgG.IL2R67A.Hl .
  • SEQ ID NO:23 is the HCDR2 clothia for IgG.IL2R67A.Hl .
  • SEQ ID NO:24 is the HCDR3 clothia for IgG.IL2R67A.Hl .
  • SEQ ID NO:25 is the HCDR1 IL-2 IMGT for IgG.IL2R67A.Hl .
  • SEQ ID NO:26 is the HCDR2 IMGT for IgG.IL2R67A.Hl .
  • SEQ ID NO:27 is the HCDR3 IMGT for IgG.IL2R67A.Hl .
  • SEQ ID NO:28 is the VH chain for IgG.IL2R67A.Hl .
  • SEQ ID NO:29 is the heavy chain for IgG.IL2R67A.Hl .
  • SEQ ID NO:30 is the LCDR1 kabat for IgG.IL2R67A.Hl.
  • SEQ ID NO:31 is the LCDR2 kabat for IgG.IL2R67A.Hl.
  • SEQ ID NO:32 is the LCDR3 kabat for IgG.IL2R67A.Hl .
  • SEQ ID NO:33 is the LCDR1 chothia for IgG.IL2R67A.Hl.
  • SEQ ID NO:34 is the LCDR2 chothia for IgG.IL2R67A.Hl.
  • SEQ ID NO:35 is the LCDR3 chothia for IgG.IL2R67A.Hl.
  • SEQ ID NO:36 is a VL chain.
  • SEQ ID NO:37 is a light chain.
  • SEQ ID NO:38 is a light chain.
  • SEQ ID NO:39 is a light chain.
  • SEQ ID NO:40 is the amino acid sequence of human 4-1BB.
  • SEQ ID NO:41 is the amino acid sequence of murine 4-1BB.
  • SEQ ID NO:42 is the heavy chain for the 4- 1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:43 is the light chain for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:44 is the heavy chain variable region (VH) for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:45 is the light chain variable region (VL) for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:46 is the heavy chain CDR1 for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:47 is the heavy chain CDR2 for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:48 is the heavy chain CDR3 for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:49 is the light chain CDR1 for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:50 is the light chain CDR2 for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:51 is the light chain CDR3 for the 4-1BB agonist monoclonal antibody utomilumab (PF-05082566).
  • SEQ ID NO:52 is the heavy chain for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:53 is the light chain for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:54 is the heavy chain variable region (VH) for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:55 is the light chain variable region (VL) for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:56 is the heavy chain CDR1 for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:57 is the heavy chain CDR2 for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:58 is the heavy chain CDR3 for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:59 is the light chain CDR1 for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:60 is the light chain CDR2 for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:61 is the light chain CDR3 for the 4-1BB agonist monoclonal antibody urelumab (BMS-663513).
  • SEQ ID NO:62 is an Fc domain for a TNFRSF agonist fusion protein.
  • SEQ ID NO:63 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:64 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:65 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:66 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:67 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:68 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:69 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:70 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:71 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:72 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:73 is an Fc domain for a TNFRSF agonist fusion protein.
  • SEQ ID NO:74 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:75 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:76 is a linker for a TNFRSF agonist fusion protein.
  • SEQ ID NO:77 is a 4-1BB ligand (4-1BBL) amino acid sequence.
  • SEQ ID NO:78 is a soluble portion of 4-1BBL polypeptide.
  • SEQ ID NO:79 is a heavy chain variable region (VH) for the 4-1BB agonist antibody 4B4- 1-1 version 1.
  • SEQ ID NO:80 is a light chain variable region (VL) for the 4-1BB agonist antibody 4B4-1-1 version 1.
  • SEQ ID NO: 81 is a heavy chain variable region (VH) for the 4-1BB agonist antibody 4B4- 1-1 version 2.
  • SEQ ID NO:82 is a light chain variable region (VL) for the 4-1BB agonist antibody 4B4-1-1 version 2.
  • SEQ ID NO:83 is a heavy chain variable region (VH) for the 4-1BB agonist antibody H39E3-2.
  • SEQ ID NO:84 is a light chain variable region (VL) for the 4-1BB agonist antibody H39E3- 2.
  • SEQ ID NO: 85 is the amino acid sequence of human OX40.
  • SEQ ID NO: 86 is the amino acid sequence of murine OX40.
  • SEQ ID NO: 87 is the heavy chain for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO: 88 is the light chain for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO: 89 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NOVO is the light chain variable region (VL) for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO:91 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO:92 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO:93 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO:94 is the light chain CDR1 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO:95 is the light chain CDR2 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO:96 is the light chain CDR3 for the OX40 agonist monoclonal antibody tavolixizumab (MEDI-0562).
  • SEQ ID NO:97 is the heavy chain for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO:98 is the light chain for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO:99 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 100 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 101 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 102 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 103 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 104 is the light chain CDR1 for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 105 is the light chain CDR2 for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 106 is the light chain CDR3 for the OX40 agonist monoclonal antibody 11D4.
  • SEQ ID NO: 107 is the heavy chain for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 108 is the light chain for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 109 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 110 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 111 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 112 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 113 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 114 is the light chain CDR1 for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 115 is the light chain CDR2 for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 116 is the light chain CDR3 for the OX40 agonist monoclonal antibody 18D8.
  • SEQ ID NO: 117 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody Hu 119- 122.
  • SEQ ID NO: 118 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody Hui 19-122.
  • SEQ ID NO: 119 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody Hui 19-122.
  • SEQ ID NO: 120 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody Hui 19-122.
  • SEQ ID NO: 121 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody Hui 19-122.
  • SEQ ID NO: 122 is the light chain CDR1 for the OX40 agonist monoclonal antibody Hui 19-122.
  • SEQ ID NO: 123 is the light chain CDR2 for the OX40 agonist monoclonal antibody Hui 19-122.
  • SEQ ID NO: 124 is the light chain CDR3 for the OX40 agonist monoclonal antibody Hui 19-122.
  • SEQ ID NO: 125 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 126 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 127 is the heavy chain CDR1 for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 128 is the heavy chain CDR2 for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 129 is the heavy chain CDR3 for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 130 is the light chain CDR1 for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 131 is the light chain CDR2 for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 132 is the light chain CDR3 for the OX40 agonist monoclonal antibody Hu 106-222.
  • SEQ ID NO: 133 is an OX40 ligand (OX40L) amino acid sequence.
  • SEQ ID NO: 134 is a soluble portion of OX40L polypeptide.
  • SEQ ID NO: 135 is an alternative soluble portion of OX40L polypeptide.
  • SEQ ID NO: 136 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 008.
  • SEQ ID NO: 137 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 008.
  • SEQ ID NO: 138 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody Oi l.
  • SEQ ID NO: 139 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody Oi l.
  • SEQ ID NO: 140 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 021.
  • SEQ ID NO: 141 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 021.
  • SEQ ID NO: 142 is the heavy chain variable region (VH) for the OX40 agonist monoclonal antibody 023.
  • SEQ ID NO: 143 is the light chain variable region (VL) for the OX40 agonist monoclonal antibody 023.
  • SEQ ID NO: 144 is the heavy chain variable region (VH) for an OX40 agonist monoclonal antibody.
  • SEQ ID NO: 145 is the light chain variable region (VL) for an OX40 agonist monoclonal antibody.
  • SEQ ID NO: 146 is the heavy chain variable region (VH) for an OX40 agonist monoclonal antibody.
  • SEQ ID NO: 147 is the light chain variable region (VL) for an OX40 agonist monoclonal antibody.
  • SEQ ID NO: 148 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 149 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 150 is the light chain variable region (VL) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 151 is the light chain variable region (VL) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 152 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 153 is the heavy chain variable region (VH) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 154 is the light chain variable region (VL) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 155 is the light chain variable region (VL) for a humanized OX40 agonist monoclonal antibody.
  • SEQ ID NO: 156 is the heavy chain variable region (VH) for an OX40 agonist monoclonal antibody.
  • SEQ ID NO: 157 is the light chain variable region (VL) for an OX40 agonist monoclonal antibody.
  • SEQ ID NO: 158 is the heavy chain amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 159 is the light chain amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 160 is the heavy chain variable region (VH) amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 161 is the light chain variable region (VL) amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 162 is the heavy chain CDR1 amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 163 is the heavy chain CDR2 amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 164 is the heavy chain CDR3 amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 165 is the light chain CDR1 amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 166 is the light chain CDR2 amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 167 is the light chain CDR3 amino acid sequence of the PD-1 inhibitor nivolumab.
  • SEQ ID NO: 168 is the heavy chain amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 169 is the light chain amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 170 is the heavy chain variable region (VH) amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 171 is the light chain variable region (VL) amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 172 is the heavy chain CDR1 amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 173 is the heavy chain CDR2 amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 174 is the heavy chain CDR3 amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 175 is the light chain CDR1 amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 176 is the light chain CDR2 amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 177 is the light chain CDR3 amino acid sequence of the PD-1 inhibitor pembrolizumab.
  • SEQ ID NO: 178 is the heavy chain amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 179 is the light chain amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 180 is the heavy chain variable region (V H ) amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 181 is the light chain variable region (V L ) amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 182 is the heavy chain CDR1 amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 183 is the heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 184 is the heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 185 is the light chain CDR1 amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 186 is the light chain CDR2 amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 187 is the light chain CDR3 amino acid sequence of the PD-L1 inhibitor durvalumab.
  • SEQ ID NO: 188 is the heavy chain amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 189 is the light chain amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 190 is the heavy chain variable region (VH) amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 191 is the light chain variable region (VL) amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 192 is the heavy chain CDR1 amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 193 is the heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 194 is the heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 195 is the light chain CDR1 amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 196 is the light chain CDR2 amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 197 is the light chain CDR3 amino acid sequence of the PD-L1 inhibitor avelumab.
  • SEQ ID NO: 198 is the heavy chain amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO: 199 is the light chain amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:200 is the heavy chain variable region (VH) amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:201 is the light chain variable region (VL) amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:202 is the heavy chain CDR1 amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:203 is the heavy chain CDR2 amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:204 is the heavy chain CDR3 amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:205 is the light chain CDR1 amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:206 is the light chain CDR2 amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:207 is the light chain CDR3 amino acid sequence of the PD-L1 inhibitor atezolizumab.
  • SEQ ID NO:208 is the heavy chain amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:209 is the light chain amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:210 is the heavy chain variable region (V H ) amino acid sequence of the CTLA- 4 inhibitor ipilimumab.
  • SEQ ID NO:211 is the light chain variable region (V L ) amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:212 is the heavy chain CDR1 amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:213 is the heavy chain CDR2 amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:214 is the heavy chain CDR3 amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:215 is the light chain CDR1 amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:216 is the light chain CDR2 amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:217 is the light chain CDR3 amino acid sequence of the CTLA-4 inhibitor ipilimumab.
  • SEQ ID NO:218 is the heavy chain amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:219 is the light chain amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:220 is the heavy chain variable region (V H ) amino acid sequence of the CTLA- 4 inhibitor tremelimumab.
  • SEQ ID NO:221 is the light chain variable region (V L ) amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:222 is the heavy chain CDR1 amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:223 is the heavy chain CDR2 amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:224 is the heavy chain CDR3 amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:225 is the light chain CDR1 amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:226 is the light chain CDR2 amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:227 is the light chain CDR3 amino acid sequence of the CTLA-4 inhibitor tremelimumab.
  • SEQ ID NO:228 is the heavy chain amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:229 is the light chain amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:230 is the heavy chain variable region (V H ) amino acid sequence of the CTLA- 4 inhibitor zalifrelimab.
  • SEQ ID NO:231 is the light chain variable region (V L ) amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:232 is the heavy chain CDR1 amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:233 is the heavy chain CDR2 amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:234 is the heavy chain CDR3 amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:235 is the light chain CDR1 amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:236 is the light chain CDR2 amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • SEQ ID NO:237 is the light chain CDR3 amino acid sequence of the CTLA-4 inhibitor zalifrelimab.
  • Adoptive cell therapy utilizing TILs cultured ex vivo by the Rapid Expansion Protocol has produced successful adoptive cell therapy following host immunosuppression in patients with cancer such as melanoma.
  • Current infusion acceptance parameters rely on readouts of the composition of TILs (e.g., CD28, CD8, or CD4 positivity) and on the numerical folds of expansion and viability of the REP product.
  • T cells undergo a profound metabolic shift during the course of their maturation from naive to effector T cells (see Chang, et al. , Nat. Immunol. 2016, 17, 364, hereby expressly incorporated in its entirety, and in particular for the discussion and markers of anaerobic and aerobic metabolism).
  • naive T cells rely on mitochondrial respiration to produce ATP
  • mature, healthy effector T cells such as TIL are highly glycolytic, relying on aerobic glycolysis to provide the bioenergetics substrates they require for proliferation, migration, activation, and antitumor efficacy.
  • TIL manufacturing and treatment processes are limited by length, cost, sterility concerns, and other factors described herein such that the potential to treat patients which are refractory to anti-PDl and as such have been severly limited.
  • the present invention meets this need by providing a shortened manufacturing process for use in generating TILs which can then be employed in the treatment of non-small cell lung carcinoma (NSCLC) patients whom are refractory to anti-PD-1 treatment.
  • NSCLC non-small cell lung carcinoma
  • co-administration encompass administration of two or more active pharmaceutical ingredients (in a preferred embodiment of the present invention, for example, a plurality of TILs) to a subject so that both active pharmaceutical ingredients and/or their metabolites are present in the subject at the same time.
  • Coadministration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which two or more active pharmaceutical ingredients are present. Simultaneous administration in separate compositions and administration in a composition in which both agents are present are preferred.
  • in vivo refers to an event that takes place in a subject's body.
  • in vitro refers to an event that takes places outside of a subject s body.
  • in vitro assays encompass cell-based assays in which cells alive or dead are employed and may also encompass a cell-free assay in which no intact cells are employed.
  • ex vivo refers to an event which involves treating or performing a procedure on a cell, tissue and/or organ which has been removed from a subject' s body. Aptly, the cell, tissue and/or organ may be returned to the subject's body in a method of surgery or treatment.
  • rapid expansion means an increase in the number of antigen-specific TILs of at least about 3-fold (or 4-, 5-, 6-, 7-, 8-, or 9-fold) over a period of a week, more preferably at least about 10-fold (or 20-, 30-, 40-, 50-, 60-, 70-, 80-, or 90-fold) over a period of a week, or most preferably at least about 100-fold over a period of a week.
  • rapid expansion protocols are described herein.
  • TILs tumor infdtrating lymphocytes
  • TILs include, but are not limited to, CD8 + cytotoxic T cells (lymphocytes), Thl and Thl7 CD4 + T cells, natural killer cells, dendritic cells and Ml macrophages.
  • TILs include both primary and secondary TILs.
  • Primary TILs are those that are obtained from patient tissue samples as outlined herein (sometimes referred to as “freshly harvested”), and “secondary TILs” are any TIL cell populations that have been expanded or proliferated as discussed herein, including, but not limited to bulk TILs and expanded TILs (“REP TILs” or “post-REP TILs”). TIL cell populations can include genetically modified TILs.
  • population of cells herein is meant a number of cells that share common traits.
  • populations generally range from 1 X 10 6 to 1 X 10 10 in number, with different TIL populations comprising different numbers.
  • initial growth of primary TILs in the presence of IL-2 results in a population of bulk TILs of roughly 1 x 10 8 cells.
  • REP expansion is generally done to provide populations of 1.5 x 10 9 to 1.5 x 10 10 cells for infusion.
  • cryopreserved TILs herein is meant that TILs, either primary, bulk, or expanded (REP TILs), are treated and stored in the range of about -150°C to -60°C. General methods for cry opreservation are also described elsewhere herein, including in the Examples. For clarity, “cryopreserved TILs” are distinguishable from frozen tissue samples which may be used as a source of primary TILs.
  • cryopreserved TILs herein is meant a population of TILs that was previously cryopreserved and then treated to return to room temperature or higher, including but not limited to cell culture temperatures or temperatures wherein TILs may be administered to a patient.
  • TILs can generally be defined either biochemically, using cell surface markers, or functionally, by their ability to infiltrate tumors and effect treatment.
  • TILs can be generally categorized by expressing one or more of the following biomarkers: CD4, CD8, TCR a , CD27, CD28, CD56, CCR7, CD45Ra, CD95, PD-1, and CD25. Additionally and alternatively, TILs can be functionally defined by their ability to infiltrate solid tumors upon reintroduction into a patient.
  • cryopreservation media refers to any medium that can be used for cryopreservation of cells. Such media can include media comprising 7% to 10% DMSO. Exemplary media include CryoStor CS10, Hyperthermasol, as well as combinations thereof.
  • CS10 refers to a cryopreservation medium which is obtained from Stemcell Technologies or from Biolife Solutions. The CS10 medium may be referred to by the trade name “CryoStor® CS10”.
  • the CS10 medium is a serum-free, animal component-free medium which comprises DMSO.
  • central memory T cell refers to a subset of T cells that in the human are CD45R0+ and constitutively express CCR7 (CCR7 hl ) and CD62L (CD62 hl ).
  • the surface phenotype of central memory T cells also includes TCR, CD3, CD127 (IL-7R), and IL-15R. Transcription factors for central memory T cells include BCL-6, BCL-6B, MBD2, and BMI1.
  • Central memory T cells primarily secret IL-2 and CD40L as effector molecules after TCR triggering.
  • Central memory T cells are predominant in the CD4 compartment in blood, and in the human are proportionally enriched in lymph nodes and tonsils.
  • effector memory T cell refers to a subset of human or mammalian T cells that, like central memory T cells, are CD45R0+, but have lost the constitutive expression of CCR7 (CCR7 10 ) and are heterogeneous or low for CD62L expression (CD62L 1o ).
  • the surface phenotype of central memory T cells also includes TCR, CD3, CD127 (IL-7R), and IL-15R.
  • Transcription factors for central memory T cells include BLIMP 1. Effector memory T cells rapidly secret high levels of inflammatory cytokines following antigenic stimulation, including interferon-y, IL-4, and IL-5. Effector memory T cells are predominant in the CD8 compartment in blood, and in the human are proportionally enriched in the lung, liver, and gut. CD8+ effector memory T cells carry large amounts of perforin.
  • closed system refers to a system that is closed to the outside environment. Any closed system appropriate for cell culture methods can be employed with the methods of the present invention. Closed systems include, for example, but are not limited to closed G-containers. Once a tumor segment is added to the closed system, the system is no opened to the outside environment until the TILs are ready to be administered to the patient.
  • fragmenting includes mechanical fragmentation methods such as crushing, slicing, dividing, and morcellating tumor tissue as well as any other method for disrupting the physical structure of tumor tissue.
  • peripheral blood mononuclear cells refers to a peripheral blood cell having a round nucleus, including lymphocytes (T cells, B cells, NK cells) and monocytes.
  • T cells lymphocytes
  • B cells lymphocytes
  • monocytes monocytes.
  • the peripheral blood mononuclear cells are preferably irradiated allogeneic peripheral blood mononuclear cells.
  • peripheral blood lymphocytes and “PBLs” refer to T cells expanded from peripheral blood.
  • PBLs are separated from whole blood or apheresis product from a donor.
  • PBLs are separated from whole blood or apheresis product from a donor by positive or negative selection of a T cell phenotype, such as the T cell phenotype of CD3+ CD45+.
  • anti-CD3 antibody refers to an antibody or variant thereof, e g , a monoclonal antibody and including human, humanized, chimeric or murine antibodies which are directed against the CD3 receptor in the T cell antigen receptor of mature T cells.
  • Anti-CD3 antibodies include OKT- 3, also known as muromonab.
  • Anti-CD3 antibodies also include the UHCT1 clone, also known as T3 and CD3s.
  • Other anti-CD3 antibodies include, for example, otelixizumab, teplizumab, and visilizumab.
  • OKT-3 refers to a monoclonal antibody or biosimilar or variant thereof, including human, humanized, chimeric, or murine antibodies, directed against the CD3 receptor in the T cell antigen receptor of mature T cells, and includes commercially- available forms such as OKT-3 (30 ng/mL, MACS GMP CD3 pure, Miltenyi Biotech, Inc., San Diego, CA, USA) and muromonab or variants, conservative amino acid substitutions, glycoforms, or biosimilars thereof.
  • the amino acid sequences of the heavy and light chains of muromonab are given in Table 1 (SEQ ID NO: 1 and SEQ ID NO:2).
  • a hybridoma capable of producing OKT-3 is deposited with the American Type Culture Collection and assigned the ATCC accession number CRL 8001.
  • a hybridoma capable of producing OKT-3 is also deposited with European Collection of Authenticated Cell Cultures (ECACC) and assigned Catalogue No. 86022706.
  • IL-2 refers to the T cell growth factor known as interleukin-2, and includes all forms of IL-2 including human and mammalian forms, conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof.
  • IL-2 is described, e.g., in Nelson, J. Immunol. 2004, 172, 3983-88 and Malek, Annu. Rev. Immunol. 2008, 26, 453-79, the disclosures of which are incorporated by reference herein.
  • the amino acid sequence of recombinant human IL-2 suitable for use in the invention is given in Table 2 (SEQ ID NO:3).
  • IL-2 encompasses human, recombinant forms of IL-2 such as aldesleukin (PROLEUKIN, available commercially from multiple suppliers in 22 million IU per single use vials), as well as the form of recombinant IL-2 commercially supplied by CellGenix, Inc., Portsmouth, NH, USA (CELLGRO GMP) or ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT- 209-b) and other commercial equivalents from other vendors.
  • Aldesleukin (des-alanyl- 1, serine-125 human IL-2) is a nonglycosylated human recombinant form of IL-2 with a molecular weight of approximately 15 kDa.
  • IL-2 also encompasses pegylated forms of IL-2, as described herein, including the pegylated IL2 prodrug bempegaldesleukin (NKTR-214, pegylated human recombinant IL-2 as in SEQ ID NO:4 in which an average of 6 lysine residues are N 6 substituted with [(2,7-bis ⁇ [methylpoly(oxyethylene)]carbamoyl ⁇ -9H-fluoren-9-yl)methoxy]carbonyl), which is available from Nektar Therapeutics, South San Francisco, CA, USA, or which may be prepared by methods known in the art, such as the methods described in Example 19 of International Patent Application Publication No.
  • NKTR-214 pegylated human recombinant IL-2 as in SEQ ID NO:4 in which an average of 6 lysine residues are N 6 substituted with [(2,7-bis ⁇ [methylpoly(oxyethylene)]carbamoyl ⁇ -9H-fluoren
  • WO 2018/132496 Al or the method described in Example 1 of U.S. Patent Application Publication No. US 2019/0275133 Al, the disclosures of which are incorporated by reference herein.
  • Bempegaldesleukin (NKTR-214) and other pegylated IL-2 molecules suitable for use in the invention is described in U.S. Patent Application Publication No. US 2014/0328791 Al and International Patent Application Publication No. WO 2012/065086 Al, the disclosures of which are incorporated by reference herein.
  • Alternative forms of conjugated IL-2 suitable for use in the invention are described in U.S. Patent Nos. 4,766,106, 5,206,344, 5,089,261 and 4,902,502, the disclosures of which are incorporated by reference herein.
  • Formulations of IL-2 suitable for use in the invention are described in U.S. Patent No. 6,706,289, the disclosure of which is incorporated by reference herein.
  • an IL-2 form suitable for use in the present invention is THOR-707, available from Synthorx, Inc.
  • THOR-707 available from Synthorx, Inc.
  • the preparation and properties of THOR-707 and additional alternative forms of IL-2 suitable for use in the invention are described in U.S. Patent Application Publication Nos. US 2020/0181220 Al and US 2020/0330601 Al, the disclosures of which are incorporated by reference herein.
  • IL-2 form suitable for use in the invention is an interleukin 2 (IL-2) conjugate comprising: an isolated and purified IL-2 polypeptide; and a conjugating moiety that binds to the isolated and purified IL-2 polypeptide at an amino acid position selected from K35, T37, R38, T41, F42, K43, F44, Y45, E61, E62, E68, K64, P65, V69, L72, and Y107, wherein the numbering of the amino acid residues corresponds to SEQ ID NO:5.
  • IL-2 interleukin 2
  • the amino acid position is selected from T37, R38, T41, F42, F44, Y45, E61, E62, E68, K64, P65, V69, L72, and Y107. In some embodiments, the amino acid position is selected from T37, R38, T41, F42, F44, Y45, E61, E62, E68, P65, V69, L72, and Y107. In some embodiments, the amino acid position is selected from T37, T41, F42, F44, Y45, P65, V69, L72, and Y107. In some embodiments, the amino acid position is selected from R38 and K64.
  • the amino acid position is selected from E61, E62, and E68. In some embodiments, the amino acid position is at E62. In some embodiments, the amino acid residue selected from K35, T37, R38, T41, F42, K43, F44, Y45, E61, E62, E68, K64, P65, V69, L72, and Y107 is further mutated to lysine, cysteine, or histidine. In some embodiments, the amino acid residue is mutated to cysteine. In some embodiments, the amino acid residue is mutated to lysine.
  • the amino acid residue selected from K35, T37, R38, T41, F42, K43, F44, Y45, E61, E62, E68, K64, P65, V69, L72, and Y 107 is further mutated to an unnatural amino acid.
  • the unnatural amino acid comprises N6-azidoethoxy-L-lysine (AzK), N6-propargylethoxy-L-lysine (PraK), BCN-L- lysine, norbomene lysine, TCO-lysine, methyltetrazine lysine, allyloxy carbonyllysine, 2-amino-8- oxononanoic acid, 2-amino-8-oxooctanoic acid, p-acetyl-L-phenylalanine, p-azidomethyl-L- phenylalanine (pAMF), p-iodo-L-phenylalanine, m-acetylphenylalanine, 2-amino-8-oxononanoic acid, p-propargyloxyphenylalanine, p-propargyl-phenylalanine, 3 -methyl -phenylalan
  • the IL-2 conjugate has a decreased affinity to IL-2 receptor a (IL-2Ra) subunit relative to a wild-type IL-2 polypeptide.
  • the decreased affinity is about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or greater than 99% decrease in binding affinity to IL-2Ra relative to a wild-type IL- 2 polypeptide.
  • the decreased affinity is about 1-fold, 2-fold, 3 -fold, 4-fold, 5- fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 30-fold, 50-fold, 100-fold, 200-fold, 300-fold, 500-fold, 1000-fold, or more relative to a wild-type IL-2 polypeptide.
  • the conjugating moiety impairs or blocks the binding of IL-2 with IL-2Ra.
  • the conjugating moiety comprises a water-soluble polymer.
  • the additional conjugating moiety comprises a water-soluble polymer.
  • each of the water-soluble polymers independently comprises polyethylene glycol (PEG), polypropylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefmic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(a-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N-acryloylmorpholine), or a combination thereof.
  • each of the water-soluble polymers independently comprises PEG.
  • the PEG is a linear PEG or a branched PEG.
  • each of the water-soluble polymers independently comprises a polysaccharide.
  • the polysaccharide comprises dextran, polysialic acid (PSA), hyaluronic acid (HA), amylose, heparin, heparan sulfate (HS), dextrin, or hydroxyethylstarch (HES).
  • each of the water-soluble polymers independently comprises a glycan.
  • each of the water-soluble polymers independently comprises polyamine.
  • the conjugating moiety comprises a protein.
  • the additional conjugating moiety comprises a protein.
  • each of the proteins independently comprises an albumin, a transferrin, or a transthyretin. In some embodiments, each of the proteins independently comprises an Fc portion. In some embodiments, each of the proteins independently comprises an Fc portion of IgG.
  • the conjugating moiety comprises a polypeptide. In some embodiments, the additional conjugating moiety comprises a polypeptide. In some embodiments, each of the polypeptides independently comprises a XTEN peptide, a glycine-rich homoamino acid polymer (HAP), a PAS polypeptide, an elastin-like polypeptide (ELP), a CTP peptide, or a gelatin-like protein (GLK) polymer.
  • the isolated and purified IL-2 polypeptide is modified by glutamylation.
  • the conjugating moiety is directly bound to the isolated and purified IL-2 polypeptide.
  • the conjugating moiety is indirectly bound to the isolated and purified IL-2 polypeptide through a linker.
  • the linker comprises a homobifunctional linker.
  • the homobifunctional linker comprises Lomant's reagent dithiobis (succinimidylpropionate) DSP, 3'3'-dithiobis(sulfosuccinimidyl proprionate) (DTSSP), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl)suberate (BS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo DST), ethylene glycobis(succinimidylsuccinate) (EGS), disuccinimidyl glutarate (DSG), N,N'-disuccinimidyl carbonate (DSC), dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS), dimethyl-3,3'-dithiobispropionimidate (DTBP), l,4-di-(3'-)
  • DFDNPS 4,4'-difluoro-3,3'-dinitrophenylsulfone
  • BASED bis-[P ⁇ (4- azidosalicylamido)ethyl]disulfide
  • formaldehyde glutaraldehyde
  • 1,4-butanediol diglycidyl ether adipic acid dihydrazide, carbohydrazide, o-toluidine, 3,3 '-dimethylbenzidine, benzidine, a,a'-p- diaminodiphenyl, diiodo-p-xylene sulfonic acid, N,N'-ethylene-bis(iodoacetamide), or N,N'- hexamethylene-bis(iodoacetamide).
  • the linker comprises a heterobifunctional linker.
  • the heterobifunctional linker comprises N-succinimidyl 3-(2- pyridyldithio)propionate (sPDP), long-chain N-succinimidyl 3-(2-pyridyldithio)propionate (LC- sPDP), water-soluble-long-chain N-succinimidyl 3 -(2 -pyridyldithio) propionate (sulfo-LC-sPDP), succinimidyloxycarbonyl-a-methyl-a-(2-pyridyldithio)toluene (sMPT), sulfosuccinimidyl-6-[a- methyl-a-(2-pyridyldithio)toluamido]hexanoate (sulfo-LC-sMPT), succinimidyl-4-(N- maleimid
  • the linker comprises a cleavable linker, optionally comprising a dipeptide linker.
  • the dipeptide linker comprises Val-Cit, Phe-Lys, Vai-Ala, or Val-Lys.
  • the linker comprises a non-cleavable linker.
  • the linker comprises a maleimide group, optionally comprising maleimidocaproyl (me), succinimidyl-4-(N- maleimidomethyl)cyclohexane-l -carboxylate (sMCC), or sulfosuccinimidyl -4-(N- maleimidomethyl)cyclohexane-l -carboxylate (sulfo-sMCC).
  • the linker further comprises a spacer.
  • the spacer comprises p-aminobenzyl alcohol (PAB), p- aminobenzyoxycarbonyl (PABC), a derivative, or an analog thereof.
  • the conjugating moiety is capable of extending the serum half-life of the IL-2 conjugate.
  • the additional conjugating moiety is capable of extending the serum half-life of the IL- 2 conjugate.
  • the IL-2 form suitable for use in the invention is a fragment of any of the IL-2 forms described herein.
  • the IL-2 form suitable for use in the invention is pegylated as disclosed in U.S. Patent Application Publication No. US 2020/0181220 Al and U.S. Patent Application Publication No.
  • the IL-2 form suitable for use in the invention is an IL-2 conjugate comprising: an IL-2 polypeptide comprising an N6-azidoethoxy-L-lysine (AzK) covalently attached to a conjugating moiety comprising a polyethylene glycol (PEG), wherein: the IL-2 polypeptide comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:5; and the AzK substitutes for an amino acid at position K35, F42, F44, K43, E62, P65, R38, T41, E68, Y45, V69, or L72 in reference to the amino acid positions within SEQ ID NO:5.
  • AzK N6-azidoethoxy-L-lysine
  • the IL-2 polypeptide comprises an N-terminal deletion of one residue relative to SEQ ID NO:5.
  • the IL-2 form suitable for use in the invention lacks IL-2R alpha chain engagement but retains normal binding to the intermediate affinity IL-2R beta-gamma signaling complex.
  • the IL-2 form suitable for use in the invention is an IL-2 conjugate comprising: an IL-2 polypeptide comprising an N6-azidoethoxy-L-lysine (AzK) covalently attached to a conjugating moiety comprising a polyethylene glycol (PEG), wherein: the IL-2 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO:5; and the AzK substitutes for an amino acid at position K35, F42, F44, K43, E62, P65, R38, T41, E68, Y45, V69, or L72 in reference to the amino acid positions within SEQ ID NO:5.
  • AzK N6-azidoethoxy-L-lysine
  • the IL-2 form suitable for use in the invention is an IL-2 conjugate comprising: an IL-2 polypeptide comprising an N6- azidoethoxy-L-lysine (AzK) covalently attached to a conjugating moiety comprising a polyethylene glycol (PEG), wherein: the IL-2 polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:5; and the AzK substitutes for an amino acid at position K35, F42, F44, K43, E62, P65, R38, T41, E68, Y45, V69, or L72 in reference to the amino acid positions within SEQ ID NO:5.
  • AzK N6- azidoethoxy-L-lysine
  • the IL-2 form suitable for use in the invention is an IL-2 conjugate comprising: an IL-2 polypeptide comprising an N6-azidoethoxy-L-lysine (AzK) covalently attached to a conjugating moiety comprising a polyethylene glycol (PEG), wherein: the IL-2 polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO:5; and the AzK substitutes for an amino acid at position K35, F42, F44, K43, E62, P65, R38, T41, E68, Y45, V69, or L72 in reference to the amino acid positions within SEQ ID NO:5.
  • AzK N6-azidoethoxy-L-lysine
  • an IL-2 form suitable for use in the invention is nemvaleukin alfa, also known as ALKS-4230 (SEQ ID NO:6), which is available from Alkermes, Inc.
  • Nemvaleukin alfa is also known as human interleukin 2 fragment (1-59), variant (Cys 125 >Ser 51 ), fused via peptidyl linker ( 60 GG 61 ) to human interleukin 2 fragment (62-132), fused via peptidyl linker ( 133 GSGGGS 138 ) to human interleukin 2 receptor a-chain fragment (139-303), produced in Chinese hamster ovary (CHO) cells, glycosylated; human interleukin 2 (IL-2) (75-133)-peptide [Cys 125 (51)>Ser]-mutant (1-59), fused via a G2 peptide linker (60-61) to human interleukin 2 (IL-2) (4-74)-peptide (62-132) and via a GSG3S peptide linker (133-138) to human interleukin 2 receptor a- chain (IL2R subunit alpha, IL2Ra, IL2RA) (l-165)-peptide (
  • nemvaleukin alfa exhibits the following post-translational modifications: disulfide bridges at positions: 31-116, 141-285, 184-242, 269-301, 166-197 or 166- 199, 168-199 or 168-197 (using the numbering in SEQ ID NO:6), and glycosylation sites at positions: N187, N206, T212 using the numbering in SEQ ID NO:6.
  • disulfide bridges at positions: 31-116, 141-285, 184-242, 269-301, 166-197 or 166- 199, 168-199 or 168-197 (using the numbering in SEQ ID NO:6)
  • glycosylation sites at positions: N187, N206, T212 using the numbering in SEQ ID NO:6.
  • an IL-2 form suitable for use in the invention is a protein having at least 80%, at least 90%, at least 95%, or at least 90% sequence identity to SEQ ID NO:6.
  • an IL-2 form suitable for use in the invention has the amino acid sequence given in SEQ ID NO:6 or conservative amino acid substitutions thereof.
  • an IL-2 form suitable for use in the invention is a fusion protein comprising amino acids 24-452 of SEQ ID NO: 7, or variants, fragments, or derivatives thereof.
  • an IL-2 form suitable for use in the invention is a fusion protein comprising an amino acid sequence having at least 80%, at least 90%, at least 95%, or at least 90% sequence identity to amino acids 24-452 of SEQ ID NO:7, or variants, fragments, or derivatives thereof.
  • Other IL-2 forms suitable for use in the present invention are described in U.S. Patent No. 10,183,979, the disclosures of which are incorporated by reference herein.
  • an IL-2 form suitable for use in the invention is a fusion protein comprising a first fusion partner that is linked to a second fusion partner by a mucin domain polypeptide linker, wherein the first fusion partner is IL-IRa or a protein having at least 98% amino acid sequence identity to IL- IRa and having the receptor antagonist activity of IL-Ra, and wherein the second fusion partner comprises all or a portion of an immunoglobulin comprising an Fc region, wherein the mucin domain polypeptide linker comprises SEQ ID NO: 8 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 8 and wherein the half-life of the fusion protein is improved as compared to a fusion of the first fusion partner to the second fusion partner in the absence of the mucin domain polypeptide linker.
  • an IL-2 form suitable for use in the invention includes a antibody cytokine engrafted protein comprises a heavy chain variable region (VH), comprising complementarity determining regions HCDR1, HCDR2, HCDR3; a light chain variable region (VL), comprising LCDR1, LCDR2, LCDR3; and an IL-2 molecule or a fragment thereof engrafted into a CDR of the VH or the VL, wherein the antibody cytokine engrafted protein preferentially expands T effector cells over regulatory T cells.
  • VH heavy chain variable region
  • VL light chain variable region
  • the antibody cytokine engrafted protein comprises a heavy chain variable region (VH), comprising complementarity determining regions HCDR1, HCDR2, HCDR3; a light chain variable region (VL), comprising LCDR1, LCDR2, LCDR3; and an IL-2 molecule or a fragment thereof engrafted into a CDR of the VH or the VL, wherein the IL- 2 molecule is a mutein, and wherein the antibody cytokine engrafted protein preferentially expands T effector cells over regulatory T cells.
  • the IL-2 regimen comprises administration of an antibody described in U.S. Patent Application Publication No.
  • the antibody cytokine engrafted protein comprises a heavy chain variable region (VH), comprising complementarity determining regions HCDR1, HCDR2, HCDR3; a light chain variable region (VL), comprising LCDR1, LCDR2, LCDR3; and an IL-2 molecule or a fragment thereof engrafted into a CDR of the VH or the VL, wherein the IL-2 molecule is a mutein, wherein the antibody cytokine engrafted protein preferentially expands T effector cells over regulatory T cells, and wherein the antibody further comprises an IgG class heavy chain and an IgG class light chain selected from the group consisting of: a IgG class light chain comprising SEQ ID NO:39 and a IgG class heavy chain comprising SEQ ID NO:38; a IgG class light chain comprising SEQ ID NO:37 and a IgG class heavy chain comprising
  • an IL-2 molecule or a fragment thereof is engrafted into HCDR1 of the VH, wherein the IL-2 molecule is a mutein. In some embodiments, an IL-2 molecule or a fragment thereof is engrafted into HCDR2 of the VH, wherein the IL-2 molecule is a mutein. In some embodiments, an IL-2 molecule or a fragment thereof is engrafted into HCDR3 of the VH, wherein the IL-2 molecule is a mutein. In some embodiments, an IL-2 molecule or a fragment thereof is engrafted into LCDR1 of the VL, wherein the IL-2 molecule is a mutein.
  • an IL-2 molecule or a fragment thereof is engrafted into LCDR2 of the VL, wherein the IL-2 molecule is a mutein. In some embodiments, an IL-2 molecule or a fragment thereof is engrafted into LCDR3 of the VL, wherein the IL-2 molecule is a mutein.
  • the insertion of the IL-2 molecule can be at or near the N-terminal region of the CDR, in the middle region of the CDR or at or near the C-terminal region of the CDR.
  • the antibody cytokine engrafted protein comprises an IL-2 molecule incorporated into a CDR, wherein the IL2 sequence does not frameshift the CDR sequence.
  • the antibody cytokine engrafted protein comprises an IL-2 molecule incorporated into a CDR, wherein the IL-2 sequence replaces all or part of a CDR sequence.
  • the replacement by the IL-2 molecule can be the N-terminal region of the CDR, in the middle region of the CDR or at or near the C-terminal region the CDR.
  • a replacement by the IL-2 molecule can be as few as one or two amino acids of a CDR sequence, or the entire CDR sequences.
  • an IL-2 molecule is engrafted directly into a CDR without a peptide linker, with no additional amino acids between the CDR sequence and the IL-2 sequence.
  • an IL-2 molecule is engrafted indirectly into a CDR with a peptide linker, with one or more additional amino acids between the CDR sequence and the IL-2 sequence.
  • the IL-2 molecule described herein is an IL-2 mutein.
  • the IL-2 mutein comprising an R67A substitution.
  • the IL-2 mutein comprises the amino acid sequence SEQ ID NO: 14 or SEQ ID NO: 15.
  • the IL- 2 mutein comprises an amino acid sequence in Table 1 in U.S. Patent Application Publication No. US 2020/0270334 Al, the disclosure of which is incorporated by reference herein.
  • the antibody cytokine engrafted protein comprises an HCDR1 selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO:22 and SEQ ID NO:25. In some embodiments, the antibody cytokine engrafted protein comprises an HCDR1 selected from the group consisting of SEQ ID NO:7, SEQ ID NO: 10, SEQ ID NO: 13 and SEQ ID NO: 16. In some embodiments, the antibody cytokine engrafted protein comprises an HCDR1 selected from the group consisting of HCDR2 selected from the group consisting of SEQ ID NO: 17, SEQ ID NO:20, SEQ ID NO:23, and SEQ ID NO:26.
  • the antibody cytokine engrafted protein comprises an HCDR3 selected from the group consisting of SEQ ID NO: 18, SEQ ID NO:21, SEQ ID NO:24, and SEQ ID NO:27. In some embodiments, the antibody cytokine engrafted protein comprises a VH region comprising the amino acid sequence of SEQ ID NO:28. In some embodiments, the antibody cytokine engrafted protein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:29. In some embodiments, the antibody cytokine engrafted protein comprises a VL region comprising the amino acid sequence of SEQ ID NO:36.
  • the antibody cytokine engrafted protein comprises a light chain comprising the amino acid sequence of SEQ ID NO:37. In some embodiments, the antibody cytokine engrafted protein comprises a VH region comprising the amino acid sequence of SEQ ID NO:28 and a VL region comprising the amino acid sequence of SEQ ID NO:36. In some embodiments, the antibody cytokine engrafted protein comprises a heavy chain region comprising the amino acid sequence of SEQ ID NO:29 and a light chain region comprising the amino acid sequence of SEQ ID NO: 37.
  • the antibody cytokine engrafted protein comprises a heavy chain region comprising the amino acid sequence of SEQ ID NO:29 and a light chain region comprising the amino acid sequence of SEQ ID NO:39. In some embodiments, the antibody cytokine engrafted protein comprises a heavy chain region comprising the amino acid sequence of SEQ ID NO:38 and a light chain region comprising the amino acid sequence of SEQ ID NO:37. In some embodiments, the antibody cytokine engrafted protein comprises a heavy chain region comprising the amino acid sequence of SEQ ID NO:38 and a light chain region comprising the amino acid sequence of SEQ ID NO:39.
  • the antibody cytokine engrafted protein comprises IgG.IL2F71A.Hl or IgG.IL2R67A.Hl of U.S. Patent Application Publication No. 2020/0270334 Al, or variants, derivatives, or fragments thereof, or conservative amino acid substitutions thereof, or proteins with at least 80%, at least 90%, at least 95%, or at least 98% sequence identity thereto.
  • the antibody components of the antibody cytokine engrafted protein described herein comprise immunoglobulin sequences, framework sequences, or CDR sequences of palivizumab.
  • the antibody cytokine engrafted protein described herein has a longer serum half-life that a wild-type IL-2 molecule such as, but not limited to, aldesleukin or a comparable molecule. In some embodiments, the antibody cytokine engrafted protein described herein has a sequence as set forth in Table 3.
  • IL-4 refers to the cytokine known as interleukin 4, which is produced by Th2 T cells and by eosinophils, basophils, and mast cells. IL-4 regulates the differentiation of naive helper T cells (ThO cells) to Th2 T cells. Steinke and Borish, Respir. Res. 2001, 2, 66-70. Upon activation by IL-4, Th2 T cells subsequently produce additional IL- 4 in a positive feedback loop. IL-4 also stimulates B cell proliferation and class II MHC expression, and induces class switching to IgE and IgGi expression from B cells.
  • ThO cells naive helper T cells
  • Recombinant human IL-4 suitable for use in the invention is commercially available from multiple suppliers, including ProSpec- Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-211) and ThermoFisher Scientific, Inc., Waltham, MA, USA (human IL-15 recombinant protein, Cat. No. Gibco CTP0043).
  • the amino acid sequence of recombinant human IL-4 suitable for use in the invention is given in Table 2 (SEQ ID NO:9).
  • IL-7 refers to a glycosylated tissue-derived cytokine known as interleukin 7, which may be obtained from stromal and epithelial cells, as well as from dendritic cells. Fry and Mackall, Blood 2002, 99, 3892-904. IL-7 can stimulate the development of T cells. IL-7 binds to the IL-7 receptor, a heterodimer consisting of IL-7 receptor alpha and common gamma chain receptor, which in a series of signals important for T cell development within the thymus and survival within the periphery.
  • Recombinant human IL-7 suitable for use in the invention is commercially available from multiple suppliers, including ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-254) and ThermoFisher Scientific, Inc., Waltham, MA, USA (human IL-15 recombinant protein, Cat. No. Gibco PHC0071).
  • the amino acid sequence of recombinant human IL-7 suitable for use in the invention is given in Table 2 (SEQ ID NO: 10).
  • IL-15 refers to the T cell growth factor known as interleukin- 15, and includes all forms of IL-2 including human and mammalian forms, conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof.
  • IL- 15 is described, e.g., in Fehniger and Caligiuri, Blood 2001, 97, 14-32, the disclosure of which is incorporated by reference herein.
  • IL-15 shares P and y signaling receptor subunits with IL-2.
  • Recombinant human IL-15 is a single, non-glycosylated polypeptide chain containing 114 amino acids (and an N-terminal methionine) with a molecular mass of 12.8 kDa.
  • Recombinant human IL-15 is commercially available from multiple suppliers, including ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-230-b) and ThermoFisher Scientific, Inc., Waltham, MA, USA (human IL-15 recombinant protein, Cat. No. 34-8159-82).
  • the amino acid sequence of recombinant human IL-15 suitable for use in the invention is given in Table 2 (SEQ ID NO: 11).
  • IL-21 refers to the pleiotropic cytokine protein known as interleukin-21, and includes all forms of IL-21 including human and mammalian forms, conservative amino acid substitutions, glycoforms, biosimilars, and variants thereof. IL-21 is described, e.g., in Spolski and Leonard, Nat. Rev. Drug. Disc. 2014, 13, 379-95, the disclosure of which is incorporated by reference herein. IL-21 is primarily produced by natural killer T cells and activated human CD4 + T cells.
  • Recombinant human IL-21 is a single, non-glycosylated polypeptide chain containing 132 amino acids with a molecular mass of 15.4 kDa.
  • Recombinant human IL-21 is commercially available from multiple suppliers, including ProSpec-Tany TechnoGene Ltd., East Brunswick, NJ, USA (Cat. No. CYT-408-b) and ThermoFisher Scientific, Inc., Waltham, MA, USA (human IL-21 recombinant protein, Cat. No. 14-8219-80).
  • the amino acid sequence of recombinant human IL-21 suitable for use in the invention is given in Table 2 (SEQ ID NO: 12).
  • an anti -tumor effective amount “a tumor-inhibiting effective amount”, or “therapeutic amount”
  • the precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject).
  • a pharmaceutical composition comprising the tumor infiltrating lymphocytes (e.g., secondary TILs or genetically modified cytotoxic lymphocytes) described herein may be administered at a dosage of 10 4 to 10 11 cells/kg body weight (e.g., 10 5 to 10 6 , 10 5 to 10 10 , 10 5 to 10 11 , 10 6 to 10 10 , 10 6 to 10 11 ,10 7 to 10 11 , 10 7 to 10 10 , 10 8 to 10 11 , 10 8 to 10 10 , 10 9 to 10 11 , or 10 9 to 10 10 cells/kg body weight), including all integer values within those ranges.
  • TILs (including in some cases, genetically modified cytotoxic lymphocytes) compositions may also be administered multiple times at these dosages.
  • the TILs (inlcuding in some cases, genetically) can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 1988, 319: 1676).
  • the optimal dosage and treatment regime for a particular patient can readily be determined by one skilled in the art of medicine by monitoring the patient for signs of disease and adjusting the treatment accordingly.
  • hematological malignancy refers to mammalian cancers and tumors of the hematopoietic and lymphoid tissues, including but not limited to tissues of the blood, bone marrow, lymph nodes, and lymphatic system.
  • Hematological malignancies are also referred to as “liquid tumors.” Hematological malignancies include, but are not limited to, acute lymphoblastic leukemia (ALL), chronic lymphocytic lymphoma (CLL), small lymphocytic lymphoma (SLL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), multiple myeloma, acute monocytic leukemia (AMoL), Hodgkin's lymphoma, and non-Hodgkin's lymphomas.
  • ALL acute lymphoblastic leukemia
  • CLL chronic lymphocytic lymphoma
  • SLL small lymphocytic lymphoma
  • AML acute myelogenous leukemia
  • CML chronic myelogenous leukemia
  • AoL acute monocytic leukemia
  • Hodgkin's lymphoma and non-Hodgkin's lymphomas.
  • liquid tumor refers to an abnormal mass of cells that is fluid in nature.
  • Liquid tumor cancers include, but are not limited to, leukemias, myelomas, and lymphomas, as well as other hematological malignancies.
  • TILs obtained from liquid tumors may also be referred to herein as marrow infdtrating lymphocytes (MILs).
  • MILs obtained from liquid tumors, including liquid tumors circulating in peripheral blood may also be referred to herein as PBLs.
  • MIL, TIL, and PBL are used interchangeably herein and differ only based on the tissue type from which the cells are derived.
  • microenvironment may refer to the solid or hematological tumor microenvironment as a whole or to an individual subset of cells within the microenvironment.
  • the tumor microenvironment refers to a complex mixture of “cells, soluble factors, signaling molecules, extracellular matrices, and mechanical cues that promote neoplastic transformation, support tumor growth and invasion, protect the tumor from host immunity, foster therapeutic resistance, and provide niches for dominant metastases to thrive,” as described in Swartz, et al., Cancer Res., 2012, 72, 2473.
  • tumors express antigens that should be recognized by T cells, tumor clearance by the immune system is rare because of immune suppression by the microenvironment.
  • the invention includes a method of treating a cancer with a population of TILs, wherein a patient is pre-treated with non-myeloablative chemotherapy prior to an infusion of TILs according to the invention.
  • the population of TILs may be provided wherein a patient is pre-treated with nonmyeloablative chemotherapy prior to an infusion of TILs according to the present invention.
  • the non-myeloablative chemotherapy is cyclophosphamide 60 mg/kg/d for 2 days (days 27 and 26 prior to TIL infusion) and fludarabine 25 mg/m2/d for 5 days (days 27 to 23 prior to TIL infusion).
  • the patient receives an intravenous infusion of IL-2 intravenously at 720,000 lU/kg every 8 hours to physiologic tolerance.
  • lymphodepletion prior to adoptive transfer of tumorspecific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system (“cytokine sinks”). Accordingly, some embodiments of the invention utilize a lymphodepletion step (sometimes also referred to as “immunosuppressive conditioning”) on the patient prior to the introduction of the TILs of the invention.
  • a lymphodepletion step sometimes also referred to as “immunosuppressive conditioning”
  • the term “effective amount” or “therapeutically effective amount” refers to that amount of a compound or combination of compounds as described herein that is sufficient to effect the intended application including, but not limited to, disease treatment.
  • a therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated (e.g., the weight, age and gender of the subject), the severity of the disease condition, or the manner of administration.
  • the term also applies to a dose that will induce a particular response in target cells (e.g., the reduction of platelet adhesion and/or cell migration).
  • the specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether the compound is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which the compound is carried.
  • treatment refers to obtaining a desired pharmacologic and/or physiologic effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.
  • Treatment covers any treatment of a disease in a mammal, particularly in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development or progression; and (c) relieving the disease, i.e., causing regression of the disease and/or relieving one or more disease symptoms.
  • Treatment is also meant to encompass delivery of an agent in order to provide for a pharmacologic effect, even in the absence of a disease or condition.
  • treatment encompasses delivery of a composition that can elicit an immune response or confer immunity in the absence of a disease condition, e.g., in the case of a vaccine.
  • heterologous when used with reference to portions of a nucleic acid or protein indicates that the nucleic acid or protein comprises two or more subsequences that are not found in the same relationship to each other in nature.
  • the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source, or coding regions from different sources.
  • a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).
  • sequence identity refers to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned (introducing gaps, if necessary) for maximum correspondence, not considering any conservative amino acid substitutions as part of the sequence identity.
  • percent identity can be measured using sequence comparison software or algorithms or by visual inspection. Various algorithms and software are known in the art that can be used to obtain alignments of amino acid or nucleotide sequences.
  • Suitable programs to determine percent sequence identity include for example the BLAST suite of programs available from the U.S. Government's National Center for Biotechnology Information BLAST web site. Comparisons between two sequences can be carried using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. ALIGN, ALIGN-2 (Genentech, South San Francisco, California) or MegAlign, available from DNASTAR, are additional publicly available software programs that can be used to align sequences. One skilled in the art can determine appropriate parameters for maximal alignment by particular alignment software. In certain embodiments, the default parameters of the alignment software are used.
  • the term “variant” encompasses but is not limited to antibodies or fusion proteins which comprise an amino acid sequence which differs from the amino acid sequence of a reference antibody by way of one or more substitutions, deletions and/or additions at certain positions within or adjacent to the amino acid sequence of the reference antibody.
  • the variant may comprise one or more conservative substitutions in its amino acid sequence as compared to the amino acid sequence of a reference antibody. Conservative substitutions may involve, e.g., the substitution of similarly charged or uncharged amino acids.
  • the variant retains the ability to specifically bind to the antigen of the reference antibody.
  • the term variant also includes pegylated antibodies or proteins.
  • TILs tumor infiltrating lymphocytes
  • TILs include, but are not limited to, CD8 + cytotoxic T cells (lymphocytes), Thl and Thl7 CD4 + T cells, natural killer cells, dendritic cells and Ml macrophages.
  • TILs include both primary and secondary TILs.
  • Primary TILs are those that are obtained from patient tissue samples as outlined herein (sometimes referred to as “freshly harvested”), and “secondary TILs” are any TIL cell populations that have been expanded or proliferated as discussed herein, including, but not limited to bulk TILs, expanded TILs (“REP TILs”) as well as “reREP TILs” as discussed herein.
  • reREP TILs can include for example second expansion TILs or second additional expansion TILs (such as, for example, those described in Step D of Figure 8, including TILs referred to as reREP TILs).
  • TILs can generally be defined either biochemically, using cell surface markers, or functionally, by their ability to infiltrate tumors and effect treatment.
  • TILs can be generally categorized by expressing one or more of the following biomarkers: CD4, CD8, TCR aP, CD27, CD28, CD56, CCR7, CD45Ra, CD95, PD-1, and CD25. Additionally, and alternatively, TILs can be functionally defined by their ability to infiltrate solid tumors upon reintroduction into a patient.
  • TILs may further be characterized by potency - for example, TILs may be considered potent if, for example, interferon (IFN) release is greater than about 50 pg/mL, greater than about 100 pg/mL, greater than about 150 pg/mL, or greater than about 200 pg/mL.
  • IFN interferon
  • TILs may be considered potent if, for example, interferon (IFNy) release is greater than about 50 pg/mL, greater than about 100 pg/mL, greater than about 150 pg/mL, or greater than about 200 pg/mL, greater than about 300 pg/mL, greater than about 400 pg/mL, greater than about 500 pg/mL, greater than about 600 pg/mL, greater than about 700 pg/mL, greater than about 800 pg/mL, greater than about 900 pg/mL, greater than about 1000 pg/mL.
  • IFNy interferon
  • deoxyribonucleotide encompasses natural and synthetic, unmodified and modified deoxyribonucleotides. Modifications include changes to the sugar moiety, to the base moiety and/or to the linkages between deoxyribonucleotide in the oligonucleotide.
  • RNA defines a molecule comprising at least one ribonucleotide residue.
  • ribonucleotide defines a nucleotide with a hydroxyl group at the 2' position of a b-D- ribofiiranose moiety.
  • RNA includes double -stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides.
  • Nucleotides of the RNA molecules described herein may also comprise non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally-occurring RNA.
  • pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and inert ingredients.
  • pharmaceutically acceptable carriers or pharmaceutically acceptable excipients for active pharmaceutical ingredients is well known in the art. Except insofar as any conventional pharmaceutically acceptable carrier or pharmaceutically acceptable excipient is incompatible with the active pharmaceutical ingredient, its use in therapeutic compositions of the invention is contemplated. Additional active pharmaceutical ingredients, such as other drugs, can also be incorporated into the described compositions and methods.
  • the terms “about” and “approximately” mean within a statistically meaningful range of a value.
  • Such a range can be within an order of magnitude, preferably within 50%, more preferably within 20%, more preferably still within 10%, and even more preferably within 5% of a given value or range.
  • the allowable variation encompassed by the terms “about” or “approximately” depends on the particular system under study, and can be readily appreciated by one of ordinary skill in the art.
  • the terms “about” and “approximately” mean that dimensions, sizes, formulations, parameters, shapes and other quantities and characteristics are not and need not be exact, but may be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art.
  • a dimension, size, formulation, parameter, shape or other quantity or characteristic is “about” or “approximate” whether or not expressly stated to be such. It is noted that embodiments of very different sizes, shapes and dimensions may employ the described arrangements.
  • compositions, methods, and kits described herein that embody the present invention can, in alternate embodiments, be more specifically defined by any of the transitional terms “comprising,” “consisting essentially of,” and “consisting of.”
  • antibody and its plural form “antibodies” refer to whole immunoglobulins and any antigen-binding fragment (“antigen-binding portion”) or single chains thereof.
  • An “antibody” further refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, or an antigen-binding portion thereof.
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three domains, CHI, CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region.
  • the light chain constant region is comprised of one domain, CL.
  • the VH and VL regions of an antibody may be further subdivided into regions of hypervariability, which are referred to as complementarity determining regions (CDR) or hypervariable regions (HVR), and which can be interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • HVR hypervariable regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen epitope or epitopes.
  • the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq
  • an antigen refers to a substance that induces an immune response.
  • an antigen is a molecule capable of being bound by an antibody or a TCR if presented by major histocompatibility complex (MHC) molecules.
  • MHC major histocompatibility complex
  • the term “antigen”, as used herein, also encompasses T cell epitopes.
  • An antigen is additionally capable of being recognized by the immune system.
  • an antigen is capable of inducing a humoral immune response or a cellular immune response leading to the activation of B lymphocytes and/or T lymphocytes. In some cases, this may require that the antigen contains or is linked to a Th cell epitope.
  • An antigen can also have one or more epitopes (e.g., B- and T-epitopes).
  • an antigen will preferably react, typically in a highly specific and selective manner, with its corresponding antibody or TCR and not with the multitude of other antibodies or TCRs which may be induced by other antigens.
  • the terms “monoclonal antibody,” “mAb,” “monoclonal antibody composition,” or their plural forms refer to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
  • Monoclonal antibodies specific to certain receptors can be made using knowledge and skill in the art of injecting test subjects with suitable antigen and then isolating hybridomas expressing antibodies having the desired sequence or functional characteristics.
  • DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below.
  • antigen-binding portion or “antigen-binding fragment” of an antibody (or simply “antibody portion” or “fragment”), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigenbinding function of an antibody can be performed by fragments of a full-length antibody.
  • binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V L , VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a domain antibody (dAb) fragment (Ward, et al., Nature, 1989, 341, 544-546), which may consist of a VH or a VL domain; and (vi) an isolated complementarity determining region (CDR).
  • a Fab fragment a monovalent fragment consisting of the V L , VH, CL and CHI domains
  • a F(ab')2 fragment a bivalent fragment
  • the two domains of the Fv fragment, VL and VH are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules known as single chain Fv (scFv); see, e.g., Bird, et al., Science 1988, 242, 423-426; and Huston, et al., Proc. Natl. Acad. Sci. USA 1988, 85, 5879-5883).
  • scFv antibodies are also intended to be encompassed within the terms “antigen-binding portion” or “antigen-binding fragment” of an antibody.
  • a scFv protein domain comprises a VH portion and a VL portion.
  • a scFv molecule is denoted as either VL-L-VH if the VL domain is the N- terminal part of the scFv molecule, or as VH-L-VL if the VH domain is the N-terminal part of the scFv molecule.
  • human antibody is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • human antibody is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • human monoclonal antibody refers to antibodies displaying a single binding specificity which have variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences.
  • the human monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.
  • recombinant human antibody includes all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (such as a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described further below), (b) antibodies isolated from a host cell transformed to express the human antibody, e.g. , from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial human antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences.
  • Such recombinant human antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences.
  • such recombinant human antibodies can be subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • isotype refers to the antibody class (e.g., IgM or IgGl) that is encoded by the heavy chain constant region genes.
  • an antibody recognizing an antigen and “an antibody specific for an antigen” are used interchangeably herein with the term “an antibody which binds specifically to an antigen.”
  • human antibody derivatives refers to any modified form of the human antibody, including a conjugate of the antibody and another active pharmaceutical ingredient or antibody.
  • conjugate refers to an antibody, or a fragment thereof, conjugated to another therapeutic moiety, which can be conjugated to antibodies described herein using methods available in the art.
  • humanized antibody “humanized antibodies,” and “humanized” are intended to refer to antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. Additional framework region modifications may be made within the human framework sequences.
  • Humanized forms of nonhuman (for example, murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a 15 hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
  • the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • the antibodies described herein may also be modified to employ any Fc variant which is known to impart an improvement (e.g., reduction) in effector function and/or FcR binding.
  • the Fc variants may include, for example, any one of the amino acid substitutions disclosed in International Patent Application Publication Nos.
  • chimeric antibody is intended to refer to antibodies in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as an antibody in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody.
  • a “diabody” is a small antibody fragment with two antigen-binding sites.
  • the fragments comprises a heavy chain variable domain (V H ) connected to a light chain variable domain (V L ) in the same polypeptide chain (VH-VL or VL-VH).
  • V H heavy chain variable domain
  • V L light chain variable domain
  • V H-VL or VL-VH polypeptide chain
  • linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.
  • Diabodies are described more fully in, e.g., European Patent No. EP 404,097, International Patent Publication No. WO 93/11161; and Bolliger, et al., Proc. Natl. Acad. Sci. USA 1993, 90, 6444-6448.
  • glycosylation refers to a modified derivative of an antibody.
  • An aglycoslated antibody lacks glycosylation.
  • Glycosylation can be altered to, for example, increase the affinity of the antibody for antigen.
  • Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site.
  • Aglycosylation may increase the affinity of the antibody for antigen, as described in U.S. Patent Nos. 5,714,350 and 6,350,861.
  • an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures.
  • altered glycosylation patterns have been demonstrated to increase the ability of antibodies.
  • carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies of the invention to thereby produce an antibody with altered glycosylation.
  • the cell lines Ms704, Ms705, and Ms709 lack the fucosyltransferase gene, FUT8 (alpha (1,6) fucosyltransferase), such that antibodies expressed in the Ms704, Ms705, and Ms709 cell lines lack fucose on their carbohydrates.
  • the Ms704, Ms705, and Ms709 FUT8-/- cell lines were created by the targeted disruption of the FUT8 gene in CHO/DG44 cells using two replacement vectors (see e.g. U.S. Patent Publication No. 2004/0110704 or Yamane-Ohnuki, et al., Biotechnol. Bioeng., 2004, 87, 614-622).
  • EP 1,176,195 describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyl transferase, such that antibodies expressed in such a cell line exhibit hypofucosylation by reducing or eliminating the alpha 1,6 bond-related enzyme, and also describes cell lines which have a low enzyme activity for adding fucose to the N-acetylglucosamine that binds to the Fc region of the antibody or does not have the enzyme activity, for example the rat myeloma cell line YB2/0 (ATCC CRL 1662).
  • WO 99/54342 describes cell lines engineered to express glycoproteinmodifying glycosyl transferases (e.g., beta(l,4)-N-acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures which results in increased ADCC activity of the antibodies (see also Umana, et al., Nat. Biotech.
  • glycoproteinmodifying glycosyl transferases e.g., beta(l,4)-N-acetylglucosaminyltransferase III (GnTIII)
  • the fucose residues of the antibody may be cleaved off using a fucosidase enzyme.
  • the fucosidase alpha-L-fucosidase removes fucosyl residues from antibodies as described in Tarentino, et al., Biochem. 1975, 14, 5516-5523.
  • PEG polyethylene glycol
  • Pegylation refers to a modified antibody, or a fragment thereof, that typically is reacted with polyethylene glycol (PEG), such as a reactive ester or aldehyde derivative of PEG, under conditions in which one or more PEG groups become attached to the antibody or antibody fragment.
  • PEG polyethylene glycol
  • Pegylation may, for example, increase the biological (e.g., serum) half life of the antibody.
  • the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive PEG molecule (or an analogous reactive water-soluble polymer).
  • polyethylene glycol is intended to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (Ci-Cio)alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol- maleimide.
  • the antibody to be pegylated may be an aglycosylated antibody. Methods for pegylation are known in the art and can be applied to the antibodies of the invention, as described for example in European Patent Nos. EP 0154316 and EP 0401384 and U.S. Patent No. 5,824,778, the disclosures of each of which are incorporated by reference herein.
  • biosimilar means a biological product, including a monoclonal antibody or protein, that is highly similar to a U.S. licensed reference biological product notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.
  • a similar biological or “biosimilar” medicine is a biological medicine that is similar to another biological medicine that has already been authorized for use by the European Medicines Agency.
  • biosimilar is also used synonymously by other national and regional regulatory agencies.
  • Biological products or biological medicines are medicines that are made by or derived from a biological source, such as a bacterium or yeast.
  • IL-2 proteins can consist of relatively small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies.
  • aldesleukin PROLEUKIN
  • a protein approved by drug regulatory authorities with reference to aldesleukin is a “biosimilar to” aldesleukin or is a “biosimilar thereof' of aldesleukin.
  • EMA European Medicines Agency
  • a biosimilar as described herein may be similar to the reference medicinal product by way of quality characteristics, biological activity, mechanism of action, safety profiles and/or efficacy.
  • the biosimilar may be used or be intended for use to treat the same conditions as the reference medicinal product.
  • a biosimilar as described herein may be deemed to have similar or highly similar quality characteristics to a reference medicinal product.
  • a biosimilar as described herein may be deemed to have similar or highly similar biological activity to a reference medicinal product.
  • a biosimilar as described herein may be deemed to have a similar or highly similar safety profde to a reference medicinal product.
  • a biosimilar as described herein may be deemed to have similar or highly similar efficacy to a reference medicinal product.
  • a biosimilar in Europe is compared to a reference medicinal product which has been authorized by the EMA.
  • the biosimilar may be compared to a biological medicinal product which has been authorized outside the European Economic Area (a non-EEA authorized “comparator”) in certain studies.
  • biosimilar also relates to a biological medicinal product which has been or may be compared to a non-EEA authorized comparator.
  • Certain biosimilars are proteins such as antibodies, antibody fragments (for example, antigen binding portions) and fusion proteins.
  • a protein biosimilar may have an amino acid sequence that has minor modifications in the amino acid structure (including for example deletions, additions, and/or substitutions of amino acids) which do not significantly affect the function of the polypeptide.
  • the biosimilar may comprise an amino acid sequence having a sequence identity of 97% or greater to the amino acid sequence of its reference medicinal product, e.g., 97%, 98%, 99% or 100%.
  • the biosimilar may comprise one or more post-translational modifications, for example, although not limited to, glycosylation, oxidation, deamidation, and/or truncation which is/are different to the post-translational modifications of the reference medicinal product, provided that the differences do not result in a change in safety and/or efficacy of the medicinal product.
  • the biosimilar may have an identical or different glycosylation pattern to the reference medicinal product. Particularly, although not exclusively, the biosimilar may have a different glycosylation pattern if the differences address or are intended to address safety concerns associated with the reference medicinal product.
  • the biosimilar may deviate from the reference medicinal product in for example its strength, pharmaceutical form, formulation, excipients and/or presentation, providing safety and efficacy of the medicinal product is not compromised.
  • the biosimilar may comprise differences in for example pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles as compared to the reference medicinal product but is still deemed sufficiently similar to the reference medicinal product as to be authorized or considered suitable for authorization.
  • PK pharmacokinetic
  • PD pharmacodynamic
  • the biosimilar exhibits different binding characteristics as compared to the reference medicinal product, wherein the different binding characteristics are considered by a Regulatory Authority such as the EMA not to be a barrier for authorization as a similar biological product.
  • biosimilar is also used synonymously by other national and regional regulatory agencies.
  • Gen 2 TIL Manufacturing Processes [00443] An exemplary family of TIL processes known as Gen 2 (also known as process 2A) containing some of these features is depicted in Figures 1 and 2. An embodiment of Gen 2 is shown in Figure 2.
  • the present invention can include a step relating to the restimulation of cryopreserved TILs to increase their metabolic activity and thus relative health prior to transplant into a patient, and methods of testing said metabolic health.
  • TILs are generally taken from a patient sample and manipulated to expand their number prior to transplant into a patient.
  • the TILs may be optionally genetically manipulated as discussed below.
  • the TILs may be cryopreserved. Once thawed, they may also be restimulated to increase their metabolism prior to infusion into a patient.
  • the first expansion (including processes referred to as the preREP as well as processes shown in Figure 1 as Step A) is shortened to 3 to 14 days and the second expansion (including processes referred to as the REP as well as processes shown in Figure 1 as Step B) is shorted to 7 to 14 days, as discussed in detail below as well as in the examples and figures.
  • the first expansion (for example, an expansion described as Step B in Figure 1) is shortened to 11 days and the second expansion (for example, an expansion as described in Step D in Figure 1) is shortened to 11 days.
  • the combination of the first expansion and second expansion (for example, expansions described as Step B and Step D in Figure 1) is shortened to 22 days, as discussed in detail below and in the examples and figures.
  • Steps A, B, C, etc., below are in reference to Figure 1 and in reference to certain embodiments described herein.
  • the ordering of the Steps below and in Figure 1 is exemplary and any combination or order of steps, as well as additional steps, repetition of steps, and/or omission of steps is contemplated by the present application and the methods disclosed herein.
  • TILs are initially obtained from a patient tumor sample and then expanded into a larger population for further manipulation as described herein, optionally cryopreserved, restimulated as outlined herein and optionally evaluated for phenotype and metabolic parameters as an indication of TIL health.
  • a patient tumor sample may be obtained using methods known in the art, generally via surgical resection, needle biopsy, core biopsy, small biopsy, or other means for obtaining a sample that contains a mixture of tumor and TIL cells.
  • multilesional sampling is used.
  • surgical resection, needle biopsy, core biopsy, small biopsy, or other means for obtaining a sample that contains a mixture of tumor and TIL cells includes multilesional sampling (i.e., obtaining samples from one or more tumor sites and/or locations in the patient, as well as one or more tumors in the same location or in close proximity).
  • the tumor sample may be from any solid tumor, including primary tumors, invasive tumors or metastatic tumors.
  • the tumor sample may also be a liquid tumor, such as a tumor obtained from a hematological malignancy.
  • the solid tumor may be of lung tissue.
  • useful TILs are obtained from non-small cell lung carcinoma (NSCLC).
  • NSCLC non-small cell lung carcinoma
  • the solid tumor may be of skin tissue.
  • useful TILs are obtained from a melanoma.
  • the tumor sample is generally fragmented using sharp dissection into small pieces of between 1 to about 8 mm 3 , with from about 2-3 mm 3 being particularly useful.
  • the TILs are cultured from these fragments using enzymatic tumor digests.
  • Such tumor digests may be produced by incubation in enzymatic media (e.g., Roswell Park Memorial Institute (RPMI) 1640 buffer, 2 mM glutamate, 10 mcg/mL gentamicine, 30 units/mL of DNase and 1.0 mg/mL of collagenase) followed by mechanical dissociation (e.g., using a tissue dissociator).
  • enzymatic media e.g., Roswell Park Memorial Institute (RPMI) 1640 buffer, 2 mM glutamate, 10 mcg/mL gentamicine, 30 units/mL of DNase and 1.0 mg/mL of collagenase
  • Tumor digests may be produced by placing the tumor in enzymatic media and mechanically dissociating the tumor for approximately 1 minute, followed by incubation for 30 minutes at 37 °C in 5% CO2, followed by repeated cycles of mechanical dissociation and incubation under the foregoing conditions until only small tissue pieces are present.
  • a density gradient separation using FICOLL branched hydrophilic polysaccharide may be performed to remove these cells.
  • Alternative methods known in the art may be used, such as those described in U.S. Patent Application Publication No. 2012/0244133 Al, the disclosure of which is incorporated by reference herein. Any of the foregoing methods may be used in any of the embodiments described herein for methods of expanding TILs or methods treating a cancer.
  • Tumor dissociating enzyme mixtures can include one or more dissociating (digesting) enzymes such as, but not limited to, collagenase (including any blend or type of collagenase), AccutaseTM, AccumaxTM, hyaluronidase, neutral protease (dispase), chymotrypsin, chymopapain, trypsin, caseinase, elastase, papain, protease type XIV (pronase), deoxyribonuclease I (DNase), trypsin inhibitor, any other dissociating or proteolytic enzyme, and any combination thereof.
  • dissociating (digesting) enzymes such as, but not limited to, collagenase (including any blend or type of collagenase), AccutaseTM, AccumaxTM, hyaluronidase, neutral protease (dispase), chymotrypsin, chymopapain, tryps
  • the dissociating enzymes are reconstituted from lyophilized enzymes.
  • lyophilized enzymes are reconstituted in an amount of sterile buffer such as HBSS.
  • collagenase (such as animal free- type 1 collagenase) is reconstitued in
  • collagenase is reconstituted in 5 mL to 15 mL buffer.
  • the collagenase stock ranges from about 100 PZ U/mL-about 400 PZ U/mL, e.g., about 100 PZ U/mL-about 400 PZ U/mL, about 100 PZ U/mL-about 350 PZ U/mL, about 100 PZ U/mL-about 300 PZ U/mL, about 150 PZ U/mL-about 400 PZ U/mL, about 100 PZ U/mL, about 150 PZ U/mL, about 150 PZ U/mL, about 200 PZ U/mL, about 210 PZ U/mL, about 220 PZ U/mL, about 230 PZ U/mL, about 240 PZ U/mL, about 250 PZ U/mL, about 260 P
  • neutral protease is reconstituted in 1-ml of sterile HBSS or another buffer.
  • the lyophilized stock enzyme may be at a concentration of 175 DMC U/vial.
  • the neutral protease stock ranges from about 100 DMC/mL-about 400 DMC/mL, e.g., about 100 DMC/mL-about 400 DMC/mL, about 100 DMC/mL-about 350 DMC/mL, about 100 DMC/mL-about 300 DMC/mL, about 150 DMC/mL-about 400 DMC/mL, about 100 DMC/mL, about 110 DMC/mL, about 120 DMC/mL, about 130 DMC/mL, about 140 DMC/mL, about 150 DMC/mL, about 160 DMC/mL, about 170 DMC/mL, about 175 DMC/mL, about 180 DMC/mL, about 190 DMC/mL, about 200 D
  • DNAse I is reconstituted in 1-ml of sterile HBSS or another buffer.
  • the lyophilized stock enzyme was at a concentration of 4 KU/vial.
  • the DNase I stock ranges from about 1 KU/mL-10 KU/mL, e.g., about 1 KU/mL, about 2 KU/mL, about 3 KU/mL, about 4 KU/mL, about 5 KU/mL, about 6 KU/mL, about 7 KU/mL, about 8 KU/mL, about 9 KU/mL, or about 10 KU/mL.
  • the stock of enzymes is variable and the concentrations may need to be determined. In some embodiments, the concentration of the lyophilized stock can be verified. In some embodiments, the final amount of enzyme added to the digest cocktail is adjusted based on the determined stock concentration.
  • the enzyme mixture includes about 10.2-ul of neutral protease (0.36 DMC U/mL), 21.3-ul of collagenase (1.2 PZ/mL) and 250-ul of DNAse I (200 U/mL) in about 4.7-ml of sterile HBSS.
  • the TILs are derived from solid tumors.
  • the solid tumors are not fragmented.
  • the solid tumors are not fragmented and are subjected to enzymatic digestion as whole tumors.
  • the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase.
  • the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase for 1-2 hours.
  • the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase for 1-2 hours at 37°C, 5% CO2. In some embodiments, the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase for 1-2 hours at 37°C, 5% CO2 with rotation. In some embodiments, the tumors are digested overnight with constant rotation. In some embodiments, the tumors are digested overnight at 37°C, 5% CO 2 with constant rotation. In some embodiments, the whole tumor is combined with the enzymes to form a tumor digest reaction mixture.
  • the tumor is reconstituted with the lyophilized enzymes in a sterile buffer.
  • the buffer is sterile HBSS.
  • the enzyme mixture comprises collagenase.
  • the collagenase is collagenase IV.
  • the working stock for the collagenase is a 100 mg/mL 10X working stock.
  • the enzyme mixture comprises DNAse.
  • the working stock for the DNAse is a 10,000IU/mL 10X working stock.
  • the enzyme mixture comprises hyaluronidase.
  • the working stock for the hyaluronidase is a 10-mg/mL 10X working stock.
  • the enzyme mixture comprises 10 mg/mL collagenase, 1000 lU/mL DNAse, and 1 mg/mL hyaluronidase.
  • the enzyme mixture comprises 10 mg/mL collagenase, 500 lU/mL DNAse, and 1 mg/mL hyaluronidase.
  • the harvested cell suspension is called a “primary cell population” or a “freshly harvested” cell population.
  • fragmentation includes physical fragmentation, including for example, dissection as well as digestion.
  • the fragmentation is physical fragmentation.
  • the fragmentation is dissection.
  • the fragmentation is by digestion.
  • TILs can be initially cultured from enzymatic tumor digests and tumor fragments obtained from digesting or fragmenting a tumor sample obtained from a patient.
  • the tumor undergoes physical fragmentation after the tumor sample is obtained in, for example, Step A (as provided in Figure 1).
  • the fragmentation occurs before cryopreservation.
  • the fragmentation occurs after cryopreservation.
  • the fragmentation occurs after obtaining the tumor and in the absence of any cryopreservation.
  • the tumor is fragmented and 10, 20, 30, 40 or more fragments or pieces are placed in each container for the first expansion.
  • the tumor is fragmented and 30 or 40 fragments or pieces are placed in each container for the first expansion.
  • the tumor is fragmented and 40 fragments or pieces are placed in each container for the first expansion.
  • the multiple fragments comprise about 4 to about 50 fragments, wherein each fragment has a volume of about 27 mm 3 .
  • the multiple fragments comprise about 30 to about 60 fragments with a total volume of about 1300 mm 3 to about 1500 mm 3 .
  • the multiple fragments comprise about 50 fragments with a total volume of about 1350 mm 3 .
  • the multiple fragments comprise about 50 fragments with a total mass of about 1 gram to about 1.5 grams.
  • the multiple fragments comprise about 4 fragments.
  • the TILs are obtained from tumor fragments.
  • the tumor fragment is obtained by sharp dissection.
  • the tumor fragment is between about 1 mm 3 and 10 mm 3 .
  • the tumor fragment is between about 1 mm 3 and 8 mm 3 .
  • the tumor fragment is about 1 mm 3 .
  • the tumor fragment is about 2 mm 3 .
  • the tumor fragment is about 3 mm 3 .
  • the tumor fragment is about 4 mm 3 .
  • the tumor fragment is about 5 mm 3 .
  • the tumor fragment is about 6 mm 3 .
  • the tumor fragment is about 7 mm 3 .
  • the tumor fragment is about 8 mm 3 . In some embodiments, the tumor fragment is about 9 mm 3 . In some embodiments, the tumor fragment is about 10 mm 3 . In some embodiments, the tumors are 1-4 mm * 1-4 mm * 1-4 mm. In some embodiments, the tumors are 1 mm x 1 mm x 1 mm. In some embodiments, the tumors are 2 mm x 2 mm x 2 mm. In some embodiments, the tumors are 3 mm x 3 mm x 3 mm. In some embodiments, the tumors are 4 mm x 4 mm x 4 mm.
  • the tumors are resected in order to minimize the amount of hemorrhagic, necrotic, and/or fatty tissues on each piece. In some embodiments, the tumors are resected in order to minimize the amount of hemorrhagic tissue on each piece. In some embodiments, the tumors are resected in order to minimize the amount of necrotic tissue on each piece. In some embodiments, the tumors are resected in order to minimize the amount of fatty tissue on each piece.
  • the tumor fragmentation is performed in order to maintain the tumor internal structure. In some embodiments, the tumor fragmentation is performed without preforming a sawing motion with a scalpel.
  • the TILs are obtained from tumor digests. In some embodiments, tumor digests were generated by incubation in enzyme media, for example but not limited to RPMI 1640, 2 mM GlutaMAX, 10 mg/mL gentamicin, 30 U/mL DNase, and 1.0 mg/mL collagenase, followed by mechanical dissociation (GentleMACS, Miltenyi Biotec, Auburn, CA). After placing the tumor in enzyme media, the tumor can be mechanically dissociated for approximately 1 minute.
  • enzyme media for example but not limited to RPMI 1640, 2 mM GlutaMAX, 10 mg/mL gentamicin, 30 U/mL DNase, and 1.0 mg/mL collagenase, followed by mechanical dissociation (GentleMACS, Miltenyi Biotec, Auburn, CA). After placing the tumor
  • the solution can then be incubated for 30 minutes at 37 °C in 5% CO2 and it then mechanically disrupted again for approximately 1 minute. After being incubated again for 30 minutes at 37 °C in 5% CO2, the tumor can be mechanically disrupted a third time for approximately 1 minute.
  • 1 or 2 additional mechanical dissociations were applied to the sample, with or without 30 additional minutes of incubation at 37 °C in 5% CO2.
  • a density gradient separation using Ficoll can be performed to remove these cells.
  • the harvested cell suspension prior to the first expansion step is called a “primary cell population” or a “freshly harvested” cell population.
  • cells can be optionally frozen after sample harvest and stored frozen prior to entry into the expansion described in Step B, which is described in further detail below, as well as exemplified in Figure 1, as well as Figure 8.
  • the sample is a pleural fluid sample.
  • the source of the T-cells or TILs for expansion according to the processes described herein is a pleural fluid sample.
  • the sample is a pleural effusion derived sample.
  • the source of the T-cells or TILs for expansion according to the processes described herein is a pleural effusion derived sample. See, for example, methods described in U.S. Patent Publication US 2014/0295426, incorporated herein by reference in its entirety for all purposes.
  • any pleural fluid or pleural effusion suspected of and/or containing TILs can be employed.
  • a sample may be derived from a primary or metastatic lung cancer, such as NSCLC or SCLC.
  • the sample may be secondary metastatic cancer cells which originated from another organ, e.g., breast, ovary, colon or prostate.
  • the sample for use in the expansion methods described herein is a pleural exudate.
  • the sample for use in the expansion methods described herein is a pleural transudate.
  • Other biological samples may include other serous fluids containing TILs, including, e.g., ascites fluid from the abdomen or pancreatic cyst fluid.
  • the pleural fluid is in unprocessed form, directly as removed from the patient.
  • the unprocessed pleural fluid is placed in a standard blood collection tube, such as an EDTA or Heparin tube, prior to the contacting step.
  • the unprocessed pleural fluid is placed in a standard CellSave® tube (Veridex) prior to the contacting step.
  • the sample is placed in the CellSave tube immediately after collection from the patient to avoid a decrease in the number of viable TILs.
  • the number of viable TILs can decrease to a significant extent within 24 hours, if left in the untreated pleural fluid, even at 4°C.
  • the sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, or up to 24 hours after removal from the patient.
  • the sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, or up to 24 hours after removal from the patient at 4°C.
  • the pleural fluid sample from the chosen subject may be diluted.
  • the dilution is 1: 10 pleural fluid to diluent.
  • the dilution is 1:9 pleural fluid to diluent.
  • the dilution is 1:8 pleural fluid to diluent.
  • the dilution is 1:5 pleural fluid to diluent.
  • the dilution is 1:2 pleural fluid to diluent.
  • the dilution is 1 : 1 pleural fluid to diluent.
  • diluents include saline, phosphate buffered saline, another buffer or a physiologically acceptable diluent.
  • the sample is placed in the CellSave tube immediately after collection from the patient and dilution to avoid a decrease in the viable TILs, which may occur to a significant extent within 24-48 hours, if left in the untreated pleural fluid, even at 4°C.
  • the pleural fluid sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, 24 hours, 36 hours, up to 48 hours after removal from the patient, and dilution.
  • the pleural fluid sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, 24 hours, 36 hours, up to 48 hours after removal from the patient, and dilution at 4°C.
  • pleural fluid samples are concentrated by conventional means prior further processing steps.
  • this pre-treatment of the pleural fluid is preferable in circumstances in which the pleural fluid must be cryopreserved for shipment to a laboratory performing the method or for later analysis (e.g., later than 24-48 hours post-collection).
  • the pleural fluid sample is prepared by centrifuging the pleural fluid sample after its withdrawal from the subject and resuspending the centrifugate or pellet in buffer.
  • the pleural fluid sample is subjected to multiple centrifugations and resuspensions, before it is cryopreserved for transport or later analysis and/or processing.
  • pleural fluid samples are concentrated prior to further processing steps by using a filtration method.
  • the pleural fluid sample used in the contacting step is prepared by filtering the fluid through a filter containing a known and essentially uniform pore size that allows for passage of the pleural fluid through the membrane but retains the tumor cells.
  • the diameter of the pores in the membrane may be at least 4 ⁇ M.
  • the pore diameter may be 5 ⁇ M or more, and in other embodiment, any of 6, 7, 8, 9, or 10 ⁇ M.
  • the cells, including TILs, retained by the membrane may be rinsed off the membrane into a suitable physiologically acceptable buffer. Cells, including TILs, concentrated in this way may then be used in the contacting step of the method.
  • pleural fluid sample (including, for example, the untreated pleural fluid), diluted pleural fluid, or the resuspended cell pellet, is contacted with a lytic reagent that differentially lyses non-nucleated red blood cells present in the sample.
  • a lytic reagent that differentially lyses non-nucleated red blood cells present in the sample.
  • this step is performed prior to further processing steps in circumstances in which the pleural fluid contains substantial numbers of RBCs.
  • Suitable lysing reagents include a single lytic reagent or a lytic reagent and a quench reagent, or a lytic agent, a quench reagent and a fixation reagent.
  • Suitable lytic systems are marketed commercially and include the BD Pharm LyseTM system (Becton Dickenson). Other lytic systems include the VersalyseTM system, the FACSlyseTM system (Becton Dickenson), the ImmunoprepTM system or Erythrolyse II system (Beckman Coulter, Inc.), or an ammonium chloride system.
  • the lytic reagent can vary with the primary requirements being efficient lysis of the red blood cells, and the conservation of the TILs and phenotypic properties of the TILs in the pleural fluid.
  • the lytic systems useful in methods described herein can include a second reagent, e.g., one that quenches or retards the effect of the lytic reagent during the remaining steps of the method, e.g., StabilyseTM reagent (Beckman Coulter, Inc.).
  • a conventional fixation reagent may also be employed depending upon the choice of lytic reagents or the preferred implementation of the method.
  • the pleural fluid sample, unprocessed, diluted or multiply centrifuged or processed as described herein above is cryopreserved at a temperature of about -140°C prior to being further processed and/or expanded as provided herein.
  • the present methods provide for obtaining young TILs, which are capable of increased replication cycles upon administration to a subject/patient and as such may provide additional therapeutic benefits over older TILs (i.e., TILs which have further undergone more rounds of replication prior to administration to a subject/patient).
  • TILs which have further undergone more rounds of replication prior to administration to a subject/patient.
  • the diverse antigen receptors of T and B lymphocytes are produced by somatic recombination of a limited, but large number of gene segments. These gene segments: V (variable), D (diversity), J (joining), and C (constant), determine the binding specificity and downstream applications of immunoglobulins and T-cell receptors (TCRs).
  • the present invention provides a method for generating TILs which exhibit and increase the T-cell repertoire diversity. In some embodiments, the TILs obtained by the present method exhibit an increase in the T-cell repertoire diversity.
  • the TILs obtained by the present method exhibit an increase in the T- cell repertoire diversity as compared to freshly harvested TILs and/or TILs prepared using other methods than those provide herein including for example, methods other than those embodied in Figure 1.
  • the TILs obtained by the present method exhibit an increase in the T- cell repertoire diversity as compared to freshly harvested TILs and/or TILs prepared using methods referred to as process 1C, as exemplified in Figure 5 and/or Figure 6.
  • the TILs obtained in the first expansion exhibit an increase in the T-cell repertoire diversity.
  • the increase in diversity is an increase in the immunoglobulin diversity and/or the T- cell receptor diversity.
  • the diversity is in the immunoglobulin is in the immunoglobulin heavy chain. In some embodiments, the diversity is in the immunoglobulin is in the immunoglobulin light chain. In some embodiments, the diversity is in the T-cell receptor. In some embodiments, the diversity is in one of the T-cell receptors selected from the group consisting of alpha, beta, gamma, and delta receptors. In some embodiments, there is an increase in the expression of T-cell receptor (TCR) alpha and/or beta. In some embodiments, there is an increase in the expression of T-cell receptor (TCR) alpha. In some embodiments, there is an increase in the expression of T-cell receptor (TCR) beta. In some embodiments, there is an increase in the expression of TCRab (z.e., TCR ⁇ / ⁇ ).
  • the resulting cells are cultured in serum containing IL-2 under conditions that favor the growth of TILs over tumor and other cells.
  • the tumor digests are incubated in 2 mL wells in media comprising inactivated human AB serum with 6000 lU/mL of IL-2.
  • This primary cell population is cultured for a period of days, generally from 3 to 14 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • this primary cell population is cultured for a period of 7 to 14 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • this primary cell population is cultured for a period of 10 to 14 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells. In some embodiments, this primary cell population is cultured for a period of about 11 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • expansion of TILs may be performed using an initial bulk TIL expansion step (for example such as those described in Step B of Figure 1, which can include processes referred to as pre-REP) as described below and herein, followed by a second expansion (Step D, including processes referred to as rapid expansion protocol (REP) steps) as described below under Step D and herein, followed by optional cryopreservation, and followed by a second Step D (including processes referred to as restimulation REP steps) as described below and herein.
  • the TILs obtained from this process may be optionally characterized for phenotypic characteristics and metabolic parameters as described herein.
  • each well can be seeded with 1 x 10 6 tumor digest cells or one tumor fragment in 2 mL of complete medium (CM) with IL-2 (6000 lU/mL; Chiron Corp., Emeryville, CA).
  • CM complete medium
  • IL-2 6000 lU/mL
  • the tumor fragment is between about 1 mm 3 and 10 mm 3 .
  • the first expansion culture medium is referred to as “CM”, an abbreviation for culture media.
  • CM for Step B consists of RPMI 1640 with GlutaMAX, supplemented with 10% human AB semm, 25 mM Hepes, and 10 mg/mL gentamicin.
  • G-REX10 Wilson Wolf Manufacturing, New Brighton, MN
  • each flask was loaded with 10-40 x 10 6 viable tumor digest cells or 5-30 tumor fragments in 10-40 mL of CM with IL-2.
  • Both the G-REX10 and 24-well plates were incubated in a humidified incubator at 37°C in 5% CO2 and 5 days after culture initiation, half the media was removed and replaced with fresh CM and IL-2 and after day 5, half the media was changed every 2-3 days.
  • the culture medium used in the expansion processes disclosed herein is a serum-free medium or a defined medium.
  • the serum-free or defined medium comprises a basal cell medium and a serum supplement and/or a serum replacement.
  • the serum-free or defined medium is used to prevent and/or decrease experimental variation due in part to the lot-to-lot variation of serum-containing media.
  • the serum-free or defined medium comprises a basal cell medium and a serum supplement and/or serum replacement.
  • the basal cell medium includes, but is not limited to CTSTM OpTmizerTM T-cell Expansion Basal Medium , CTSTM OpTmizerTM T-Cell Expansion SFM, CTSTM AIM-V Medium, CTSTM AIM-V SFM, LymphoONETM T-Cell Expansion Xeno-Free Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-12, Minimal Essential Medium (aMEM), Glasgow's Minimal Essential Medium (G-MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10, F-12, Minimal
  • the serum supplement or serum replacement includes, but is not limited to one or more of CTSTM OpTmizer T-Cell Expansion Serum Supplement, CTSTM Immune Cell Serum Replacement, one or more albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, one or more antibiotics, and one or more trace elements.
  • the defined medium comprises albumin and one or more ingredients selected from the group consisting of glycine, L- histidine, L-isoleucine, L- methionine, L-phenylalanine, L-proline, L- hydroxyproline, L-serine, L-threonine, L-tryptophan, L- tyrosine, L-valine, thiamine, reduced glutathione, L-ascorbic acid-2 -phosphate, iron saturated transferrin, insulin, and compounds containing the trace element moieties Ag + , Al 3+ , Ba 2+ , Cd 2+ , Co 2+ , Cr 3+ , Ge 4+ , Se 4+ , Br, T, Mn 2+ , P, Si 4+ , V 5+ , Mo 6+ , Ni 2+ , Rb + , Sn 2+ and Zr 4+ .
  • the defined medium further comprises L-glutamine, sodium bicarbonate and/or 2-mer
  • the CTSTMOpTmizerTM T-cell Immune Cell Serum Replacement is used with conventional growth media, including but not limited to CTSTM OpTmizerTM T-cell Expansion Basal Medium, CTSTM OpTmizerTM T-cell Expansion SFM, CTSTM AIM-V Medium, CSTTM AIM-V SFM, LymphoONETM T-Cell Expansion Xeno-Free Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-12, Minimal Essential Medium (aMEM), Glasgow's Minimal Essential Medium (G- MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10, F-12
  • aMEM Minimal Essential Medium
  • the total serum replacement concentration (vo1%) in the serum-free or defined medium is from about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% by volume of the total serum-free or defined medium.
  • the total serum replacement concentration is about 3% of the total volume of the serum-free or defined medium.
  • the total serum replacement concentration is about 5% of the total volume of the serum-free or defined medium.
  • the total serum replacement concentration is about 10% of the total volume of the serum -free or defined medium.
  • the serum -free or defined medium is CTSTM OpTmizerTM T-cell Expansion SFM (ThermoFisher Scientific). Any formulation of CTSTM OpTmizerTM is useful in the present invention.
  • CTSTM OpTmizerTM T-cell Expansion SFM is a combination of IL CTSTM OpTmizerTM T-cell Expansion Basal Medium and 26 mL CTSTM OpTmizerTM T-Cell Expansion Supplement, which are mixed together prior to use.
  • the CTSTM OpTmizerTM T- cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific).
  • SR Immune Cell Serum Replacement
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), along with 2-mercaptoethanol at 55mM. In some embodiments, the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and the final concentration of 2-mercaptoethanol in the media is 55 ⁇ M.
  • SR Immune Cell Serum Replacement
  • the defined medium is CTSTM OpTmizerTM T-cell Expansion SFM (ThermoFisher Scientific). Any formulation of CTSTM OpTmizerTM is useful in the present invention.
  • CTSTM OpTmizerTM T-cell Expansion SFM is a combination of IL CTSTM OpTmizerTM T-cell Expansion Basal Medium and 26 mL CTSTM OpTmizerTM T-Cell Expansion Supplement, which are mixed together prior to use.
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), along with 2-mercaptoethanol at 55mM.
  • the CTSTMOpTmizerTM T- cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2- mercaptoethanol, and 2mM of L-glutamine, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine, and further comprises about 3000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine, and further comprises about 6000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2-mercaptoethanol, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2-mercaptoethanol, and further comprises about 3000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2- mercaptoethanol, and further comprises about 1000 lU/mL to about 6000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and about 2mM glutamine, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and about 2mM glutamine, and further comprises about 3000 lU/mL of IL-2. In some embodiments, the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and about 2mM glutamine, and further comprises about 6000 lU/mL of IL- 2.
  • SR Immune Cell Serum Replacement
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and the final concentration of 2-mercaptoethanol in the media is 55 ⁇ M.
  • SR Immune Cell Serum Replacement
  • the serum-free medium or defined medium is supplemented with glutamine (i.e., GlutaMAX®) at a concentration of from about O.lmM to about lOmM, 0.5mM to about 9mM, ImM to about 8mM, 2mM to about 7mM, 3mM to about 6mM, or 4mM to about 5 mM.
  • glutamine i.e., GlutaMAX®
  • the serum-free medium or defined medium is supplemented with glutamine (i.e., GlutaMAX®) at a concentration of about 2mM.
  • the serum-free medium or defined medium is supplemented with 2- mercaptoethanol at a concentration of from about 5mM to about 150mM, lOmM to about 140mM, 15mM to about 130mM, 20mM to about 120mM, 25mM to about 1 lOmM, 30mM to about 100mM, 35mM to about 95mM, 40mM to about 90mM, 45mM to about 85mM, 50mM to about 80mM, 55mM to about 75mM, 60mM to about 70mM, or about 65mM.
  • the serum-free medium or defined medium is supplemented with 2-mercaptoethanol at a concentration of about 55mM. In some embodiments, the final concentration of 2-mercaptoethanol in the media is 55 ⁇ M.
  • the defined media described in International PCT Publication No. WO/1998/030679, which is herein incorporated by reference, are useful in the present invention.
  • serum-free eukaryotic cell culture media are described.
  • the serum-free, eukaryotic cell culture medium includes a basal cell culture medium supplemented with a serum-free supplement capable of supporting the growth of cells in serum- free culture.
  • the serum-free eukaryotic cell culture medium supplement comprises or is obtained by combining one or more ingredients selected from the group consisting of one or more albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, one or more trace elements, and one or more antibiotics.
  • the defined medium further comprises L ⁇ ghitamine, sodium bicarbonate and/or beta-mercaptoethanol.
  • the defined medium comprises an albumin or an albumin substitute and one or more ingredients selected from group consisting of one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, and one or more trace elements.
  • the defined medium comprises albumin and one or more ingredients selected from the group consisting of glycine, L- histidme, L-isoleucine, L-methionine, L-pbenylalanine, L-proline, L- hydroxyproline, L-serine, L- threonine, L-tryptophan, L-tyrosine, L-valine, thiamine, reduced glutathione, L-ascorbic acid -diphosphate, iron saturated transferrin, insulin, and compounds containing die trace element moieties Ag 4 , Al 3+ , Ba 2+ , Cd 2+ , Co 2+ , Cr 3+ , Ge 4+ , Se 4+ , Br, T, Mn 2+ , P, Si 4 *, V 54 , Mo 6: , Ni 2+ , Rb + , Sn 24 and Zr 44 .
  • the basal cell media is selected from the group consisting of Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-12, Minimal Essential Medium (aMEM), Glasgow's Minimal Essential Medium (G-MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10, F-12
  • aMEM Minimal Essential Medium
  • G-MEM Glasgow's Minimal Essential Medium
  • RPMI growth medium RPMI growth medium
  • Iscove's Modified Dulbecco's Medium Iscove's Modified Dulbecco's Medium.
  • the concentration of glycine in the defined medium is in the range of from about 5-200 mg/L, the concentration of L- histidine is about 5-250 mg/L, the concentration of L- isoleucine is about 5-300 mg/L, the concentration of L-methionine is about 5-200 mg/L, the concentration of L-phenylalanine is about 5-400 mg/L, the concentration of L-proline is about 1-1000 mg/L, the concentration of L- hydroxyproline is about 1-45 mg/L, the concentration of L-serine is about 1-250 mg/L, the concentration of L-threonine is about 10-500 mg/L, the concentration of L- tryptophan is about 2-110 mg/L, the concentration of L-tyrosine is about 3-175 mg/L, the concentration of L-valine is about 5-500 mg/L, the concentration of thiamine is about 1-20 mg/L, the concentration of reduced glutathione is about 1-20 mg/L, the concentration of L-as
  • the non-trace element moiety ingredients in the defined medium are present in the concentration ranges listed in the column under the heading “Concentration Range in IX Medium” in Table 4. In other embodiments, the non-trace element moiety ingredients in the defined medium are present in the final concentrations listed in the column under the heading “A Preferred Embodiment of the IX Medium” in Table 4.
  • the defined medium is a basal cell medium comprising a serum free supplement. In some of these embodiments, the serum free supplement comprises non-trace moiety ingredients of the type and in the concentrations listed in the column under the heading “A Preferred Embodiment in Supplement” in Table 4 below.
  • the osmolarity of the defined medium is between about 260 and 350 mOsmol. In some embodiments, the osmolarity is between about 280 and 310 mOsmol. In some embodiments, the defined medium is supplemented with up to about 3.7 g/L, or about 2.2 g/L sodium bicarbonate. The defined medium can be further supplemented with L-glutamine (final concentration of about 2 mM), one or more antibiotics, non-essential amino acids (NEAA; final concentration of about 100 ⁇ M), 2-mercaptoethanol (final concentration of about 100 ⁇ M).
  • the cell medium in the first and/or second gas permeable container is unfiltered.
  • the use of unfiltered cell medium may simplify the procedures necessary to expand the number of cells.
  • the cell medium in the first and/or second gas permeable container lacks beta-mercaptoethanol (BME or ⁇ ME; also known as 2-mercaptoethanol, CAS 60-24- 2).
  • the resulting cells are cultured in serum containing IL-2 under conditions that favor the growth of TILs over tumor and other cells.
  • the tumor digests are incubated in 2 mL wells in media comprising inactivated human AB serum (or, in some cases, as outlined herein, in the presence of an APC cell population) with 6000 lU/mL of IL-2.
  • This primary cell population is cultured for a period of days, generally from 10 to 14 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • the growth media during the first expansion comprises IL-2 or a variant thereof.
  • the IL is recombinant human IL-2 (rhIL-2).
  • the IL-2 stock solution has a specific activity of 20-30x 10 6 lU/mg for a 1 mg vial.
  • the IL-2 stock solution has a specific activity of 20 x 10 6 lU/mg for a 1 mg vial.
  • the IL-2 stock solution has a specific activity of 25 x 10 6 lU/mg for a 1 mg vial.
  • the IL-2 stock solution has a specific activity of 30x 10 6 lU/mg for a 1 mg vial.
  • the IL- 2 stock solution has a final concentration of 4-8 x 10 6 lU/mg of IL-2. In some embodiments, the IL- 2 stock solution has a final concentration of 5-7x 10 6 lU/mg of IL-2. In some embodiments, the IL- 2 stock solution has a final concentration of 6x 10 6 lU/mg of IL-2. In some embodiments, the IL-2 stock solution is prepare as described in Example 5.
  • the first expansion culture media comprises about 10,000 lU/mL of IL-2, about 9,000 lU/mL of IL-2, about 8,000 lU/mL of IL- 2, about 7,000 lU/mL of IL-2, about 6000 lU/mL of IL-2 or about 5,000 lU/mL of IL-2. In some embodiments, the first expansion culture media comprises about 9,000 lU/mL of IL-2 to about 5,000 lU/mL of IL-2. In some embodiments, the first expansion culture media comprises about 8,000 lU/mL of IL-2 to about 6,000 lU/mL of IL-2.
  • the first expansion culture media comprises about 7,000 lU/mL of IL-2 to about 6,000 lU/mL of IL-2. In some embodiments, the first expansion culture media comprises about 6,000 lU/mL of IL-2. In some embodiments, the cell culture medium further comprises IL-2. In some embodiments, the cell culture medium comprises about 3000 lU/mL of IL-2. In some embodiments, the cell culture medium further comprises IL-2. In some embodiments, the cell culture medium comprises about 3000 lU/mL of IL-2.
  • the cell culture medium comprises about 1000 lU/mL, about 1500 lU/mL, about 2000 lU/mL, about 2500 lU/mL, about 3000 lU/mL, about 3500 lU/mL, about 4000 lU/mL, about 4500 lU/mL, about 5000 lU/mL, about 5500 lU/mL, about 6000 lU/mL, about 6500 lU/mL, about 7000 lU/mL, about 7500 lU/mL, or about 8000 lU/mL of IL-2.
  • the cell culture medium comprises between 1000 and 2000 lU/mL, between 2000 and 3000 lU/mL, between 3000 and 4000 lU/mL, between 4000 and 5000 lU/mL, between 5000 and 6000 lU/mL, between 6000 and 7000 lU/mL, between 7000 and 8000 lU/mL, or about 8000 lU/mL of IL-2.
  • first expansion culture media comprises about 500 lU/mL of IL-15, about 400 lU/mL of IL-15, about 300 lU/mL of IL-15, about 200 lU/mL of IL-15, about 180 lU/mL of IL- 15, about 160 lU/mL of IL- 15, about 140 lU/mL of IL- 15, about 120 lU/mL of IL- 15, or about 100 lU/mL of IL-15.
  • the first expansion culture media comprises about 500 lU/mL of IL- 15 to about 100 lU/mL of IL-15.
  • the first expansion culture media comprises about 400 lU/mL of IL- 15 to about 100 lU/mL of IL-15. In some embodiments, the first expansion culture media comprises about 300 lU/mL of IL-15 to about 100 lU/mL of IL-15. In some embodiments, the first expansion culture media comprises about 200 lU/mL of IL-15. In some embodiments, the cell culture medium comprises about 180 lU/mL of IL-15. In some embodiments, the cell culture medium further comprises IL-15. In some embodiments, the cell culture medium comprises about 180 lU/mL of IL-15.
  • first expansion culture media comprises about 20 lU/mL of IL-21, about 15 lU/mL of IL-21, about 12 lU/mL of IL-21, about 10 lU/mL of IL-21, about 5 lU/mL of IL- 21, about 4 lU/mL of IL-21, about 3 lU/mL of IL-21, about 2 lU/mL of IL-21, about 1 lU/mL of IL- 21, or about 0.5 lU/mL of IL-21.
  • the first expansion culture media comprises about 20 lU/mL of IL-21 to about 0.5 lU/mL of IL-21.
  • the first expansion culture media comprises about 15 lU/mL of IL-21 to about 0.5 lU/mL of IL-21. In some embodiments, the first expansion culture media comprises about 12 lU/mL of IL-21 to about 0.5 lU/mL of IL-21. In some embodiments, the first expansion culture media comprises about 10 lU/mL of IL-21 to about 0.5 lU/mL of IL-21. In some embodiments, the first expansion culture media comprises about 5 lU/mL of IL-21 to about 1 lU/mL of IL-21. In some embodiments, the first expansion culture media comprises about 2 lU/mL of IL-21.
  • the cell culture medium comprises about 1 lU/mL of IL-21. In some embodiments, the cell culture medium comprises about 0.5 lU/mL of IL-21. In some embodiments, the cell culture medium further comprises IL-21. In some embodiments, the cell culture medium comprises about 1 lU/mL of IL-21.
  • the cell culture medium comprises an anti-CD3 agonist antibody, e.g., OKT-3 antibody. In some embodiments, the cell culture medium comprises about 30 ng/mL of OKT-3 antibody. In some embodiments, the cell culture medium comprises about 0.1 ng/mL, about 0.5 ng/mL, about 1 ng/mL, about 2.5 ng/mL, about 5 ng/mL, about 7.5 ng/mL, about 10 ng/mL, about 15 ng/mL, about 20 ng/mL, about 25 ng/mL, about 30 ng/mL, about 35 ng/mL, about 40 ng/mL, about 50 ng/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, about 200 ng/mL, about 500 ng/mL, and about 1 pg/mL of OKT-3 antibody.
  • the cell culture medium comprises between 0.1 ng/mL and 1 ng/mL, between 1 ng/mL and 5 ng/mL, between 5 ng/mL and 10 ng/mL, between 10 ng/mL and 20 ng/mL, between 20 ng/mL and 30 ng/mL, between 30 ng/mL and 40 ng/mL, between 40 ng/mL and 50 ng/mL, and between 50 ng/mL and 100 ng/mL of OKT-3 antibody.
  • the cell culture medium does not comprise OKT-3 antibody.
  • the OKT-3 antibody is muromonab. See, for example, Table 1.
  • the cell culture medium comprises one or more TNFRSF agonists in a cell culture medium.
  • the TNFRSF agonist comprises a 4- 1BB agonist.
  • the TNFRSF agonist is a 4- 1BB agonist, and the 4- 1BB agonist is selected from the group consisting of urelumab, utomilumab, EU-101, a fusion protein, and fragments, derivatives, variants, biosimilars, and combinations thereof.
  • the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 0. 1 pg/mL and 100 pg/mL.
  • the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 20 pg/mL and 40 pg/mL.
  • the cell culture medium further comprises IL-2 at an initial concentration of about 3000 lU/mL and OKT-3 antibody at an initial concentration of about 30 ng/mL, and wherein the one or more TNFRSF agonists comprises a 4- 1BB agonist.
  • the first expansion culture medium is referred to as “CM”, an abbreviation for culture media.
  • CM1 culture medium 1
  • CM consists of RPMI 1640 with GlutaMAX, supplemented with 10% human AB serum, 25 mM Hepes, and 10 mg/mL gentamicin.
  • each flask was loaded with 10-40x10 6 viable tumor digest cells or 5-30 tumor fragments in 10-40mL of CM with IL-2.
  • Both the G-REX10 and 24-well plates were incubated in a humidified incubator at 37°C in 5% CO2 and 5 days after culture initiation, half the media was removed and replaced with fresh CM and IL-2 and after day 5, half the media was changed every 2-3 days.
  • the CM is the CM1 described in the Examples, see, Example 1.
  • the first expansion occurs in an initial cell culture medium or a first cell culture medium.
  • the initial cell culture medium or the first cell culture medium comprises IL-2.
  • the first expansion (including processes such as for example those described in Step B of Figure 1, which can include those sometimes referred to as the pre-REP) process is shortened to 3-14 days, as discussed in the examples and figures.
  • the first expansion (including processes such as for example those described in Step B of Figure 1, which can include those sometimes referred to as the pre-REP) is shortened to 7 to 14 days, as discussed in the Examples and shown in Figures 4 and 5, as well as including for example, an expansion as described in Step B of Figure 1.
  • the first expansion of Step B is shortened to 10-14 days.
  • the first expansion is shortened to 11 days, as discussed in, for example, an expansion as described in Step B of Figure 1.
  • the first TIL expansion can proceed for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days. In some embodiments, the first TIL expansion can proceed for 1 day to 14 days. In some embodiments, the first TIL expansion can proceed for 2 days to 14 days. In some embodiments, the first TIL expansion can proceed for 3 days to 14 days. In some embodiments, the first TIL expansion can proceed for 4 days to 14 days. In some embodiments, the first TIL expansion can proceed for 5 days to 14 days. In some embodiments, the first TIL expansion can proceed for 6 days to 14 days.
  • the first TIL expansion can proceed for 7 days to 14 days. In some embodiments, the first TIL expansion can proceed for 8 days to 14 days. In some embodiments, the first TIL expansion can proceed for 9 days to 14 days. In some embodiments, the first TIL expansion can proceed for 10 days to 14 days. In some embodiments, the first TIL expansion can proceed for 11 days to 14 days. In some embodiments, the first TIL expansion can proceed for 12 days to 14 days. In some embodiments, the first TIL expansion can proceed for 13 days to 14 days. In some embodiments, the first TIL expansion can proceed for 14 days. In some embodiments, the first TIL expansion can proceed for 1 day to 11 days. In some embodiments, the first TIL expansion can proceed for 2 days to 11 days.
  • the first TIL expansion can proceed for 3 days to 11 days. In some embodiments, the first TIL expansion can proceed for 4 days to 11 days. In some embodiments, the first TIL expansion can proceed for 5 days to 11 days. In some embodiments, the first TIL expansion can proceed for 6 days to 11 days. In some embodiments, the first TIL expansion can proceed for 7 days to 11 days. In some embodiments, the first TIL expansion can proceed for 8 days to 11 days. In some embodiments, the first TIL expansion can proceed for 9 days to 11 days. In some embodiments, the first TIL expansion can proceed for 10 days to 11 days. In some embodiments, the first TIL expansion can proceed for 11 days.
  • a combination of IL-2, IL-7, IL- 15, and/or IL-21 are employed as a combination during the first expansion.
  • IL-2, IL-7, IL-15, and/or IL-21 as well as any combinations thereof can be included during the first expansion, including for example during a Step B processes according to Figure 1, as well as described herein.
  • a combination of IL-2, IL-15, and IL-21 are employed as a combination during the first expansion.
  • IL-2, IL- 15, and IL-21 as well as any combinations thereof can be included during Step B processes according to Figure 1 and as described herein.
  • the first expansion (including processes referred to as the pre-REP; for example, Step B according to Figure 1) process is shortened to 3 to 14 days, as discussed in the examples and figures.
  • the first expansion of Step B is shortened to 7 to 14 days.
  • the first expansion of Step B is shortened to 10 to 14 days.
  • the first expansion is shortened to 11 days.
  • the first expansion is performed in a closed system bioreactor.
  • a closed system is employed for the TIL expansion, as described herein.
  • a single bioreactor is employed.
  • the single bioreactor employed is for example a G-REX-10 or a G-REX-100.
  • the closed system bioreactor is a single bioreactor.
  • the expansion methods described herein generally use culture media with high doses of a cytokine, in particular IL-2, as is known in the art.
  • cytokines for the rapid expansion and or second expansion of TILs is additionally possible, with combinations of two or more of IL-2, IL- 15 and IL-21 as is described in U.S. Patent Application Publication No. US 2017/0107490 Al, the disclosure of which is incorporated by reference herein.
  • possible combinations include IL-2 and IL-15, IL-2 and IL- 21, IL- 15 and IL-21 and IL-2, or IL- 15 and IL-21, with the latter finding particular use in many embodiments.
  • the use of combinations of cytokines specifically favors the generation of lymphocytes, and in particular T-cells as described therein.
  • Step B may also include the addition of OKT-3 antibody or muromonab to the culture media, as described elsewhere herein.
  • Step B may also include the addition of a 4- 1BB agonist to the culture media, as described elsewhere herein.
  • Step B may also include the addition of an OX-40 agonist to the culture media, as described elsewhere herein.
  • additives such as peroxisome proliferator-activated receptor gamma coactivator I-alpha agonists, including proliferator-activated receptor (PPAR)-gamma agonists such as a thiazolidinedione compound, may be used in the culture media during Step B, as described in U.S. Patent Application Publication No. US 2019/0307796 Al, the disclosure of which is incorporated by reference herein.
  • PPAR proliferator-activated receptor
  • the bulk TIL population obtained from the first expansion can be cryopreserved immediately, using the protocols discussed herein below.
  • the TIL population obtained from the first expansion referred to as the second TIL population
  • a second expansion which can include expansions sometimes referred to as REP
  • the first TIL population (sometimes referred to as the bulk TIL population) or the second TIL population (which can in some embodiments include populations referred to as the REP TIL populations) can be subjected to genetic modifications for suitable treatments prior to expansion or after the first expansion and prior to the second expansion.
  • the TILs obtained from the first expansion are stored until phenotyped for selection.
  • the TILs obtained from the first expansion are not stored and proceed directly to the second expansion.
  • the TILs obtained from the first expansion are not cryopreserved after the first expansion and prior to the second expansion.
  • the transition from the first expansion to the second expansion occurs at about 3 days, 4, days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days from when fragmentation occurs.
  • the transition from the first expansion to the second expansion occurs at about 3 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs at about 4 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs at about 4 days to 10 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs at about 7 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs at about 14 days from when fragmentation occurs.
  • the transition from the first expansion to the second expansion occurs at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 1 day to 14 days from when fragmentation occurs. In some embodiments, the first TIL expansion can proceed for 2 days to 14 days. In some embodiments, the transition from the first expansion to the second expansion occurs 3 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 4 days to 14 days from when fragmentation occurs.
  • the transition from the first expansion to the second expansion occurs 5 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 6 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 7 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 8 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 9 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 10 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 11 days to 14 days from when fragmentation occurs.
  • the transition from the first expansion to the second expansion occurs 12 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 13 days to 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 14 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 1 day to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 2 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 3 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 4 days to 11 days from when fragmentation occurs.
  • the transition from the first expansion to the second expansion occurs 5 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 6 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 7 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 8 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 9 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 10 days to 11 days from when fragmentation occurs. In some embodiments, the transition from the first expansion to the second expansion occurs 11 days from when fragmentation occurs.
  • the TILs are not stored after the first expansion and prior to the second expansion, and the TILs proceed directly to the second expansion (for example, in some embodiments, there is no storage during the transition from Step B to Step D as shown in Figure 1).
  • the transition occurs in closed system, as described herein.
  • the TILs from the first expansion, the second population of TILs proceeds directly into the second expansion with no transition period.
  • the transition from the first expansion to the second expansion is performed in a closed system bioreactor.
  • a closed system is employed for the TIL expansion, as described herein.
  • a single bioreactor is employed.
  • the single bioreactor employed is for example a G-REX -10 or a G-REX -100.
  • the closed system bioreactor is a single bioreactor.
  • the TIL cell population is expanded in number after harvest and initial bulk processing for example, after Step A and Step B, and the transition referred to as Step C, as indicated in Figure 1).
  • This further expansion is referred to herein as the second expansion, which can include expansion processes generally referred to in the art as a rapid expansion process (REP; as well as processes as indicated in Step D of Figure 1).
  • the second expansion is generally accomplished using a culture media comprising a number of components, including feeder cells, a cytokine source, and an anti-CD3 antibody, in a gas-permeable container.
  • the second expansion or second TIL expansion (which can include expansions sometimes referred to as REP; as well as processes as indicated in Step D of Figure 1) of TIL can be performed using any TIL flasks or containers known by those of skill in the art.
  • the second TIL expansion can proceed for 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days.
  • the second TIL expansion can proceed for about 7 days to about 14 days.
  • the second TIL expansion can proceed for about 8 days to about 14 days.
  • the second TIL expansion can proceed for about 9 days to about 14 days.
  • the second TIL expansion can proceed for about 10 days to about 14 days.
  • the second TIL expansion can proceed for about 11 days to about 14 days. In some embodiments, the second TIL expansion can proceed for about 12 days to about 14 days. In some embodiments, the second TIL expansion can proceed for about 13 days to about 14 days. In some embodiments, the second TIL expansion can proceed for about 14 days.
  • the second expansion can be performed in a gas permeable container using the methods of the present disclosure (including for example, expansions referred to as REP; as well as processes as indicated in Step D of Figure 1).
  • TILs can be rapidly expanded using non-specific T-cell receptor stimulation in the presence of interleukin-2 (IL-2) or interleukin- 15 (IL- 15).
  • IL-2 interleukin-2
  • IL- 15 interleukin- 15
  • the non-specific T-cell receptor stimulus can include, for example, an anti-CD3 antibody, such as about 30 ng/mL of OKT3, a mouse monoclonal anti-CD3 antibody (commercially available from Ortho-McNeil, Raritan, NJ or Miltenyi Biotech, Auburn, CA) or UHCT-1 (commercially available from BioLegend, San Diego, CA, USA).
  • an anti-CD3 antibody such as about 30 ng/mL of OKT3
  • a mouse monoclonal anti-CD3 antibody commercially available from Ortho-McNeil, Raritan, NJ or Miltenyi Biotech, Auburn, CA
  • UHCT-1 commercially available from BioLegend, San Diego, CA, USA.
  • TILs can be expanded to induce further stimulation of the TILs in vitro by including one or more antigens during the second expansion, including antigenic portions thereof, such as epitope(s), of the cancer, which can be optionally expressed from a vector, such as a human leukocyte antigen A2 (HLA-A2) binding peptide, e.g., 0.3 ⁇ M MART-1 :26- 35 (27 L) or gpl 00:209-217 (210M), optionally in the presence of a T-cell growth factor, such as 300 lU/mL IL-2 or IL-15.
  • HLA-A2 human leukocyte antigen A2
  • TIL may include, e.g., NY-ESO-1, TRP-1, TRP-2, tyrosinase cancer antigen, MAGE-A3, SSX-2, and VEGFR2, or antigenic portions thereof.
  • TIL may also be rapidly expanded by re -stimulation with the same antigen(s) of the cancer pulsed onto HLA- A2 -expressing antigen-presenting cells.
  • the TILs can be further re-stimulated with, e.g., example, irradiated, autologous lymphocytes or with irradiated HLA-A2+ allogeneic lymphocytes and IL-2.
  • the re-stimulation occurs as part of the second expansion.
  • the second expansion occurs in the presence of irradiated, autologous lymphocytes or with irradiated HLA-A2+ allogeneic lymphocytes and IL-2.
  • the cell culture medium further comprises IL-2. In some embodiments, the cell culture medium comprises about 3000 lU/mL of IL-2. In some embodiments, the cell culture medium comprises about 1000 lU/mL, about 1500 lU/mL, about 2000 lU/mL, about 2500 lU/mL, about 3000 lU/mL, about 3500 lU/mL, about 4000 lU/mL, about 4500 lU/mL, about 5000 lU/mL, about 5500 lU/mL, about 6000 lU/mL, about 6500 lU/mL, about 7000 lU/mL, about 7500 lU/mL, or about 8000 lU/mL of IL-2.
  • the cell culture medium comprises between 1000 and 2000 lU/mL, between 2000 and 3000 lU/mL, between 3000 and 4000 lU/mL, between 4000 and 5000 lU/mL, between 5000 and 6000 lU/mL, between 6000 and 7000 lU/mL, between 7000 and 8000 lU/mL, or between 8000 lU/mL of IL-2.
  • the cell culture medium comprises OKT-3 antibody. In some embodiments, the cell culture medium comprises about 30 ng/mL of OKT-3 antibody. In some embodiments, the cell culture medium comprises about 0.1 ng/mL, about 0.5 ng/mL, about 1 ng/mL, about 2.5 ng/mL, about 5 ng/mL, about 7.5 ng/mL, about 10 ng/mL, about 15 ng/mL, about 20 ng/mL, about 25 ng/mL, about 30 ng/mL, about 35 ng/mL, about 40 ng/mL, about 50 ng/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, about 200 ng/mL, about 500 ng/mL, and about 1 pg/mL of OKT-3 antibody.
  • the cell culture medium comprises between 0.1 ng/mL and 1 ng/mL, between 1 ng/mL and 5 ng/mL, between 5 ng/mL and 10 ng/mL, between 10 ng/mL and 20 ng/mL, between 20 ng/mL and 30 ng/mL, between 30 ng/mL and 40 ng/mL, between 40 ng/mL and 50 ng/mL, and between 50 ng/mL and 100 ng/mL of OKT-3 antibody.
  • the cell culture medium does not comprise OKT-3 antibody.
  • the OKT-3 antibody is muromonab.
  • the cell culture medium comprises one or more TNFRSF agonists in a cell culture medium.
  • the TNFRSF agonist comprises a 4-1BB agonist.
  • the TNFRSF agonist is a 4- 1BB agonist, and the 4- 1BB agonist is selected from the group consisting of urelumab, utomilumab, EU-101, a fusion protein, and fragments, derivatives, variants, biosimilars, and combinations thereof.
  • the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 0. 1 pg/mL and 100 pg/mL.
  • the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 20 pg/mL and 40 pg/mL.
  • the cell culture medium further comprises IL-2 at an initial concentration of about 3000 lU/mL and OKT-3 antibody at an initial concentration of about 30 ng/mL, and wherein the one or more TNFRSF agonists comprises a 4- 1BB agonist.
  • a combination of IL-2, IL-7, IL- 15, and/or IL-21 are employed as a combination during the second expansion.
  • IL-2, IL-7, IL-15, and/or IL-21 as well as any combinations thereof can be included during the second expansion, including for example during a Step D processes according to Figure 1, as well as described herein.
  • a combination of IL-2, IL- 15, and IL-21 are employed as a combination during the second expansion.
  • IL-2, IL- 15, and IL-21 as well as any combinations thereof can be included during Step D processes according to Figure 1 and as described herein.
  • the second expansion can be conducted in a supplemented cell culture medium comprising IL-2, OKT-3, antigen-presenting feeder cells, and optionally a TNFRSF agonist.
  • the second expansion occurs in a supplemented cell culture medium.
  • the supplemented cell culture medium comprises IL-2, OKT-3, and antigen- presenting feeder cells.
  • the second cell culture medium comprises IL-2, OKT- 3, and antigen-presenting cells (APCs; also referred to as antigen-presenting feeder cells).
  • the second expansion occurs in a cell culture medium comprising IL-2, OKT-3, and antigen-presenting feeder cells (i.e., antigen presenting cells).
  • the second expansion culture media comprises about 500 lU/mL of IL-15, about 400 lU/mL of IL-15, about 300 lU/mL of IL-15, about 200 lU/mL of IL-15, about 180 lU/mL of IL- 15, about 160 lU/mL of IL- 15, about 140 lU/mL of IL- 15, about 120 lU/mL of IL- 15, or about 100 lU/mL of IL-15.
  • the second expansion culture media comprises about 500 lU/mL of IL- 15 to about 100 lU/mL of IL-15.
  • the second expansion culture media comprises about 400 lU/mL of IL- 15 to about 100 lU/mL of IL-15. In some embodiments, the second expansion culture media comprises about 300 lU/mL of IL- 15 to about 100 lU/mL of IL-15. In some embodiments, the second expansion culture media comprises about 200 lU/mL of IL-15. In some embodiments, the cell culture medium comprises about 180 lU/mL of IL-15. In some embodiments, the cell culture medium further comprises IL-15. In some embodiments, the cell culture medium comprises about 180 lU/mL of IL-15.
  • the second expansion culture media comprises about 20 lU/mL of IL-21, about 15 lU/mL of IL-21, about 12 lU/mL of IL-21, about 10 lU/mL of IL-21, about 5 lU/mL of IL-21, about 4 lU/mL of IL-21, about 3 lU/mL of IL-21, about 2 lU/mL of IL-21, about 1 lU/mL of IL-21, or about 0.5 lU/mL of IL-21.
  • the second expansion culture media comprises about 20 lU/mL of IL-21 to about 0.5 lU/mL of IL-21.
  • the second expansion culture media comprises about 15 lU/mL of IL-21 to about 0.5 lU/mL of IL-21. In some embodiments, the second expansion culture media comprises about 12 lU/mL of IL-21 to about 0.5 lU/mL of IL-21. In some embodiments, the second expansion culture media comprises about 10 lU/mL of IL-21 to about 0.5 lU/mL of IL-21. In some embodiments, the second expansion culture media comprises about 5 lU/mL of IL-21 to about 1 lU/mL of IL-21. In some embodiments, the second expansion culture media comprises about 2 lU/mL of IL-21.
  • the cell culture medium comprises about 1 lU/mL of IL-21. In some embodiments, the cell culture medium comprises about 0.5 lU/mL of IL-21. In some embodiments, the cell culture medium further comprises IL-21. In some embodiments, the cell culture medium comprises about 1 lU/mL of IL-21.
  • the antigen-presenting feeder cells are PBMCs.
  • the ratio of TILs to PBMCs and/or antigen-presenting cells in the rapid expansion and/or the second expansion is about 1 to 25, about 1 to 50, about 1 to 100, about 1 to 125, about 1 to 150, about 1 to 175, about 1 to 200, about 1 to 225, about 1 to 250, about 1 to 275, about 1 to 300, about 1 to 325, about 1 to 350, about 1 to 375, about 1 to 400, or about 1 to 500.
  • the ratio of TILs to PBMCs in the rapid expansion and/or the second expansion is between 1 to 50 and 1 to 300.
  • the ratio of TILs to PBMCs in the rapid expansion and/or the second expansion is between 1 to 100 and 1 to 200.
  • REP and/or the second expansion is performed in flasks with the bulk TILs being mixed with a 100- or 200-fold excess of inactivated feeder cells, 30 mg/mL OKT3 anti-CD3 antibody and 3000 lU/mL IL-2 in 150 mL media.
  • Media replacement is done (generally 2/3 media replacement via respiration with fresh media) until the cells are transferred to an alternative growth chamber.
  • Alternative growth chambers include G-REX flasks and gas permeable containers as more fully discussed below.
  • the second expansion (which can include processes referred to as the REP process) is shortened to 7-14 days, as discussed in the examples and figures. In some embodiments, the second expansion is shortened to 11 days.
  • REP and/or the second expansion may be performed using T-175 flasks and gas permeable bags as previously described (Tran, et al., J. Immunother. 2008, 31, 742-51; Dudley, et al., J. Immunother. 2003, 26, 332-42) or gas permeable cultureware (G-REX flasks).
  • the second expansion (including expansions referred to as rapid expansions) is performed in T-175 flasks, and about 1 x 10 6 TILs suspended in 150 mL of media may be added to each T-175 flask.
  • the TILs may be cultured in a 1 to 1 mixture of CM and AIM-V medium, supplemented with 3000 IU per mL of IL-2 and 30 ng per mL of anti-CD3.
  • the T-175 flasks may be incubated at 37° C in 5% CO2. Half the media may be exchanged on day 5 using 50/50 medium with 3000 IU per mL of IL-2.
  • cells from two T-175 flasks may be combined in a 3 L bag and 300 mL of AIM V with 5% human AB serum and 3000 IU per mL of IL-2 was added to the 300 mL of TIL suspension. The number of cells in each bag was counted every day or two and fresh media was added to keep the cell count between 0.5 and 2.0 x 10 6 cells/mL.
  • the second expansion (which can include expansions referred to as REP, as well as those referred to in Step D of Figure 1) may be performed in 500 mL capacity gas permeable flasks with 100 cm gas-permeable silicon bottoms (G-REX 100, commercially available from Wilson Wolf Manufacturing Corporation, New Brighton, MN, USA), 5 x 10 6 or 10 x 10 6 TIL may be cultured with PBMCs in 400 mL of 50/50 medium, supplemented with 5% human AB serum, 3000 IU per mL of IL-2 and 30 ng per mL of anti-CD3 (OKT3).
  • the G-REX 100 flasks may be incubated at 37°C in 5% CO2.
  • TIL may be removed and placed into centrifuge bottles and centrifuged at 1500 rpm (491 x g) for 10 minutes.
  • the TIL pellets may be resuspended with 150 mL of fresh medium with 5% human AB serum, 3000 IU per mL of IL-2, and added back to the original G-REX 100 flasks.
  • the TIL in each G-REX 100 may be suspended in the 300 mL of media present in each flask and the cell suspension may be divided into 3 100 mL aliquots that may be used to seed 3 G-REX 100 flasks.
  • AIM-V with 5% human AB serum and 3000 IU per mL of IL-2 may be added to each flask.
  • the G-REX 100 flasks may be incubated at 37° C in 5% CO2 and after 4 days 150 mL of AIM-V with 3000 IU per mL of IL-2 may be added to each G-REX 100 flask.
  • the cells may be harvested on day 14 of culture.
  • the second expansion (including expansions referred to as REP) is performed in flasks with the bulk TILs being mixed with a 100- or 200-fold excess of inactivated feeder cells, 30 mg/mL OKT3 anti-CD3 antibody and 3000 lU/mL IL-2 in 150 mL media.
  • media replacement is done until the cells are transferred to an alternative growth chamber.
  • 2/3 of the media is replaced by respiration with fresh media.
  • alternative growth chambers include G-REX flasks and gas permeable containers as more fully discussed below.
  • the second expansion (including expansions referred to as REP) is performed and further comprises a step wherein TILs are selected for superior tumor reactivity.
  • Any selection method known in the art may be used.
  • the methods described in U.S. Patent Application Publication No. 2016/0010058 Al, the disclosures of which are incorporated herein by reference, may be used for selection of TILs for superior tumor reactivity.
  • a cell viability assay can be performed after the second expansion (including expansions referred to as the REP expansion), using standard assays known in the art.
  • a trypan blue exclusion assay can be done on a sample of the bulk TILs, which selectively labels dead cells and allows a viability assessment.
  • TIL samples can be counted and viability determined using a Cellometer K2 automated cell counter (Nexcelom Bioscience, Lawrence, MA).
  • viability is determined according to the standard Cellometer K2 Image Cytometer Automatic Cell Counter protocol.
  • the second expansion (including expansions referred to as REP) of TIL can be performed using T-175 flasks and gas-permeable bags as previously described (Tran, et al., 2008, J Immunother., 31:742-751, and Dudley, et al., 2003, J Immunother. , 26:332-342) or gas- permeable G-REX flasks.
  • the second expansion is performed using flasks.
  • the second expansion is performed using gas-permeable G-REX flasks.
  • the second expansion is performed in T-175 flasks, and about 1 x 10 6 TIL are suspended in about 150 mL of media and this is added to each T-175 flask.
  • the TIL are cultured with irradiated (50 Gy) allogeneic PBMC as “feeder” cells at a ratio of 1 to 100 and the cells were cultured in a 1 to 1 mixture of CM and AIM-V medium (50/50 medium), supplemented with 3000 lU/mL of IL-2 and 30 ng/mL of anti-CD3.
  • the T-175 flasks are incubated at 37°C in 5% CO2.
  • half the media is changed on day 5 using 50/50 medium with 3000 lU/mL of IL-2.
  • cells from 2 T-175 flasks are combined in a 3 L bag and 300 mL of AIM-V with 5% human AB serum and 3000 lU/mL of IL-2 is added to the 300 mL of TIL suspension.
  • the number of cells in each bag can be counted every day or two and fresh media can be added to keep the cell count between about 0.5 and about 2.0 x 10 6 cells/mL.
  • the second expansion (including expansions referred to as REP) are performed in 500 mL capacity flasks with 100 cm 2 gas-permeable silicon bottoms (G-REX 100, Wilson Wolf), about 5 x 10 6 or 10 x 10 6 TIL are cultured with irradiated allogeneic PBMC at a ratio of 1 to 100 in 400 mL of 50/50 medium, supplemented with 3000 lU/mL of IL-2 and 30 ng/ mL of anti-CD3.
  • the G-REX 100 flasks are incubated at 37°C in 5% CO2.
  • TILs are expanded serially in G-REX 100 flasks
  • the TIL in each G-REX 100 are suspended in the 300 mL of media present in each flask and the cell suspension was divided into three 100 mL aliquots that are used to seed 3 G-REX 100 flasks.
  • AIM-V with 5% human AB serum and 3000 lU/mL of IL-2 is added to each flask.
  • the G-REX 100 flasks are incubated at 37°C in 5% CO2 and after 4 days 150 mL of AIM-V with 3000 lU/mL of IL-2 is added to each G-REX 100 flask.
  • the cells are harvested on day 14 of culture.
  • the diverse antigen receptors of T and B lymphocytes are produced by somatic recombination of a limited, but large number of gene segments. These gene segments: V (variable), D (diversity), J (joining), and C (constant), determine the binding specificity and downstream applications of immunoglobulins and T-cell receptors (TCRs).
  • the present invention provides a method for generating TILs which exhibit and increase the T-cell repertoire diversity.
  • the TILs obtained by the present method exhibit an increase in the T-cell repertoire diversity.
  • the TILs obtained in the second expansion exhibit an increase in the T-cell repertoire diversity.
  • the increase in diversity is an increase in the immunoglobulin diversity and/or the T-cell receptor diversity.
  • the diversity is in the immunoglobulin is in the immunoglobulin heavy chain.
  • the diversity is in the immunoglobulin is in the immunoglobulin light chain.
  • the diversity is in the T-cell receptor.
  • the diversity is in one of the T-cell receptors selected from the group consisting of alpha, beta, gamma, and delta receptors.
  • TCR T-cell receptor
  • TCR TCR beta
  • TCRab i.e., TCR ⁇ / ⁇ .
  • the second expansion culture medium (e.g., sometimes referred to as CM2 or the second cell culture medium), comprises IL-2, OKT-3, as well as the antigen- presenting feeder cells (APCs), as discussed in more detail below.
  • the culture medium used in the expansion processes disclosed herein is a serum -free medium or a defined medium.
  • the serum -free or defined medium comprises a basal cell medium and a serum supplement and/or a serum replacement.
  • the serum-free or defined medium is used to prevent and/or decrease experimental variation due in part to the lot-to-lot variation of serum-containing media.
  • the serum-free or defined medium comprises a basal cell medium and a serum supplement and/or serum replacement.
  • the basal cell medium includes, but is not limited to CTSTM OpTmizerTM T-cell Expansion Basal Medium , CTSTM OpTmizerTM T-Cell Expansion SFM, CTSTM AIM-V Medium, CTSTM AIM-V SFM, LymphoONETM T-Cell Expansion Xeno-Free Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-12, Minimal Essential Medium (aMEM), Glasgow's Minimal Essential Medium (G-MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10, F-12
  • aMEM Minimal Essential Medium
  • G-MEM Glasgow's Minimal Essential Medium
  • RPMI growth medium
  • the serum supplement or serum replacement includes, but is not limited to one or more of CTSTM OpTmizer T-Cell Expansion Serum Supplement, CTSTM Immune Cell Serum Replacement, one or more albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, one or more antibiotics, and one or more trace elements.
  • the defined medium comprises albumin and one or more ingredients selected from the group consisting of glycine, L- histidine, L-isoleucine, L- methionine, L-phenylalanine, L-proline, L- hydroxyproline, L-serine, L-threonine, L-tryptophan, L- tyrosine, L-valine, thiamine, reduced glutathione, L-ascorbic acid-2 -phosphate, iron saturated transferrin, insulin, and compounds containing the trace element moieties Ag + , Al 3+ , Ba 2+ , Cd 2+ , Co 2+ , Cr 3+ .
  • the defined medium further comprises L-glutamine, sodium bicarbonate and/or 2-mercaptoethanol.
  • the CTSTMOpTmizerTM T-cell Immune Cell Serum Replacement is used with conventional growth media, including but not limited to CTSTM OpTmizerTM T-cell Expansion Basal Medium, CTSTM OpTmizerTM T-cell Expansion SFM, CTSTM AIM-V Medium, CSTTM AIM-V SFM, LymphoONETM T-Cell Expansion Xeno-Free Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-12, Minimal Essential Medium (aMEM), Glasgow's Minimal Essential Medium (G- MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10, F-12
  • aMEM Minimal Essential Medium
  • the total serum replacement concentration (vo1%) in the serum-free or defined medium is from about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% by volume of the total serum-free or defined medium.
  • the total serum replacement concentration is about 3% of the total volume of the serum -free or defined medium.
  • the total serum replacement concentration is about 5% of the total volume of the serum -free or defined medium.
  • the total serum replacement concentration is about 10% of the total volume of the serum -free or defined medium.
  • the serum -free or defined medium is CTSTM OpTmizerTM T-cell Expansion SFM (ThermoFisher Scientific). Any formulation of CTSTM OpTmizerTM is useful in the present invention.
  • CTSTM OpTmizerTM T-cell Expansion SFM is a combination of IL CTSTM OpTmizerTM T-cell Expansion Basal Medium and 26 mL CTSTM OpTmizerTM T-Cell Expansion Supplement, which are mixed together prior to use.
  • the CTSTM OpTmizerTM T- cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific).
  • SR Immune Cell Serum Replacement
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), along with 2-mercaptoethanol at 55mM. In some embodiments, the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and the final concentration of 2-mercaptoethanol in the media is 55 ⁇ M.
  • SR Immune Cell Serum Replacement
  • the defined medium is CTSTM OpTmizerTM T-cell Expansion SFM (ThermoFisher Scientific). Any formulation of CTSTM OpTmizerTM is useful in the present invention.
  • CTSTM OpTmizerTM T-cell Expansion SFM is a combination of IL CTSTM OpTmizerTM T-cell Expansion Basal Medium and 26 mL CTSTM OpTmizerTM T-Cell Expansion Supplement, which are mixed together prior to use.
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), along with 2-mercaptoethanol at 55mM.
  • the CTSTMOpTmizerTM T- cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2- mercaptoethanol, and 2mM of L-glutamine, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine, and further comprises about 3000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine, and further comprises about 6000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2-mercaptoethanol, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2-mercaptoethanol, and further comprises about 3000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2- mercaptoethanol, and further comprises about 1000 lU/mL to about 6000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and about 2mM glutamine, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and about 2mM glutamine, and further comprises about 3000 lU/mL of IL-2. In some embodiments, the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and about 2mM glutamine, and further comprises about 6000 lU/mL of IL- 2.
  • SR Immune Cell Serum Replacement
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and the final concentration of 2-mercaptoethanol in the media is 55 ⁇ M.
  • SR Immune Cell Serum Replacement
  • the serum-free medium or defined medium is supplemented with glutamine (i.e., GlutaMAX®) at a concentration of from about O.lmM to about lOmM, 0.5mM to about 9mM, ImM to about 8mM, 2mM to about 7mM, 3mM to about 6mM, or 4mM to about 5 mM.
  • glutamine i.e., GlutaMAX®
  • the serum-free medium or defined medium is supplemented with glutamine (i.e., GlutaMAX®) at a concentration of about 2mM.
  • the serum-free medium or defined medium is supplemented with 2- mercaptoethanol at a concentration of from about 5mM to about 150mM, lOmM to about 140mM, 15mM to about 130mM, 20mM to about 120mM, 25mM to about 1 lOmM, 30mM to about 100mM, 35mM to about 95mM, 40mM to about 90mM, 45mM to about 85mM, 50mM to about 80mM, 55mM to about 75mM, 60mM to about 70mM, or about 65mM.
  • the serum-free medium or defined medium is supplemented with 2-mercaptoethanol at a concentration of about 55mM. In some embodiments, the final concentration of 2-mercaptoethanol in the media is 55 ⁇ M.
  • the defined media described in International PCT Publication No. WO/1998/030679, which is herein incorporated by reference, are useful in the present invention.
  • serum-free eukaryotic cell culture media are described.
  • the serum-free, eukaryotic cell culture medium includes a basal cell culture medium supplemented with a serum-free supplement capable of supporting the growth of cells in serum- free culture.
  • the serum-free eukaryotic cell culture medium supplement comprises or is obtained by combining one or more ingredients selected from the group consisting of one or more albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, one or more trace elements, and one or more antibiotics.
  • the defined medium further composes L -glutamine, sodium bicarbonate and/or beta-mercaptoethanol.
  • die defined medium comprises an albumin or an albumin substitute and one or more ingredients selected from group consisting of one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, and one or more trace elements.
  • the defined medium comprises albumin and one or more ingredients selected from the group consisting of glycine, L- bistidine, L-isoleucine, L-methionine, L-phenylalanine, L-proline, L ⁇ hydroxyproline, L-serine, L ⁇ threonine, L-tryptophan.
  • the basal cell media is selected from the group consisting of Dulbecco's Modified Eagle s Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-l 2, Minimal Essential Medium ( ⁇ MEM), Glasgow's Minimal Essential Medium (G-MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle s Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10
  • F-l 2 Minimal Essential Medium
  • ⁇ MEM Minimal Essential Medium
  • G-MEM Glasgow's Minimal Essential Medium
  • RPMI growth medium RPMI growth medium
  • Iscove's Modified Dulbecco's Medium Iscove's Modified Dulbecco's Medium.
  • the concentration of glycine in the defined medium is in the range of from about 5-200 mg/L, the concentration of L- histidine is about 5-250 mg/L, the concentration of L- isoleucine is about 5-300 mg/L, the concentration of L-methionine is about 5-200 mg/L, the concentration of L-phenylalanine is about 5-400 mg/L, the concentration of L-proline is about 1-1000 mg/L, the concentration of L- hydroxyproline is about 1-45 mg/L, the concentration of L-serine is about 1-250 mg/L, the concentration of L-threonine is about 10-500 mg/L, the concentration of L- tryptophan is about 2-110 mg/L, the concentration of L-tyrosine is about 3-175 mg/L, the concentration of L-valine is about 5-500 mg/L, the concentration of thiamine is about 1-20 mg/L, the concentration of reduced glutathione is about 1-20 mg/L, the concentration of L-as
  • the non-trace element moiety ingredients in the defined medium are present in the concentration ranges listed in the column under the heading “Concentration Range in IX Medium” in Table 4. In other embodiments, the non-trace element moiety ingredients in the defined medium are present in the final concentrations listed in the column under the heading “A Preferred Embodiment of the IX Medium” in Table 4. In other embodiments, the defined medium is a basal cell medium comprising a serum free supplement. In some of these embodiments, the serum free supplement comprises non-trace moiety ingredients of the type and in the concentrations listed in the column under the heading “A Preferred Embodiment in Supplement” in Table 4.
  • the osmolarity of the defined medium is between about 260 and 350 mOsmol. In some embodiments, the osmolarity is between about 280 and 310 mOsmol. In some embodiments, the defined medium is supplemented with up to about 3.7 g/L, or about 2.2 g/L sodium bicarbonate. The defined medium can be further supplemented with L-glutamine (final concentration of about 2 mM), one or more antibiotics, non-essential amino acids (NEAA; final concentration of about 100 ⁇ M), 2-mercaptoethanol (final concentration of about 100 ⁇ M).
  • the defined media described in Smith, et al. , Clin Transl Immunology, 4(1) 2015 (doi: 10.1038/cti.2014.31) are useful in the present invention. Briefly, RPMI or CTSTM OpTmizerTM was used as the basal cell medium, and supplemented with either 0, 2%, 5%, or 10% CTSTM Immune Cell Serum Replacement.
  • the cell medium in the first and/or second gas permeable container is unfiltered.
  • the use of unfiltered cell medium may simplify the procedures necessary to expand the number of cells.
  • the cell medium in the first and/or second gas permeable container lacks beta-mercaptoethanol (BME or ⁇ ME; also known as 2-mercaptoethanol, CAS 60-24- 2).
  • the second expansion is performed in a closed system bioreactor.
  • a closed system is employed for the TIL expansion, as described herein.
  • a single bioreactor is employed.
  • the single bioreactor employed is for example a G-REX -10 or a G-REX -100.
  • the closed system bioreactor is a single bioreactor.
  • the step of rapid or second expansion is split into a plurality of steps to achieve a scaling up of the culture by: (a) performing the rapid or second expansion by culturing TILs in a small scale culture in a first container, e.g., a G-REX- 100 MCS container, for a period of about 3 to 7 days, and then (b) effecting the transfer of the TILs in the small scale culture to a second container larger than the first container, e.g. , a G-REX-500-MCS container, and culturing the TILs from the small scale culture in a larger scale culture in the second container for a period of about 4 to 7 days.
  • a first container e.g., a G-REX- 100 MCS container
  • a second container larger than the first container e.g. , a G-REX-500-MCS container
  • the step of rapid or second expansion is split into a plurality of steps to achieve a scaling out of the culture by: (a) performing the rapid or second expansion by culturing TILs in a first small scale culture in a first container, e.g., a G-REX- 100 MCS container, for a period of about 3 to 7 days, and then (b) effecting the transfer and apportioning of the TILs from the first small scale culture into and amongst at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 second containers that are equal in size to the first container, wherein in each second container the portion of the TILs from first small scale culture transferred to such second container is cultured in a second small scale culture for a period of about 4 to 7 days.
  • a first container e.g., a G-REX- 100 MCS container
  • the first small scale TIL culture is apportioned into a plurality of about 2 to 5 subpopulations of TILs.
  • the step of rapid or second expansion is split into a plurality of steps to achieve a scaling out and scaling up of the culture by: (a) performing the rapid or second expansion by culturing TILs in a small scale culture in a first container, e.g., a G-REX-100 MCS container, for a period of about 3 to 7 days, and then (b) effecting the transfer and apportioning of the TILs from the small scale culture into and amongst at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 second containers that are larger in size than the first container, e.g., G-REX- 500MCS containers, wherein in each second container the portion of the TILs from the small scale culture transferred to such second container is cultured in a larger scale culture for a period of about 4 to 7 days.
  • a first container e.g., a G-REX-100 MCS container
  • the step of rapid or second expansion is split into a plurality of steps to achieve a scaling out and scaling up of the culture by: (a) performing the rapid or second expansion by culturing TILs in a small scale culture in a first container, e.g., a G-REX-100 MCS container, for a period of about 5 days, and then (b) effecting the transfer and apportioning of the TILs from the small scale culture into and amongst 2, 3 or 4 second containers that are larger in size than the first container, e.g., G-REX-500 MCS containers, wherein in each second container the portion of the TILs from the small scale culture transferred to such second container is cultured in a larger scale culture for a period of about 6 days.
  • a first container e.g., a G-REX-100 MCS container
  • each second container upon the splitting of the rapid or second expansion, comprises at least 10 8 TILs. In some embodiments, upon the splitting of the rapid or second expansion, each second container comprises at least 10 8 TILs, at least 10 9 TILs, or at least 10 10 TILs. In one exemplary embodiment, each second container comprises at least 10 10 TILs.
  • the first small scale TIL culture is apportioned into a plurality of subpopulations. In some embodiments, the first small scale TIL culture is apportioned into a plurality of about 2 to 5 subpopulations. In some embodiments, the first small scale TIL culture is apportioned into a plurality of about 2, 3, 4, or 5 subpopulations.
  • the plurality of subpopulations comprises a therapeutically effective amount of TILs.
  • one or more subpopulations of TILs are pooled together to produce a therapeutically effective amount of TILs.
  • each subpopulation of TILs comprises a therapeutically effective amount of TILs.
  • the rapid or second expansion is performed for a period of about 3 to 7 days before being split into a plurality of steps. In some embodiments, the splitting of the rapid or second expansion occurs at about day 3, day 4, day 5, day 6, or day 7 after the initiation of the rapid or second expansion.
  • the splitting of the rapid or second expansion occurs at about day 7, day 8, day 9, day 10, day 11, day 12, day 13, day 14, day 15, or day 16 day 17, or day 18 after the initiation of the first expansion (z. e. , pre-REP expansion). In one exemplary embodiment, the splitting of the rapid or second expansion occurs at about day 16 after the initiation of the first expansion.
  • the rapid or second expansion is further performed for a period of about 7 to 11 days after the splitting. In some embodiments, the rapid or second expansion is further performed for a period of about 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, or 11 days after the splitting.
  • the cell culture medium used for the rapid or second expansion before the splitting comprises the same components as the cell culture medium used for the rapid or second expansion after the splitting. In some embodiments, the cell culture medium used for the rapid or second expansion before the splitting comprises different components from the cell culture medium used for the rapid or second expansion after the splitting.
  • the cell culture medium used for the rapid or second expansion before the splitting comprises IL-2, optionally OKT-3 and further optionally APCs. In some embodiments, the cell culture medium used for the rapid or second expansion before the splitting comprises IL-2, OKT-3, and further optionally APCs. In some embodiments, the cell culture medium used for the rapid or second expansion before the splitting comprises IL-2, OKT-3 and APCs.
  • the cell culture medium used for the rapid or second expansion before the splitting is generated by supplementing the cell culture medium in the first expansion with fresh culture medium comprising IL-2, optionally OKT-3 and further optionally APCs. In some embodiments, the cell culture medium used for the rapid or second expansion before the splitting is generated by supplementing the cell culture medium in the first expansion with fresh culture medium comprising IL-2, OKT-3 and APCs. In some embodiments, the cell culture medium used for the rapid or second expansion before the splitting is generated by replacing the cell culture medium in the first expansion with fresh cell culture medium comprising IL-2, optionally OKT-3 and further optionally APCs. In some embodiments, the cell culture medium used for the rapid or second expansion before the splitting is generated by replacing the cell culture medium in the first expansion with fresh cell culture medium comprising IL-2, OKT-3 and APCs.
  • the cell culture medium used for the rapid or second expansion after the splitting comprises IL-2, and optionally OKT-3. In some embodiments, the cell culture medium used for the rapid or second expansion after the splitting comprises IL-2, and OKT-3. In some embodiments, the cell culture medium used for the rapid or second expansion after the splitting is generated by replacing the cell culture medium used for the rapid or second expansion before the splitting with fresh culture medium comprising IL-2 and optionally OKT-3. In some embodiments, the cell culture medium used for the rapid or second expansion after the splitting is generated by replacing the cell culture medium used for the rapid or second expansion before the splitting with fresh culture medium comprising IL-2 and OKT-3.
  • the splitting of the rapid expansion occurs in a closed system.
  • the scaling up of the TIL culture during the rapid or second expansion comprises adding fresh cell culture medium to the TIL culture (also referred to as feeding the TILs).
  • the feeding comprises adding fresh cell culture medium to the TIL culture frequently.
  • the feeding comprises adding fresh cell culture medium to the TIL culture at a regular interval.
  • the fresh cell culture medium is supplied to the TILs via a constant flow.
  • an automated cell expansion system such as Xuri W25 is used for the rapid expansion and feeding.
  • the second expansion procedures described herein require an excess of feeder cells during REP TIL expansion and/or during the second expansion.
  • the feeder cells are peripheral blood mononuclear cells (PBMCs) obtained from standard whole blood units from healthy blood donors.
  • PBMCs are obtained using standard methods such as Ficoll-Paque gradient separation.
  • the allogenic PBMCs are inactivated, either via irradiation or heat treatment, and used in the REP procedures, as described in the examples, which provides an exemplary protocol for evaluating the replication incompetence of irradiate allogeneic PBMCs.
  • PBMCs are considered replication incompetent and accepted for use in the TIL expansion procedures described herein if the total number of viable cells on day 14 is less than the initial viable cell number put into culture on day 0 of the REP and/or day 0 of the second expansion (i.e., the start day of the second expansion).
  • PBMCs are considered replication incompetent and accepted for use in the TIL expansion procedures described herein if the total number of viable cells, cultured in the presence of OKT3 and IL-2, on day 7 and day 14 has not increased from the initial viable cell number put into culture on day 0 of the REP and/or day 0 of the second expansion (z. e. , the start day of the second expansion).
  • the PBMCs are cultured in the presence of 30 ng/mL OKT3 antibody and 3000 lU/mL IL-2.
  • PBMCs are considered replication incompetent and accepted for use in the TIL expansion procedures described herein if the total number of viable cells, cultured in the presence of OKT3 and IL-2, on day 7 and day 14 has not increased from the initial viable cell number put into culture on day 0 of the REP and/or day 0 of the second expansion (z. e. , the start day of the second expansion).
  • the PBMCs are cultured in the presence of 5-60 ng/mL OKT3 antibody and 1000-6000 lU/mL IL-2.
  • the PBMCs are cultured in the presence of 10-50 ng/mL OKT3 antibody and 2000-5000 lU/mL IL-2. In some embodiments, the PBMCs are cultured in the presence of 20-40 ng/mL OKT3 antibody and 2000-4000 lU/mL IL-2. In some embodiments, the PBMCs are cultured in the presence of 25-35 ng/mL OKT3 antibody and 2500-3500 lU/mL IL-2.
  • the antigen-presenting feeder cells are PBMCs. In some embodiments, the antigen-presenting feeder cells are artificial antigen-presenting feeder cells. In some embodiments, the ratio of TILs to antigen-presenting feeder cells in the second expansion is about 1 to 25, about 1 to 50, about 1 to 100, about 1 to 125, about 1 to 150, about 1 to 175, about 1 to 200, about 1 to 225, about 1 to 250, about 1 to 275, about 1 to 300, about 1 to 325, about 1 to 350, about 1 to 375, about 1 to 400, or about 1 to 500. In some embodiments, the ratio of TILs to antigen-presenting feeder cells in the second expansion is between 1 to 50 and 1 to 300. In some embodiments, the ratio of TIL to antigen-presenting feeder cells in the second expansion is between 1 to 100 and 1 to 200.
  • the second expansion procedures described herein require a ratio of about 2.5x10 9 feeder cells to about 100x10 6 TIL. In some embodiments, the second expansion procedures described herein require a ratio of about 2.5x10 9 feeder cells to about 50x10 6 TIL. In yet another embodiment, the second expansion procedures described herein require about 2.5x10 9 feeder cells to about 25x10 6 TIL.
  • the second expansion procedures described herein require an excess of feeder cells during the second expansion.
  • the feeder cells are peripheral blood mononuclear cells (PBMCs) obtained from standard whole blood units from healthy blood donors.
  • PBMCs peripheral blood mononuclear cells
  • the PBMCs are obtained using standard methods such as Ficoll-Paque gradient separation.
  • aAPC artificial antigen-presenting cells are used in place of PBMCs.
  • the allogenic PBMCs are inactivated, either via irradiation or heat treatment, and used in the TIL expansion procedures described herein, including the exemplary procedures described in the figures and examples.
  • artificial antigen presenting cells are used in the second expansion as a replacement for, or in combination with, PBMCs.
  • the expansion methods described herein generally use culture media with high doses of a cytokine, in particular IL-2, as is known in the art.
  • cytokines for the rapid expansion and or second expansion of TILs is additionally possible, with combinations of two or more of IL-2, IL- 15 and IL- 21 as is described in U.S. Patent Application US 2017/0107490 Al, the disclosure of which is incorporated by reference herein.
  • possible combinations include IL-2 and IL-15, IL-2 and IL- 21, IL- 15 and IL-21 and IL-2, IL- 15 and IL-21, with the latter finding particular use in many embodiments.
  • the use of combinations of cytokines specifically favors the generation of lymphocytes, and in particular T-cells as described therein.
  • Step D may also include the addition of OKT-3 antibody or muromonab to the culture media, as described elsewhere herein.
  • Step D may also include the addition of a 4-1BB agonist to the culture media, as described elsewhere herein.
  • Step D may also include the addition of an OX-40 agonist to the culture media, as described elsewhere herein.
  • additives such as peroxisome proliferator-activated receptor gamma coactivator I-alpha agonists, including proliferator-activated receptor (PPAR)-gamma agonists such as a thiazolidinedione compound, may be used in the culture media during Step D, as described in U.S. Patent Application Publication No. US 2019/0307796 Al, the disclosure of which is incorporated by reference herein.
  • TILs can be harvested.
  • the TILs are harvested after one, two, three, four or more expansion steps, for example as provided in Figure 1 .
  • the TILs are harvested after two expansion steps, for example as provided in Figure 1.
  • TILs can be harvested in any appropriate and sterile manner, including for example by centrifugation. Methods for TIL harvesting are well known in the art and any such know methods can be employed with the present process. In some embodiments, TILs are harvested using an automated system.
  • Cell harvesters and/or cell processing systems are commercially available from a variety of sources, including, for example, Fresenius Kabi, Tomtec Life Science, Perkin Elmer, and Inotech Biosystems International, Inc. Any cell based harvester can be employed with the present methods.
  • the cell harvester and/or cell processing systems is a membrane-based cell harvester.
  • cell harvesting is via a cell processing system, such as the LOVO system (manufactured by Fresenius Kabi).
  • LOVO cell processing system also refers to any instrument or device manufactured by any vendor that can pump a solution comprising cells through a membrane or filter such as a spinning membrane or spinning filter in a sterile and/or closed system environment, allowing for continuous flow and cell processing to remove supernatant or cell culture media without pelletization.
  • the cell harvester and/or cell processing system can perform cell separation, washing, fluid-exchange, concentration, and/or other cell processing steps in a closed, sterile system.
  • the harvest for example, Step E according to Figure 1, is performed from a closed system bioreactor.
  • a closed system is employed for the TIL expansion, as described herein.
  • a single bioreactor is employed.
  • the single bioreactor employed is for example a G-REX -10 or a G-REX -100.
  • the closed system bioreactor is a single bioreactor.
  • Step E according to Figure 1 is performed according to the processes described herein.
  • the closed system is accessed via syringes under sterile conditions in order to maintain the sterility and closed nature of the system.
  • a closed system as described in the Examples is employed.
  • TILs are harvested according to the methods described in the Examples.
  • TILs between days 1 and 11 are harvested using the methods as described in the steps referred herein, such as in the day 11 TIL harvest in the Examples.
  • TILs between days 12 and 24 are harvested using the methods as described in the steps referred herein, such as in the Day 22 TIL harvest in the Examples.
  • TILs between days 12 and 22 are harvested using the methods as described in the steps referred herein, such as in the Day 22 TIL harvest in the Examples.
  • Steps A through E as provided in an exemplary order in Figure 1 and as outlined in detailed above and herein are complete, cells are transferred to a container for use in administration to a patient, such as an infusion bag or sterile vial.
  • a container for use in administration to a patient such as an infusion bag or sterile vial.
  • TILs expanded using APCs of the present disclosure are administered to a patient as a pharmaceutical composition.
  • the pharmaceutical composition is a suspension of TILs in a sterile buffer.
  • TILs expanded using PBMCs of the present disclosure may be administered by any suitable route as known in the art.
  • the T-cells are administered as a single intra-arterial or intravenous infusion, which preferably lasts approximately 30 to 60 minutes.
  • Other suitable routes of administration include intraperitoneal, intrathecal, and intralymphatic administration.
  • the priming first expansion that primes an activation of T cells followed by the rapid second expansion that boosts the activation of T cells as described in the methods of the invention allows the preparation of expanded T cells that retain a “younger” phenotype, and as such the expanded T cells of the invention are expected to exhibit greater cytotoxicity against cancer cells than T cells expanded by other methods.
  • an activation of T cells that is primed by exposure to an anti-CD3 antibody e.g. OKT-3
  • IL-2 IL-2
  • APCs optionally antigen-presenting cells
  • the step of rapid second expansion is split into a plurality of steps to achieve a scaling up of the culture by: (a) performing the rapid second expansion by culturing T cells in a small scale culture in a first container, e.g., a G-REX 100MCS container, for a period of about 3 to 4 days, and then (b) effecting the transfer of the T cells in the small scale culture to a second container larger than the first container, e.g.
  • the step of rapid expansion is split into a plurality of steps to achieve a scaling out of the culture by: (a) performing the rapid second expansion by culturing T cells in a first small scale culture in a first container, e.g., a G-REX 100MCS container, for a period of about 3 to 4 days, and then (b) effecting the transfer and apportioning of the T cells from the first small scale culture into and amongst at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 second containers that are equal in size to the first container, wherein in each second container the portion of the T cells from first small scale culture transferred to such second container is cultured in a second small scale culture for a period of about 4 to 7 days.
  • the step of rapid expansion is split into a plurality of steps to achieve a scaling out and scaling up of the culture by: (a) performing the rapid second expansion by culturing T cells in a small scale culture in a first container, e.g., a G-REX 100MCS container, for a period of about 3 to 4 days, and then (b) effecting the transfer and apportioning of the T cells from the small scale culture into and amongst at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 second containers that are larger in size than the first container, e.g., G-REX 500MCS containers, wherein in each second container the portion of the T cells from the small scale culture transferred to such second container is cultured in a larger scale culture for a period of about 4 to 7 days.
  • a first container e.g., a G-REX 100MCS container
  • the step of rapid expansion is split into a plurality of steps to achieve a scaling out and scaling up of the culture by: (a) performing the rapid second expansion by culturing T cells in a small scale culture in a first container, e.g., a G-REX 100MCS container, for a period of about 4 days, and then (b) effecting the transfer and apportioning of the T cells from the small scale culture into and amongst 2, 3 or 4 second containers that are larger in size than the first container, e.g., G-REX 500MCS containers, wherein in each second container the portion of the T cells from the small scale culture transferred to such second container is cultured in a larger scale culture for a period of about 5 days.
  • a first container e.g., a G-REX 100MCS container
  • each second container upon the splitting of the rapid expansion, comprises at least 10 8 TILs. In some embodiments, upon the splitting of the rapid expansion, each second container comprises at least 10 8 TILs, at least 10 9 TILs, or at least 10 10 TILs. In one exemplary embodiment, each second container comprises at least 10 10 TILs.
  • the first small scale TIL culture is apportioned into a plurality of subpopulations. In some embodiments, the first small scale TIL culture is apportioned into a plurality of about 2 to 5 subpopulations. In some embodiments, the first small scale TIL culture is apportioned into a plurality of about 2, 3, 4, or 5 subpopulations.
  • the plurality of subpopulations comprises a therapeutically effective amount of TILs.
  • one or more subpopulations of TILs are pooled together to produce a therapeutically effective amount of TILs.
  • each subpopulation of TILs comprises a therapeutically effective amount of TILs.
  • the rapid expansion is performed for a period of about 1 to 5 days before being split into a plurality of steps.
  • the splitting of the rapid expansion occurs at about day 1, day 2, day 3, day 4, or day 5 after the initiation of the rapid expansion.
  • the splitting of the rapid expansion occurs at about day 8, day 9, day 10, day 11, day 12, or day 13 after the initiation of the first expansion (i.e., pre-REP expansion).
  • the splitting of the rapid expansion occurs at about day 10 after the initiation of the priming first expansion.
  • the splitting of the rapid expansion occurs at about day 11 after the initiation of the priming first expansion.
  • the rapid expansion is further performed for a period of about 4 to 11 days after the splitting. In some embodiments, the rapid expansion is further performed for a period of about 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, or 11 days after the splitting.
  • the cell culture medium used for the rapid expansion before the splitting comprises the same components as the cell culture medium used for the rapid expansion after the splitting. In some embodiments, the cell culture medium used for the rapid expansion before the splitting comprises different components from the cell culture medium used for the rapid expansion after the splitting.
  • the cell culture medium used for the rapid expansion before the splitting comprises IL-2, optionally OKT-3 and further optionally APCs. In some embodiments, the cell culture medium used for the rapid expansion before the splitting comprises IL-2, OKT-3, and further optionally APCs. In some embodiments, the cell culture medium used for the rapid expansion before the splitting comprises IL-2, OKT-3 and APCs.
  • the cell culture medium used for the rapid expansion before the splitting is generated by supplementing the cell culture medium in the first expansion with fresh culture medium comprising IL-2, optionally OKT-3 and further optionally APCs. In some embodiments, the cell culture medium used for the rapid expansion before the splitting is generated by supplementing the cell culture medium in the first expansion with fresh culture medium comprising IL-2, OKT-3 and APCs. In some embodiments, the cell culture medium used for the rapid expansion before the splitting is generated by replacing the cell culture medium in the first expansion with fresh cell culture medium comprising IL-2, optionally OKT-3 and further optionally APCs. In some embodiments, the cell culture medium used for the rapid expansion before the splitting is generated by replacing the cell culture medium in the first expansion with fresh cell culture medium comprising IL-2, OKT-3 and APCs.
  • the cell culture medium used for the rapid expansion after the splitting comprises IL-2, and optionally OKT-3. In some embodiments, the cell culture medium used for the rapid expansion after the splitting comprises IL-2, and OKT-3. In some embodiments, the cell culture medium used for the rapid expansion after the splitting is generated by replacing the cell culture medium used for the rapid expansion before the splitting with fresh culture medium comprising IL-2 and optionally OKT-3. In some embodiments, the cell culture medium used for the rapid expansion after the splitting is generated by replacing the cell culture medium used for the rapid expansion before the splitting with fresh culture medium comprising IL-2 and OKT-3.
  • the splitting of the rapid expansion occurs in a closed system.
  • the scaling up of the TIL culture during the rapid expansion comprises adding fresh cell culture medium to the TIL culture (also referred to as feeding the TILs).
  • the feeding comprises adding fresh cell culture medium to the TIL culture frequently.
  • the feeding comprises adding fresh cell culture medium to the TIL culture at a regular interval.
  • the fresh cell culture medium is supplied to the TILs via a constant flow.
  • an automated cell expansion system such as Xuri W25 is used for the rapid expansion and feeding.
  • the rapid second expansion is performed after the activation of T cells effected by the priming first expansion begins to decrease, abate, decay or subside.
  • the rapid second expansion is performed after the activation of T cells effected by the priming first expansion has decreased by at or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
  • the rapid second expansion is performed after the activation of T cells effected by the priming first expansion has decreased by a percentage in the range of at or about 1% to 100%.
  • the rapid second expansion is performed after the activation of T cells effected by the priming first expansion has decreased by a percentage in the range of at or about 1% to 10%, 10% to 20%, 20% to 30%, 30% to 40%, 40% to 50%, 50% to 60%, 60% to 70%, 70% to 80%, 80% to 90%, or 90% to 100%.
  • the rapid second expansion is performed after the activation of T cells effected by the priming first expansion has decreased by at least at or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
  • the rapid second expansion is performed after the activation of T cells effected by the priming first expansion has decreased by up to at or about 1, 2, 3, 4, 5, 6, 7, 8, 9,
  • the decrease in the activation of T cells effected by the priming first expansion is determined by a reduction in the amount of interferon gamma released by the T cells in response to stimulation with antigen.
  • the priming first expansion of T cells is performed during a period of up to at or about 7 days or about 8 days.
  • the priming first expansion of T cells is performed during a period of up to at or about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 8 days.
  • the priming first expansion of T cells is performed during a period of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 8 days.
  • the rapid second expansion of T cells is performed during a period of up to at or about 11 days.
  • the rapid second expansion of T cells is performed during a period of up to at or about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or 11 days.
  • the rapid second expansion of T cells is performed during a period of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or 11 days.
  • the priming first expansion of T cells is performed during a period of from at or about 1 day to at or about 7 days and the rapid second expansion of T cells is performed during a period of from at or about 1 day to at or about 11 days.
  • the priming first expansion of T cells is performed during a period of up to at or about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or 8 days and the rapid second expansion of T cells is performed during a period of up to at or about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or 11 days.
  • the priming first expansion of T cells is performed during a period of from at or about 1 day to at or about 8 days and the rapid second expansion of T cells is performed during a period of from at or about 1 day to at or about 9 days.
  • the priming first expansion of T cells is performed during a period of 8 days and the rapid second expansion of T cells is performed during a period of 9 days.
  • the priming first expansion of T cells is performed during a period of from at or about 1 day to at or about 7 days and the rapid second expansion of T cells is performed during a period of from at or about 1 day to at or about 9 days.
  • the priming first expansion of T cells is performed during a period of 7 days and the rapid second expansion of T cells is performed during a period of 9 days.
  • the T cells are tumor infiltrating lymphocytes (TILs).
  • TILs tumor infiltrating lymphocytes
  • the T cells are marrow infiltrating lymphocytes (MILs).
  • MILs marrow infiltrating lymphocytes
  • the T cells are peripheral blood lymphocytes (PBLs).
  • PBLs peripheral blood lymphocytes
  • the T cells are obtained from a donor suffering from a cancer.
  • the T cells are TILs obtained from a tumor excised from a patient suffering from a cancer.
  • the T cells are MILs obtained from bone marrow of a patient suffering from a hematologic malignancy.
  • the T cells are PBLs obtained from peripheral blood mononuclear cells (PBMCs) from a donor.
  • PBMCs peripheral blood mononuclear cells
  • the donor is suffering from a cancer.
  • the cancer is the cancer is selected from the group consisting of melanoma, ovarian cancer, endometrial cancer, thyroid cancer, cervical cancer, non-small-cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papilloma virus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), glioblastoma (including GBM), gastrointestinal cancer, renal cancer, and renal cell carcinoma.
  • PBMCs peripheral blood mononuclear cells
  • the cancer is selected from the group consisting of melanoma, ovarian cancer, cervical cancer, non-small-cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papilloma virus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), glioblastoma (including GBM), gastrointestinal cancer, renal cancer, and renal cell carcinoma.
  • the donor is suffering from a tumor.
  • the tumor is a liquid tumor.
  • the tumor is a solid tumor.
  • the donor is suffering from a hematologic malignancy.
  • immune effector cells e.g., T cells
  • T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLL separation.
  • cells from the circulating blood of an individual are obtained by apheresis.
  • the apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets.
  • the cells collected by apheresis may be washed to remove the plasma fraction and, optionally, to place the cells in an appropriate buffer or media for subsequent processing steps.
  • the cells are washed with phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations.
  • T cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL gradient or by counterflow centrifugal elutriation.
  • the T cells are PBLs separated from whole blood or apheresis product enriched for lymphocytes from a donor.
  • the donor is suffering from a cancer.
  • the cancer is the cancer is selected from the group consisting of melanoma, ovarian cancer, endometrial cancer, thyroid cancer, cervical cancer, non-small-cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papilloma virus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), glioblastoma (including GBM), gastrointestinal cancer, renal cancer, and renal cell carcinoma.
  • the cancer is selected from the group consisting of melanoma, ovarian cancer, cervical cancer, non-small-cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papilloma virus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), glioblastoma (including GBM), gastrointestinal cancer, renal cancer, and renal cell carcinoma.
  • the donor is suffering from a tumor.
  • the tumor is a liquid tumor.
  • the tumor is a solid tumor.
  • the donor is suffering from a hematologic malignancy.
  • the PBLs are isolated from whole blood or apheresis product enriched for lymphocytes by using positive or negative selection methods, i.e., removing the PBLs using a marker(s), e.g., CD3+ CD45+, for T cell phenotype, or removing non-T cell phenotype cells, leaving PBLs.
  • the PBLs are isolated by gradient centrifugation.
  • the priming first expansion of PBLs can be initiated by seeding a suitable number of isolated PBLs (in some embodiments, approximately 1 x 10 7 PBLs) in the priming first expansion culture according to the priming first expansion step of any of the methods described herein.
  • Process 3 also referred to herein as Gen 3 containing some of these features is depicted in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D), and some of the advantages of this embodiment of the present invention over Gen 2 are described in Figures 1, 2, 8, 30, and 31 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D).
  • Embodiments of Gen 3 are shown in Figures 1, 8, and 30 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D).
  • Process 2A or Gen 2 or Gen 2A is also described in U.S. Patent Publication No. 2018/0280436, incorporated by reference herein in its entirety.
  • the Gen 3 process is also described in International Patent Publication WO 2020/096988.
  • TILs are taken from a patient sample and manipulated to expand their number prior to transplant into a patient using the TIL expansion process described herein and referred to as Gen 3.
  • the TILs may be optionally genetically manipulated as discussed below.
  • the TILs may be cryopreserved prior to or after expansion. Once thawed, they may also be restimulated to increase their metabolism prior to infusion into a patient.
  • the priming first expansion (including processes referred herein as the pre-Rapid Expansion (Pre-REP), as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step B) is shortened to 1 to 8 days and the rapid second expansion (including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is shortened to 1 to 9 days, as discussed in detail below as well as in the examples and figures.
  • Pre-REP pre-Rapid Expansion
  • the rapid second expansion including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is shortened
  • the priming first expansion (including processes referred herein as the pre-Rapid Expansion (Pre-REP), as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step B) is shortened to 1 to 8 days and the rapid second expansion (including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8 A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is shortened to 1 to 8 days, as discussed in detail below as well as in the examples and figures.
  • Pre-REP pre-Rapid Expansion
  • the rapid second expansion including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8 A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is shortened
  • the priming first expansion (including processes referred herein as the pre-Rapid Expansion (Pre-REP), as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step B) is shortened to 1 to 7 days and the rapid second expansion (including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is shortened to 1 to 9 days, as discussed in detail below as well as in the examples and figures.
  • Pre-REP pre-Rapid Expansion
  • the rapid second expansion including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is shortened
  • the priming first expansion (including processes referred herein as the pre-Rapid Expansion (Pre-REP), as well as processes shown in Figure 8 (in particular, e.g., Figure IB and/or Figure 8C) as Step B) is 1 to 7 days and the rapid second expansion (including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is 1 to 10 days, as discussed in detail below as well as in the examples and figures.
  • Pre-REP pre-Rapid Expansion
  • the rapid second expansion including processes referred to herein as Rapid Expansion Protocol (REP) as well as processes shown in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) as Step D) is 1 to 10 days, as discussed in detail below as well as in the examples and figures.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is shortened to 8 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 7 to 9 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 8 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 8 to 9 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is shortened to 7 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 7 to 8 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is shortened to 8 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 8 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 8 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 9 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 8 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 10 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 7 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 7 to 10 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 7 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 8 to 10 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 7 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 9 to 10 days.
  • the priming first expansion (for example, an expansion described as Step B in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is shortened to 7 days and the rapid second expansion (for example, an expansion as described in Step D in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)) is 7 to 9 days.
  • the combination of the priming first expansion and rapid second expansion (for example, expansions described as Step B and Step D in Figure 8 (in particular, e.g., Figure IB and/or Figure 8C)) is 14-16 days, as discussed in detail below and in the examples and figures.
  • certain embodiments of the present invention comprise a priming first expansion step in which TILs are activated by exposure to an anti-CD3 antibody, e.g., OKT-3 in the presence of IL-2 or exposure to an antigen in the presence of at least IL-2 and an anti-CD3 antibody e. g. OKT-3.
  • the TILs which are activated in the priming first expansion step as described above are a first population of TILs i.e., which are a primary cell population.
  • Steps A, B, C, etc., below are in reference to the non-limiting example in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D) and in reference to certain non-limiting embodiments described herein.
  • the ordering of the Steps below and in Figure 8 is exemplary and any combination or order of steps, as well as additional steps, repetition of steps, and/or omission of steps is contemplated by the present application and the methods disclosed herein.
  • TILs are initially obtained from a patient tumor sample (“primary TILs”) or from circulating lymphocytes, such as peripheral blood lymphocytes, including peripheral blood lymphocytes having TIL-like characteristics, and are then expanded into a larger population for further manipulation as described herein, optionally cryopreserved, and optionally evaluated for phenotype and metabolic parameters as an indication of TIL health.
  • primary TILs a patient tumor sample
  • circulating lymphocytes such as peripheral blood lymphocytes, including peripheral blood lymphocytes having TIL-like characteristics
  • a patient tumor sample may be obtained using methods known in the art, generally via surgical resection, needle biopsy or other means for obtaining a sample that contains a mixture of tumor and TIL cells.
  • the tumor sample may be from any solid tumor, including primary tumors, invasive tumors or metastatic tumors.
  • the tumor sample may also be a liquid tumor, such as a tumor obtained from a hematological malignancy.
  • the solid tumor may be of any cancer type, including, but not limited to, breast, pancreatic, prostate, colorectal, lung, brain, renal, stomach, and skin (including but not limited to squamous cell carcinoma, basal cell carcinoma, and melanoma).
  • the cancer is selected from cervical cancer, head and neck cancer (including, for example, head and neck squamous cell carcinoma (HNSCC)), glioblastoma (GBM), gastrointestinal cancer, ovarian cancer, sarcoma, pancreatic cancer, bladder cancer, breast cancer, triple negative breast cancer, and non-small cell lung carcinoma.
  • the cancer is melanoma.
  • useful TILs are obtained from malignant melanoma tumors, as these have been reported to have particularly high levels of TILs.
  • the tumor sample is generally fragmented using sharp dissection into small pieces of between 1 to about 8 mm 3 , with from about 2-3 mm 3 being particularly useful.
  • the TILs are cultured from these fragments using enzymatic tumor digests.
  • Such tumor digests may be produced by incubation in enzymatic media (e.g., Roswell Park Memorial Institute (RPMI) 1640 buffer, 2 mM glutamate, 10 mcg/mL gentamicine, 30 units/mL of DNase and 1.0 mg/mL of collagenase) followed by mechanical dissociation (e.g., using a tissue dissociator).
  • enzymatic media e.g., Roswell Park Memorial Institute (RPMI) 1640 buffer, 2 mM glutamate, 10 mcg/mL gentamicine, 30 units/mL of DNase and 1.0 mg/mL of collagenase
  • Tumor digests may be produced by placing the tumor in enzymatic media and mechanically dissociating the tumor for approximately 1 minute, followed by incubation for 30 minutes at 37 °C in 5% CO2, followed by repeated cycles of mechanical dissociation and incubation under the foregoing conditions until only small tissue pieces are present.
  • a density gradient separation using FICOLL branched hydrophilic polysaccharide may be performed to remove these cells.
  • Alternative methods known in the art may be used, such as those described in U.S. Patent Application Publication No. 2012/0244133 Al, the disclosure of which is incorporated by reference herein. Any of the foregoing methods may be used in any of the embodiments described herein for methods of expanding TILs or methods treating a cancer.
  • the TILs are derived from solid tumors.
  • the solid tumors are not fragmented.
  • the solid tumors are not fragmented and are subjected to enzymatic digestion as whole tumors.
  • the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase.
  • the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase for 1-2 hours.
  • the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase for 1-2 hours at 37°C, 5% CO2. In some embodiments, the tumors are digested in in an enzyme mixture comprising collagenase, DNase, and hyaluronidase for 1-2 hours at 37°C, 5% CO2 with rotation. In some embodiments, the tumors are digested overnight with constant rotation. In some embodiments, the tumors are digested overnight at 37°C, 5% CO2 with constant rotation. In some embodiments, the whole tumor is combined with the enzymes to form a tumor digest reaction mixture. [00646] In some embodiments, the tumor is reconstituted with the lyophilized enzymes in a sterile buffer. In some embodiments, the buffer is sterile HBSS.
  • the enzyme mixture comprises collagenase.
  • the collagenase is collagenase IV.
  • the working stock for the collagenase is a 100 mg/mL 10X working stock.
  • the enzyme mixture comprises DNAse.
  • the working stock for the DNAse is a 10,000IU/mL 10X working stock.
  • the enzyme mixture comprises hyaluronidase.
  • the working stock for the hyaluronidase is a 10-mg/mL 10X working stock.
  • the enzyme mixture comprises 10 mg/mL collagenase, 1000 lU/mL DNAse, and 1 mg/mL hyaluronidase.
  • the enzyme mixture comprises 10 mg/mL collagenase, 500 lU/mL DNAse, and 1 mg/mL hyaluronidase.
  • the cell suspension obtained from the tumor is called a “primary cell population” or a “freshly obtained” or a “freshly isolated” cell population.
  • the freshly obtained cell population of TILs is exposed to a cell culture medium comprising antigen presenting cells, IL- 12 and OKT-3.
  • fragmentation includes physical fragmentation, including, for example, dissection as well as digestion. In some embodiments, the fragmentation is physical fragmentation. In some embodiments, the fragmentation is dissection. In some embodiments, the fragmentation is by digestion.
  • TILs can be initially cultured from enzymatic tumor digests and tumor fragments obtained from patients. In some embodiments, TILs can be initially cultured from enzymatic tumor digests and tumor fragments obtained from patients.
  • the tumor undergoes physical fragmentation after the tumor sample is obtained in, for example, Step A (as provided in Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D)).
  • the fragmentation occurs before cryopreservation.
  • the fragmentation occurs after cryopreservation.
  • the fragmentation occurs after obtaining the tumor and in the absence of any cryopreservation.
  • the step of fragmentation is an in vitro or ex-vivo process.
  • the tumor is fragmented and 10, 20, 30, 40 or more fragments or pieces are placed in each container for the priming first expansion. In some embodiments, the tumor is fragmented and 30 or 40 fragments or pieces are placed in each container for the priming first expansion. In some embodiments, the tumor is fragmented and 40 fragments or pieces are placed in each container for the priming first expansion. In some embodiments, the multiple fragments comprise about 4 to about 50 fragments, wherein each fragment has a volume of about 27 mm 3 . In some embodiments, the multiple fragments comprise about 30 to about 60 fragments with a total volume of about 1300 mm 3 to about 1500 mm 3 .
  • the multiple fragments comprise about 50 fragments with a total volume of about 1350 mm 3 . In some embodiments, the multiple fragments comprise about 50 fragments with a total mass of about 1 gram to about 1.5 grams. In some embodiments, the multiple fragments comprise about 4 fragments.
  • the TILs are obtained from tumor fragments.
  • the tumor fragment is obtained by sharp dissection.
  • the tumor fragment is between about 1 mm 3 and 10 mm 3 .
  • the tumor fragment is between about 1 mm 3 and 8 mm 3 .
  • the tumor fragment is about 1 mm 3 .
  • the tumor fragment is about 2 mm 3 .
  • the tumor fragment is about 3 mm 3 .
  • the tumor fragment is about 4 mm 3 .
  • the tumor fragment is about 5 mm 3 .
  • the tumor fragment is about 6 mm 3 .
  • the tumor fragment is about 7 mm 3 .
  • the tumor fragment is about 8 mm 3 . In some embodiments, the tumor fragment is about 9 mm 3 . In some embodiments, the tumor fragment is about 10 mm 3 . In some embodiments, the tumor fragments are 1-4 mm x 1-4 mm * 1-4 mm. In some embodiments, the tumor fragments are 1 mm x 1 mm x 1 mm. In some embodiments, the tumor fragments are 2 mm x 2 mm x 2 mm. In some embodiments, the tumor fragments are 3 mm x 3 mm x 3 mm. In some embodiments, the tumor fragments are 4 mm x 4 mm x 4 mm.
  • the tumors are fragmented in order to minimize the amount of hemorrhagic, necrotic, and/or fatty tissues on each piece. In some embodiments, the tumors are fragmented in order to minimize the amount of hemorrhagic tissue on each piece. In some embodiments, the tumors are fragmented in order to minimize the amount of necrotic tissue on each piece. In some embodiments, the tumors are fragmented in order to minimize the amount of fatty tissue on each piece. In certain embodiments, the step of fragmentation of the tumor is an in vitro or ex-vivo method.
  • the tumor fragmentation is performed in order to maintain the tumor internal structure. In some embodiments, the tumor fragmentation is performed without performing a sawing motion with a scalpel.
  • the TILs are obtained from tumor digests.
  • tumor digests were generated by incubation in enzyme media, for example but not limited to RPMI 1640, 2 mM GlutaMAX, 10 mg/mL gentamicin, 30 U/mL DNase, and 1.0 mg/mL collagenase, followed by mechanical dissociation (GentleMACS, Miltenyi Biotec, Auburn, CA). After placing the tumor in enzyme media, the tumor can be mechanically dissociated for approximately 1 minute.
  • the solution can then be incubated for 30 minutes at 37 °C in 5% CO2 and it then mechanically disrupted again for approximately 1 minute. After being incubated again for 30 minutes at 37 °C in 5% CO2, the tumor can be mechanically disrupted a third time for approximately 1 minute.
  • 1 or 2 additional mechanical dissociations were applied to the sample, with or without 30 additional minutes of incubation at 37 °C in 5% CO2.
  • a density gradient separation using Ficoll can be performed to remove these cells.
  • the cell suspension prior to the priming first expansion step is called a “primary cell population” or a “freshly obtained” or “freshly isolated” cell population.
  • cells can be optionally frozen after sample isolation (e.g., after obtaining the tumor sample and/or after obtaining the cell suspension from the tumor sample) and stored frozen prior to entry into the expansion described in Step B, which is described in further detail below, as well as exemplified in Figure 8 (in particular, e.g., Figure 8B).
  • TILs are initially obtained from a patient tumor sample (“primary TILs”) obtained by a core biopsy or similar procedure and then expanded into a larger population for further manipulation as described herein, optionally cryopreserved, and optionally evaluated for phenotype and metabolic parameters.
  • primary TILs obtained by a core biopsy or similar procedure and then expanded into a larger population for further manipulation as described herein, optionally cryopreserved, and optionally evaluated for phenotype and metabolic parameters.
  • a patient tumor sample may be obtained using methods known in the art, generally via small biopsy, core biopsy, needle biopsy or other means for obtaining a sample that contains a mixture of tumor and TIL cells.
  • the tumor sample may be from any solid tumor, including primary tumors, invasive tumors or metastatic tumors.
  • the tumor sample may also be a liquid tumor, such as a tumor obtained from a hematological malignancy.
  • the sample can be from multiple small tumor samples or biopsies.
  • the sample can comprise multiple tumor samples from a single tumor from the same patient.
  • the sample can comprise multiple tumor samples from one, two, three, or four tumors from the same patient.
  • the sample can comprise multiple tumor samples from multiple tumors from the same patient.
  • the solid tumor may of lung and/or non-small cell lung carcinoma (NSCLC).
  • NSCLC non-small cell lung carcinoma
  • the cell suspension obtained from the tumor core or fragment is called a “primary cell population” or a “freshly obtained” or a “freshly isolated” cell population.
  • the freshly obtained cell population of TILs is exposed to a cell culture medium comprising antigen presenting cells, IL-2 and OKT-3.
  • the least invasive approach is to remove a skin lesion, or a lymph node on the neck or axillary area when available.
  • a skin lesion is removed or small biopsy thereof is removed.
  • a lymph node or small biopsy thereof is removed.
  • a lung or liver metastatic lesion, or an intra-abdominal or thoracic lymph node or small biopsy is removed.
  • the tumor is a melanoma.
  • the small biopsy for a melanoma comprises a mole or portion thereof.
  • the small biopsy is a punch biopsy.
  • the punch biopsy is obtained with a circular blade pressed into the skin.
  • the punch biopsy is obtained with a circular blade pressed into the skin, around a suspicious mole.
  • the punch biopsy is obtained with a circular blade pressed into the skin, and a round piece of skin is removed.
  • the small biopsy is a punch biopsy and round portion of the tumor is removed.
  • the small biopsy is an excisional biopsy. In some embodiments, the small biopsy is an excisional biopsy and the entire mole or growth is removed. In some embodiments, the small biopsy is an excisional biopsy and the entire mole or growth is removed along with a small border of normal-appearing skin.
  • the small biopsy is an incisional biopsy.
  • the small biopsy is an incisional biopsy and only the most irregular part of a mole or growth is taken.
  • the small biopsy is an incisional biopsy and the incisional biopsy is used when other techniques can't be completed, such as if a suspicious mole is very large.
  • the small biopsy is a lung biopsy.
  • the small biopsy is obtained by bronchoscopy.
  • bronchoscopy the patient is put under anesthesia, and a small tool goes through the nose or mouth, down the throat, and into the bronchial passages, where small tools are used to remove some tissue.
  • a transthoracic needle biopsy can be employed.
  • the patient is also under anesthesia and a needle is inserted through the skin directly into the suspicious spot to remove a small sample of tissue.
  • a transthoracic needle biopsy may require interventional radiology (for example, the use of x-rays or CT scan to guide the needle).
  • the small biopsy is obtained by needle biopsy.
  • the small biopsy is obtained endoscopic ultrasound (for example, an endoscope with a light and is placed through the mouth into the esophagus).
  • the small biopsy is obtained surgically.
  • the small biopsy is a head and neck biopsy. In some embodiments, the small biopsy is an incisional biopsy. In some embodiments, the small biopsy is an incisional biopsy, wherein a small piece of tissue is cut from an abnormal -looking area. In some embodiments, if the abnormal region is easily accessed, the sample may be taken without hospitalization. In some embodiments, if the tumor is deeper inside the mouth or throat, the biopsy may need to be done in an operating room, with general anesthesia. In some embodiments, the small biopsy is an excisional biopsy. In some embodiments, the small biopsy is an excisional biopsy, wherein the whole area is removed. In some embodiments, the small biopsy is a fine needle aspiration (FNA).
  • FNA fine needle aspiration
  • the small biopsy is a fine needle aspiration (FNA), wherein a very thin needle attached to a syringe is used to extract (aspirate) cells from a tumor or lump.
  • FNA fine needle aspiration
  • the small biopsy is a punch biopsy.
  • the small biopsy is a punch biopsy, wherein punch forceps are used to remove a piece of the suspicious area.
  • the small biopsy is a cervical biopsy.
  • the small biopsy is obtained via colposcopy.
  • colposcopy methods employ the use of a lighted magnifying instrument attached to magnifying binoculars (a colposcope) which is then used to biopsy a small section of the surface of the cervix.
  • the small biopsy is a conization/cone biopsy.
  • the small biopsy is a conization/cone biopsy, wherein an outpatient surgery may be needed to remove a larger piece of tissue from the cervix.
  • the cone biopsy in addition to helping to confirm a diagnosis, a cone biopsy can serve as an initial treatment.
  • solid tumor refers to an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • solid tumor cancer refers to malignant, neoplastic, or cancerous solid tumors. Solid tumor cancers include cancers of the lung. In some embodiments, the cancer is melanoma. In some embodiments, the cancer is non-small cell lung carcinoma (NSCLC).
  • the tissue structure of solid tumors includes interdependent tissue compartments including the parenchyma (cancer cells) and the supporting stromal cells in which the cancer cells are dispersed and which may provide a supporting microenvironment.
  • the sample from the tumor is obtained as a fine needle aspirate (FNA), a core biopsy, a small biopsy (including, for example, a punch biopsy).
  • FNA fine needle aspirate
  • sample is placed first into a G-REX 10.
  • sample is placed first into a G-REX 10 when there are 1 or 2 core biopsy and/or small biopsy samples.
  • sample is placed first into a G-REX 100 when there are 3, 4, 5, 6, 8, 9, or 10 or more core biopsy and/or small biopsy samples.
  • sample is placed first into a G-REX 500 when there are 3, 4, 5, 6, 8, 9, or 10 or more core biopsy and/or small biopsy samples.
  • the FNA can be obtained from a skin tumor, including, for example, a melanoma.
  • the FNA is obtained from a skin tumor, such as a skin tumor from a patient with metastatic melanoma.
  • the patient with melanoma has previously undergone a surgical treatment.
  • the FNA can be obtained from a lung tumor, including, for example, an NSCLC.
  • the FNA is obtained from a lung tumor, such as a lung tumor from a patient with nonsmall cell lung cancer (NSCLC).
  • NSCLC nonsmall cell lung cancer
  • the patient with NSCLC has previously undergone a surgical treatment.
  • TILs described herein can be obtained from an FNA sample.
  • the FNA sample is obtained or isolated from the patient using a fine gauge needle ranging from an 18 gauge needle to a 25 gauge needle.
  • the fine gauge needle can be 18 gauge, 19 gauge, 20 gauge, 21 gauge, 22 gauge, 23 gauge, 24 gauge, or 25 gauge.
  • the FNA sample from the patient can contain at least 400,000 TILs, e.g., 400,000 TILs, 450,000 TILs, 500,000 TILs, 550,000 TILs, 600,000 TILs, 650,000 TILs, 700,000 TILs, 750,000 TILs, 800,000 TILs, 850,000 TILs, 900,000 TILs, 950,000 TILs, or more.
  • 400,000 TILs e.g., 400,000 TILs, 450,000 TILs, 500,000 TILs, 550,000 TILs, 600,000 TILs, 650,000 TILs, 700,000 TILs, 750,000 TILs, 800,000 TILs, 850,000 TILs, 900,000 TILs, 950,000 TILs, or more.
  • the TILs described herein are obtained from a core biopsy sample.
  • the core biopsy sample is obtained or isolated from the patient using a surgical or medical needle ranging from an 11 gauge needle to a 16 gauge needle.
  • the needle can be 11 gauge, 12 gauge, 13 gauge, 14 gauge, 15 gauge, or 16 gauge.
  • the core biopsy sample from the patient can contain at least 400,000 TILs, e.g., 400,000 TILs, 450,000 TILs, 500,000 TILs, 550,000 TILs, 600,000 TILs, 650,000 TILs, 700,000 TILs, 750,000 TILs, 800,000 TILs, 850,000 TILs, 900,000 TILs, 950,000 TILs, or more.
  • the harvested cell suspension is called a “primary cell population” or a “freshly harvested” cell population.
  • the TILs are not obtained from tumor digests. In some embodiments, the solid tumor cores are not fragmented.
  • the TILs are obtained from tumor digests.
  • tumor digests were generated by incubation in enzyme media, for example but not limited to RPMI 1640, 2mM GlutaMAX, 10 mg/mL gentamicin, 30 U/mL DNase, and 1.0 mg/mL collagenase, followed by mechanical dissociation (Gentle MACS, Miltenyi Biotec, Auburn, CA). After placing the tumor in enzyme media, the tumor can be mechanically dissociated for approximately 1 minute. The solution can then be incubated for 30 minutes at 37 °C in 5% CO2 and it then mechanically disrupted again for approximately 1 minute.
  • the tumor can be mechanically disrupted a third time for approximately 1 minute.
  • 1 or 2 additional mechanical dissociations were applied to the sample, with or without 30 additional minutes of incubation at 37 °C in 5% CO 2 .
  • a density gradient separation using Ficoll can be performed to remove these cells.
  • obtaining the first population of TILs comprises a multilesional sampling method.
  • Tumor dissociating enzyme mixtures can include one or more dissociating (digesting) enzymes such as, but not limited to, collagenase (including any blend or type of collagenase), AccutaseTM, AccumaxTM, hyaluronidase, neutral protease (dispase), chymotrypsin, chymopapain, trypsin, caseinase, elastase, papain, protease type XIV (pronase), deoxyribonuclease I (DNase), trypsin inhibitor, any other dissociating or proteolytic enzyme, and any combination thereof.
  • dissociating enzymes such as, but not limited to, collagenase (including any blend or type of collagenase), AccutaseTM, AccumaxTM, hyaluronidase, neutral protease (dispase), chymotrypsin, chymopapain, trypsin, caseina
  • the dissociating enzymes are reconstituted from lyophilized enzymes.
  • lyophilized enzymes are reconstituted in an amount of sterile buffer such as Hank's balance salt solution (HBSS).
  • HBSS Hank's balance salt solution
  • collagenase (such as animal free- type 1 collagenase) is reconstituted in 10 mL of sterile HBSS or another buffer.
  • the lyophilized stock enzyme may be at a concentration of 2892 PZ U/vial.
  • collagenase is reconstituted in 5 mL to 15 mL buffer.
  • the collagenase stock ranges from about 100 PZ U/mL-about 400 PZ U/mL, e.g., about 100 PZ U/mL-about 400 PZ U/mL, about 100 PZ U/mL-about 350 PZ U/mL, about 100 PZ U/mL-about 300 PZ U/mL, about 150 PZ U/mL-about 400 PZ U/mL, about 100 PZ U/mL, about 150 PZ U/mL, about 200 PZ U/mL, about 210 PZ U/mL, about 220 PZ U/mL, about 230 PZ U/mL, about 240 PZ U/mL, about 250 PZ U/mL, about 260 PZ U/mL, about 270 PZ U/mL, about 280 PZ U/mL, about 289.2 PZ U/mL, about 300 PZ U/mL, about 350 PZ U/mL, or about 400 PZ U/mL
  • neutral protease is reconstituted in 1-ml of sterile HBSS or another buffer.
  • the lyophilized stock enzyme may be at a concentration of 175 DMC U/vial.
  • the neutral protease stock ranges from about 100 DMC/mL-about 400 DMC/mL, e.g., about 100 DMC/mL-about 400 DMC/mL, about 100 DMC/mL-about 350 DMC/mL, about 100 DMC/mL-about 300 DMC/mL, about 150 DMC/mL-about 400 DMC/mL, about 100 DMC/mL, about 110 DMC/mL, about 120 DMC/mL, about 130 DMC/mL, about 140 DMC/mL, about 150 DMC/mL, about 160 DMC/mL, about 170 DMC/mL, about 175 DMC/mL, about 180 DMC/mL, about 190 DMC/mL, about 200 DMC
  • DNAse I is reconstituted in 1-ml of sterile HBSS or another buffer.
  • the lyophilized stock enzyme was at a concentration of 4 KU/vial.
  • the DNase I stock ranges from about 1 KU/mL-10 KU/mL, e.g, about 1 KU/mL, about 2 KU/mL, about 3 KU/mL, about 4 KU/mL, about 5 KU/mL, about 6 KU/mL, about 7 KU/mL, about 8 KU/mL, about 9 KU/mL, or about 10 KU/mL.
  • the stock of enzymes could change so verify the concentration of the lyophilized stock and amend the final amount of enzyme added to the digest cocktail accordingly.
  • the enzyme mixture includes about 10.2-ul of neutral protease (0.36 DMC U/mL), 21.3-ul of collagenase (1.2 PZ/mL) and 250-ul of DNAse I (200 U/mL) in about 4.7-ml of sterile HBSS.
  • the sample is a pleural fluid sample.
  • the source of the T-cells or TILs for expansion according to the processes described herein is a pleural fluid sample.
  • the sample is a pleural effusion derived sample.
  • the source of the T-cells or TILs for expansion according to the processes described herein is a pleural effusion derived sample. See, for example, methods described in U.S. Patent Publication US 2014/0295426, incorporated herein by reference in its entirety for all purposes.
  • any pleural fluid or pleural effusion suspected of and/or containing TILs can be employed.
  • a sample may be derived from a primary or metastatic lung cancer, such as NSCLC or SCLC.
  • the sample may be derived from secondary metastatic cancer cells which originated from another organ, e.g., breast, ovary, colon or prostate.
  • the sample for use in the expansion methods described herein is a pleural exudate.
  • the sample for use in the expansion methods described herein is a pleural transudate.
  • Other biological samples may include other serous fluids containing TILs, including, e.g., ascites fluid from the abdomen or pancreatic cyst fluid.
  • the pleural fluid is in unprocessed form, directly as removed from the patient.
  • the unprocessed pleural fluid is placed in a standard blood collection tube, such as an EDTA or Heparin tube, prior to further processing steps.
  • the unprocessed pleural fluid is placed in a standard CellSave® tube (Veridex) prior to the further processing steps.
  • the sample is placed in the CellSave tube immediately after collection from the patient to avoid a decrease in the number of viable TILs.
  • the number of viable TILs can decrease to a significant extent within 24 hours, if left in the untreated pleural fluid, even at 4°C.
  • the sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, or up to 24 hours after removal from the patient.
  • the sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, or up to 24 hours after removal from the patient at 4°C.
  • the pleural fluid sample from the chosen subject may be diluted.
  • the dilution is 1: 10 pleural fluid to diluent.
  • the dilution is 1:9 pleural fluid to diluent.
  • the dilution is 1 : 8 pleural fluid to diluent.
  • the dilution is 1:5 pleural fluid to diluent.
  • the dilution is 1:2 pleural fluid to diluent.
  • the dilution is 1 : 1 pleural fluid to diluent.
  • diluents include saline, phosphate buffered saline, another buffer or a physiologically acceptable diluent.
  • the sample is placed in the CellSave tube immediately after collection from the patient and dilution to avoid a decrease in the viable TILs, which may occur to a significant extent within 24-48 hours, if left in the untreated pleural fluid, even at 4°C.
  • the pleural fluid sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, 24 hours, 36 hours, up to 48 hours after removal from the patient, and dilution.
  • the pleural fluid sample is placed in the appropriate collection tube within 1 hour, 5 hours, 10 hours, 15 hours, 24 hours, 36 hours, up to 48 hours after removal from the patient, and dilution at 4°C.
  • pleural fluid samples are concentrated by conventional means prior to further processing steps.
  • this pre-treatment of the pleural fluid is preferable in circumstances in which the pleural fluid must be cryopreserved for shipment to a laboratory performing the method or for later analysis (e.g., later than 24-48 hours post-collection).
  • the pleural fluid sample is prepared by centrifuging the pleural fluid sample after its withdrawal from the subject and resuspending the centrifugate or pellet in buffer.
  • the pleural fluid sample is subjected to multiple centrifugations and resuspensions, before it is cryopreserved for transport or later analysis and/or processing.
  • pleural fluid samples are concentrated prior to further processing steps by using a filtration method.
  • the pleural fluid sample used in the further processing is prepared by filtering the fluid through a filter containing a known and essentially uniform pore size that allows for passage of the pleural fluid through the membrane but retains the tumor cells.
  • the diameter of the pores in the membrane may be at least 4 ⁇ M.
  • the pore diameter may be 5 ⁇ M or more, and in other embodiment, any of 6, 7, 8, 9, or 10 ⁇ M.
  • the cells, including TILs, retained by the membrane may be rinsed off the membrane into a suitable physiologically acceptable buffer. Cells, including TILs, concentrated in this way may then be used in the further processing steps of the method.
  • pleural fluid sample (including, for example, the untreated pleural fluid), diluted pleural fluid, or the resuspended cell pellet, is contacted with a lytic reagent that differentially lyses non-nucleated red blood cells present in the sample.
  • a lytic reagent that differentially lyses non-nucleated red blood cells present in the sample.
  • this step is performed prior to further processing steps in circumstances in which the pleural fluid contains substantial numbers of RBCs.
  • Suitable lysing reagents include a single lytic reagent or a lytic reagent and a quench reagent, or a lytic agent, a quench reagent and a fixation reagent.
  • Suitable lytic systems are marketed commercially and include the BD Pharm LyseTM system (Becton Dickenson). Other lytic systems include the VersalyseTM system, the FACSlyseTM system (Becton Dickenson), the ImmunoprepTM system or Erythrolyse II system (Beckman Coulter, Inc.), or an ammonium chloride system.
  • the lytic reagent can vary with the primary requirements being efficient lysis of the red blood cells, and the conservation of the TILs and phenotypic properties of the TILs in the pleural fluid.
  • the lytic systems useful in methods described herein can include a second reagent, e.g., one that quenches or retards the effect of the lytic reagent during the remaining steps of the method, e.g., StabilyseTM reagent (Beckman Coulter, Inc.).
  • a conventional fixation reagent may also be employed depending upon the choice of lytic reagents or the preferred implementation of the method.
  • the pleural fluid sample, unprocessed, diluted or multiply centrifuged or processed as described herein above is cryopreserved at a temperature of about -140°C prior to being further processed and/or expanded as provided herein.
  • PBL Method 1 PBLs are expanded using the processes described herein.
  • the method comprises obtaining a PBMC sample from whole blood.
  • the method comprises enriching T-cells by isolating pure T-cells from PBMCs using negative selection of a non-CD19+ fraction.
  • the method comprises enriching T-cells by isolating pure T-cells from PBMCs using magnetic bead-based negative selection of a non-CD19+ fraction.
  • PBL Method 1 is performed as follows: On Day 0, a cryopreserved PBMC sample is thawed and PBMCs are counted. T-cells are isolated using a Human Pan T-Cell Isolation Kit and LS columns (Miltenyi Biotec).
  • PBLs are expanded using PBL Method 2, which comprises obtaining a PBMC sample from whole blood.
  • the T-cells from the PBMCs are enriched by incubating the PBMCs for at least three hours at 37°C and then isolating the non-adherent cells.
  • PBL Method 2 is performed as follows: On Day 0, the cryopreserved PMBC sample is thawed and the PBMC cells are seeded at 6 million cells per well in a 6 well plate in CM-2 media and incubated for 3 hours at 37 degrees Celsius. After 3 hours, the non-adherent cells, which are the PBLs, are removed and counted.
  • PBLs are expanded using PBL Method 3, which comprises obtaining a PBMC sample from peripheral blood. B-cells are isolated using a CD 19+ selection and T-cells are selected using negative selection of the non-CD19+ fraction of the PBMC sample.
  • PBL Method 3 is performed as follows: On Day 0, cryopreserved PBMCs derived from peripheral blood are thawed and counted. CD 19+ B-cells are sorted using a CD19 Multisort Kit, Human (Miltenyi Biotec). Of the non-CD19+ cell fraction, T-cells are purified using the Human Pan T-cell Isolation Kit and LS Columns (Miltenyi Biotec).
  • PBMCs are isolated from a whole blood sample.
  • the PBMC sample is used as the starting material to expand the PBLs.
  • the sample is cryopreserved prior to the expansion process.
  • a fresh sample is used as the starting material to expand the PBLs.
  • T-cells are isolated from PBMCs using methods known in the art.
  • the T-cells are isolated using a Human Pan T-cell isolation kit and LS columns.
  • T-cells are isolated from PBMCs using antibody selection methods known in the art, for example, CD 19 negative selection.
  • the PBMC sample is incubated for a period of time at a desired temperature effective to identify the non-adherent cells. In some embodiments of the invention, the incubation time is about 3 hours. In some embodiments of the invention, the temperature is about 37° Celsius.
  • the non-adherent cells are then expanded using the process described above.
  • the PBMC sample is from a subject or patient who has been optionally pre-treated with a regimen comprising a kinase inhibitor or an ITK inhibitor. In some embodiments, the tumor sample is from a subject or patient who has been pre-treated with a regimen comprising a kinase inhibitor or an ITK inhibitor.
  • the PBMC sample is from a subject or patient who has been pre-treated with a regimen comprising a kinase inhibitor or an ITK inhibitor, has undergone treatment for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or 1 year or more.
  • the PBMCs are derived from a patient who is currently on an ITK inhibitor regimen, such as ibrutinib.
  • the PBMC sample is from a subject or patient who has been pretreated with a regimen comprising a kinase inhibitor or an ITK inhibitor and is refractory to treatment with a kinase inhibitor or an ITK inhibitor, such as ibrutinib.
  • the PBMC sample is from a subject or patient who has been pretreated with a regimen comprising a kinase inhibitor or an ITK inhibitor but is no longer undergoing treatment with a kinase inhibitor or an ITK inhibitor.
  • the PBMC sample is from a subject or patient who has been pre-treated with a regimen comprising a kinase inhibitor or an ITK inhibitor but is no longer undergoing treatment with a kinase inhibitor or an ITK inhibitor and has not undergone treatment for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or at least 1 year or more.
  • the PBMCs are derived from a patient who has prior exposure to an ITK inhibitor, but has not been treated in at least 3 months, at least 6 months, at least 9 months, or at least 1 year.
  • cells are selected for CD 19+ and sorted accordingly.
  • the selection is made using antibody binding beads.
  • pure T-cells are isolated on Day 0 from the PBMCs.
  • the expansion process will yield about 20 x 10 9 PBLs. In some embodiments of the invention, 40.3 x 10 6 PBMCs will yield about 4.7x 10 5 PBLs.
  • PBMCs may be derived from a whole blood sample, by apheresis, from the buffy coat, or from any other method known in the art for obtaining PBMCs.
  • PBLs are prepared using the methods described in U.S. Patent Application Publication No. US 2020/0347350 Al, the disclosures of which are incorporated by reference herein.
  • MILs Marrow Infdtrating Eymphocytes
  • the method comprises obtaining PBMCs from the bone marrow.
  • the PBMCs are selected for CD3+/CD33+/CD20+/CD14+ and sorted, and the non-CD3+/CD33+/CD20+/CD14+ cell fraction is sonicated and a portion of the sonicated cell fraction is added back to the selected cell fraction.
  • MIL Method 3 is performed as follows: On Day 0, a cryopreserved sample of PBMCs is thawed and PBMCs are counted. The cells are stained with CD3, CD33, CD20, and CD14 antibodies and sorted using a S3e cell sorted (Bio-Rad). The cells are sorted into two fractions - an immune cell fraction (or the MIL fraction) (CD3+CD33+CD20+CD14+) and an AML blast cell fraction (non-CD3+CD33+CD20+CD14+).
  • PBMCs are obtained from bone marrow.
  • the PBMCs are obtained from the bone marrow through apheresis, aspiration, needle biopsy, or other similar means known in the art.
  • the PBMCs are fresh.
  • the PBMCs are cryopreserved.
  • MILs are expanded from 10-50 mL of bone marrow aspirate.
  • 10 mL of bone marrow aspirate is obtained from the patient.
  • 20 mL of bone marrow aspirate is obtained from the patient.
  • 30 mL of bone marrow aspirate is obtained from the patient.
  • 40 mL of bone marrow aspirate is obtained from the patient.
  • 50 mL of bone marrow aspirate is obtained from the patient.
  • the number of PBMCs yielded from about 10-50 mL of bone marrow aspirate is about 5x 10 7 to about 10x10 7 PBMCs. In other embodiments, the number of PMBCs yielded is about 7x 10 7 PBMCs.
  • about 5 x 10 7 to about 10x 10 7 PBMCs yields about 0.5 x 10 6 to about 1.5 x 10 6 MILs. In some embodiments of the invention, about 1 x 10 6 MILs is yielded.
  • PBMCs may be derived from a whole blood sample, from bone marrow, by apheresis, from the buffy coat, or from any other method known in the art for obtaining PBMCs.
  • MILs are prepared using the methods described in U.S. Patent Application Publication No. US 2020/0347350 Al, the disclosures of which are incorporated by reference herein.
  • the present methods provide for younger TIEs, which may provide additional therapeutic benefits over older TILs (i.e., TILs which have further undergone more rounds of replication prior to administration to a subject/patient).
  • TILs which have further undergone more rounds of replication prior to administration to a subject/patient.
  • the resulting cells are cultured in serum containing IL-2, OKT-3, and feeder cells (e.g., antigen-presenting feeder cells), under conditions that favor the growth of TILs over tumor and other cells.
  • IL-2, OKT-3, and feeder cells are added at culture initiation along with the tumor digest and/or tumor fragments (e.g., at Day 0).
  • the tumor digests and/or tumor fragments are incubated in a container with up to 60 fragments per container and with 6000 lU/mL of IL-2.
  • this primary cell population is cultured for a period of days, generally from 1 to 8 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • this primary cell population is cultured for a period of days, generally from 1 to 7 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • priming first expansion occurs for a period of 1 to 8 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • priming first expansion occurs for a period of 1 to 7 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells. In some embodiments, this priming first expansion occurs for a period of 5 to 8 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells. In some embodiments, this priming first expansion occurs for a period of 5 to 7 days, resulting in a bulk TIL population, generally about 1 X 10 8 bulk TIL cells. In some embodiments, this priming first expansion occurs for a period of about 6 to 8 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • this priming first expansion occurs for a period of about 6 to 7 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells. In some embodiments, this priming first expansion occurs for a period of about 7 to 8 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells. In some embodiments, this priming first expansion occurs for a period of about 7 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells. In some embodiments, this priming first expansion occurs for a period of about 8 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • expansion of TILs may be performed using a priming first expansion step (for example such as those described in Step B of Figure 8 (in particular, e.g., Figure 8A and/or Figure 8B and/or Figure 8C and/or Figure 8D), which can include processes referred to as pre-REP or priming REP and which contains feeder cells from Day 0 and/or from culture initiation) as described below and herein, followed by a rapid second expansion (Step D, including processes referred to as rapid expansion protocol (REP) steps) as described below under Step D and herein, followed by optional cryopreservation, and followed by a second Step D (including processes referred to as restimulation REP steps) as described below and herein.
  • the TILs obtained from this process may be optionally characterized for phenotypic characteristics and metabolic parameters as described herein.
  • the tumor fragment is between about 1 mm 3 and 10 mm 3 .
  • CM the first expansion culture medium
  • CM for Step B consists of RPMI 1640 with GlutaMAX, supplemented with 10% human AB serum, 25 mM Hepes, and 10 mg/mL gentamicin.
  • each container comprises less than or equal to 500 mL of media per container.
  • the media comprises IL-2.
  • the media comprises 6000 lU/mL of IL-2.
  • the media comprises antigen-presenting feeder cells (also referred to herein as “antigen-presenting cells”).
  • the media comprises 2.5 x 10 8 antigen-presenting feeder cells per container.
  • the media comprises OKT-3.
  • the media comprises 30 ng/mL of OKT-3 per container.
  • the container is a G- REX100 MCS flask.
  • the media comprises 6000 lU/mL of IL-2, 30 ng of OKT- 3, and 2.5 x 10 8 antigen-presenting feeder cells.
  • the media comprises 6000 lU/mL of IL-2, 30 ng/mL of OKT-3, and 2.5 x 10 8 antigen-presenting feeder cells per container.
  • the resulting cells are cultured in media containing IL-2, antigen-presenting feeder cells and OKT-3 under conditions that favor the growth of TILs over tumor and other cells and which allow for TIL priming and accelerated growth from initiation of the culture on Day 0.
  • the tumor digests and/or tumor fragments are incubated in with 6000 lU/mL of IL-2, as well as antigen-presenting feeder cells and OKT-3.
  • This primary cell population is cultured for a period of days, generally from 1 to 8 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells.
  • the growth media during the priming first expansion comprises IL-2 or a variant thereof, as well as antigen-presenting feeder cells and OKT-3. In some embodiments, this primary cell population is cultured for a period of days, generally from 1 to 7 days, resulting in a bulk TIL population, generally about 1 x 10 8 bulk TIL cells. In some embodiments, the growth media during the priming first expansion comprises IL-2 or a variant thereof, as well as antigen-presenting feeder cells and OKT-3. In some embodiments, the IL-2 is recombinant human IL-2 (rhIL-2). In some embodiments the IL-2 stock solution has a specific activity of 20-30x 10 6 lU/mg for a 1 mg vial.
  • the IL-2 stock solution has a specific activity of 20 x 10 6 lU/mg for a 1 mg vial. In some embodiments the IL-2 stock solution has a specific activity of 25 x 10 6 lU/mg for a 1 mg vial. In some embodiments the IL-2 stock solution has a specific activity of 30x 10 6 lU/mg for a 1 mg vial. In some embodiments, the IL- 2 stock solution has a final concentration of 4-8 x 10 6 lU/mg of IL-2. In some embodiments, the IL- 2 stock solution has a final concentration of 5-7x 10 6 lU/mg of IL-2.
  • the IL- 2 stock solution has a final concentration of 6x10 6 lU/mg of IL-2.
  • the IL-2 stock solution is prepare as described in Example C.
  • the priming first expansion culture media comprises about 10,000 lU/mL of IL-2, about 9,000 lU/mL of IL-2, about 8,000 lU/mL of IL-2, about 7,000 lU/mL of IL-2, about 6000 lU/mL of IL-2 or about 5,000 lU/mL of IL-2.
  • the priming first expansion culture media comprises about 9,000 lU/mL of IL-2 to about 5,000 lU/mL of IL-2.
  • the priming first expansion culture media comprises about 8,000 lU/mL of IL-2 to about 6,000 lU/mL of IL-2. In some embodiments, the priming first expansion culture media comprises about 7,000 lU/mL of IL-2 to about 6,000 lU/mL of IL-2. In some embodiments, the priming first expansion culture media comprises about 6,000 lU/mL of IL-2. In some embodiments, the cell culture medium further comprises IL-2. In some embodiments, the priming first expansion cell culture medium comprises about 3000 lU/mL of IL-2. In some embodiments, the priming first expansion cell culture medium further comprises IL-2.
  • the priming first expansion cell culture medium comprises about 3000 lU/mL of IL-2. In some embodiments, the priming first expansion cell culture medium comprises about 1000 lU/mL, about 1500 lU/mL, about 2000 lU/mL, about 2500 lU/mL, about 3000 lU/mL, about 3500 lU/mL, about 4000 lU/mL, about 4500 lU/mL, about 5000 lU/mL, about 5500 lU/mL, about 6000 lU/mL, about 6500 lU/mL, about 7000 lU/mL, about 7500 lU/mL, or about 8000 lU/mL of IL-2.
  • the priming first expansion cell culture medium comprises between 1000 and 2000 lU/mL, between 2000 and 3000 lU/mL, between 3000 and 4000 lU/mL, between 4000 and 5000 lU/mL, between 5000 and 6000 lU/mL, between 6000 and 7000 lU/mL, between 7000 and 8000 lU/mL, or about 8000 lU/mL of IL-2.
  • priming first expansion culture media comprises about 500 lU/mL of IL-15, about 400 lU/mL of IL-15, about 300 lU/mL of IL-15, about 200 lU/mL of IL-15, about 180 lU/mL of IL- 15, about 160 lU/mL of IL- 15, about 140 lU/mL of IL- 15, about 120 lU/mL of IL- 15, or about 100 lU/mL of IL-15.
  • the priming first expansion culture media comprises about 500 lU/mL of IL-15 to about 100 lU/mL of IL-15.
  • the priming first expansion culture media comprises about 400 lU/mL of IL- 15 to about 100 lU/mL of IL- 15. In some embodiments, the priming first expansion culture media comprises about 300 lU/mL of IL- 15 to about 100 lU/mL of IL-15. In some embodiments, the priming first expansion culture media comprises about 200 lU/mL of IL-15. In some embodiments, the priming first expansion cell culture medium comprises about 180 lU/mL of IL-15. In some embodiments, the priming first expansion cell culture medium further comprises IL-15. In some embodiments, the priming first expansion cell culture medium comprises about 180 lU/mL of IL-15.
  • priming first expansion culture media comprises about 20 lU/mL of IL-21, about 15 lU/mL of IL-21, about 12 lU/mL of IL-21, about 10 lU/mL of IL-21, about 5 lU/mL of IL-21, about 4 lU/mL of IL-21, about 3 lU/mL of IL-21, about 2 lU/mL of IL-21, about 1 lU/mL of IL-21, or about 0.5 lU/mL of IL-21.
  • the priming first expansion culture media comprises about 20 lU/mL of IL-21 to about 0.5 lU/mL of IL-21.
  • the priming first expansion culture media comprises about 15 lU/mL of IL-21 to about 0.5 lU/mL of IL- 21. In some embodiments, the priming first expansion culture media comprises about 12 lU/mL of IL- 21 to about 0.5 lU/mL of IL-21. In some embodiments, the priming first expansion culture media comprises about 10 lU/mL of IL-21 to about 0.5 lU/mL of IL-21. In some embodiments, the priming first expansion culture media comprises about 5 lU/mL of IL-21 to about 1 lU/mL of IL-21. In some embodiments, the priming first expansion culture media comprises about 2 lU/mL of IL-21.
  • the priming first expansion cell culture medium comprises about 1 lU/mL of IL-21. In some embodiments, the priming first expansion cell culture medium comprises about 0.5 lU/mL of IL-21. In some embodiments, the cell culture medium further comprises IL-21. In some embodiments, the priming first expansion cell culture medium comprises about 1 lU/mL of IL-21.
  • the priming first expansion cell culture medium comprises OKT-3 antibody. In some embodiments, the priming first expansion cell culture medium comprises about 30 ng/mL of OKT-3 antibody. In some embodiments, the priming first expansion cell culture medium comprises about 0.1 ng/mL, about 0.5 ng/mL, about 1 ng/mL, about 2.5 ng/mL, about 5 ng/mL, about 7.5 ng/mL, about 10 ng/mL, about 15 ng/mL, about 20 ng/mL, about 25 ng/mL, about 30 ng/mL, about 35 ng/mL, about 40 ng/mL, about 50 ng/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, about 200 ng/mL, about 500 ng/mL, and about 1 pg/mL of OKT-3 antibody.
  • the cell culture medium comprises between 0.1 ng/mL and 1 ng/mL, between 1 ng/mL and 5 ng/mL, between 5 ng/mL and 10 ng/mL, between 10 ng/mL and 20 ng/mL, between 20 ng/mL and 30 ng/mL, between 30 ng/mL and 40 ng/mL, between 40 ng/mL and 50 ng/mL, and between 50 ng/mL and 100 ng/mL of OKT-3 antibody.
  • the cell culture medium comprises between 15 ng/mL and 30 ng/mL of OKT-3 antibody.
  • the cell culture medium comprises 30 ng/mL of OKT-3 antibody.
  • the OKT-3 antibody is muromonab. See, Table 1.
  • the priming first expansion cell culture medium comprises one or more TNFRSF agonists in a cell culture medium.
  • the TNFRSF agonist comprises a 4-1BB agonist.
  • the TNFRSF agonist is a 4-1BB agonist, and the 4- 1BB agonist is selected from the group consisting of urelumab, utomilumab, EU-101, a fusion protein, and fragments, derivatives, variants, biosimilars, and combinations thereof.
  • the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 0.1 pg/mL and 100 pg/mL.
  • the TNFRSF agonist is added at a concentration sufficient to achieve a concentration in the cell culture medium of between 20 pg/mL and 40 pg/mL.
  • the priming first expansion cell culture medium further comprises IL-2 at an initial concentration of about 3000 lU/mL and OKT-3 antibody at an initial concentration of about 30 ng/mL, and wherein the one or more TNFRSF agonists comprises a 4- 1BB agonist.
  • the priming first expansion cell culture medium further comprises IL-2 at an initial concentration of about 6000 lU/mL and OKT-3 antibody at an initial concentration of about 30 ng/mL, and wherein the one or more TNFRSF agonists comprises a 4- 1BB agonist.
  • the priming first expansion culture medium is referred to as “CM”, an abbreviation for culture media. In some embodiments, it is referred to as CM1 (culture medium 1).
  • CM consists of RPMI 1640 with GlutaMAX, supplemented with 10% human AB serum, 25 mM Hepes, and 10 mg/mL gentamicin.
  • the CM is the CM1 described in the Examples, see, Example A.
  • the priming first expansion occurs in an initial cell culture medium or a first cell culture medium.
  • the priming first expansion culture medium or the initial cell culture medium or the first cell culture medium comprises IL-2, OKT-3 and antigen-presenting feeder cells (also referred to herein as feeder cells).
  • the culture medium used in the expansion processes disclosed herein is a serum-free medium or a defined medium.
  • the serum-free or defined medium comprises a basal cell medium and a serum supplement and/or a serum replacement.
  • the serum-free or defined medium is used to prevent and/or decrease experimental variation due in part to the lot-to-lot variation of serum-containing media.
  • the serum-free or defined medium comprises a basal cell medium and a serum supplement and/or serum replacement.
  • the basal cell medium includes, but is not limited to CTSTM OpTmizerTM T-cell Expansion Basal Medium , CTSTM OpTmizerTM T-Cell Expansion SFM, CTSTM AIM-V Medium, CTSTM AIM-V SFM, LymphoONETM T-Cell Expansion Xeno-Free Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-12, Minimal Essential Medium (aMEM), Glasgow's Minimal Essential Medium (G-MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10, F-12, Minimal
  • the serum supplement or serum replacement includes, but is not limited to one or more of CTSTM OpTmizer T-Cell Expansion Serum Supplement, CTSTM Immune Cell Serum Replacement, one or more albumins or albumin substitutes, one or more amino acids, one or more vitamins, one or more transferrins or transferrin substitutes, one or more antioxidants, one or more insulins or insulin substitutes, one or more collagen precursors, one or more antibiotics, and one or more trace elements.
  • the defined medium comprises albumin and one or more ingredients selected from the group consisting of glycine, L- histidine, L-isoleucine, L- methionine, L-phenylalanine, L-proline, L- hydroxyproline, L-serine, L-threonine, L-tryptophan, L- tyrosine, L-valine, thiamine, reduced glutathione, L-ascorbic acid-2 -phosphate, iron saturated transferrin, insulin, and compounds containing the trace element moieties Ag + , Al 3+ , Ba 2+ , Cd 2+ , Co 2+ , Cr 3+ , Ge 4+ , Se 4+ , Br, T, Mn 2+ , P, Si 4+ , V 5+ , Mo 6+ , Ni 2+ , Rb + , Sn 2+ and Zr 4+ .
  • the defined medium further comprises L-glutamine, sodium bicarbonate and/or 2-mer
  • the CTSTMOpTmizerTM T-cell Immune Cell Serum Replacement is used with conventional growth media, including but not limited to CTSTM OpTmizerTM T-cell Expansion Basal Medium, CTSTM OpTmizerTM T-cell Expansion SFM, CTSTM AIM-V Medium, CSTTM AIM-V SFM, LymphoONETM T-Cell Expansion Xeno-Free Medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal Medium Eagle (BME), RPMI 1640, F-10, F-12, Minimal Essential Medium (aMEM), Glasgow's Minimal Essential Medium (G- MEM), RPMI growth medium, and Iscove's Modified Dulbecco's Medium.
  • DMEM Dulbecco's Modified Eagle's Medium
  • MEM Minimal Essential Medium
  • BME Basal Medium Eagle
  • RPMI 1640 F-10, F-12
  • aMEM Minimal Essential Medium
  • the total serum replacement concentration (vo1%) in the serum-free or defined medium is from about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% by volume of the total serum-free or defined medium.
  • the total serum replacement concentration is about 3% of the total volume of the serum -free or defined medium.
  • the total serum replacement concentration is about 5% of the total volume of the serum -free or defined medium.
  • the total serum replacement concentration is about 10% of the total volume of the serum -free or defined medium.
  • the serum -free or defined medium is CTSTM OpTmizerTM T-cell Expansion SFM (ThermoFisher Scientific). Any formulation of CTSTM OpTmizerTM is useful in the present invention.
  • CTSTM OpTmizerTM T-cell Expansion SFM is a combination of IL CTSTM OpTmizerTM T-cell Expansion Basal Medium and 26 mL CTSTM OpTmizerTM T-Cell Expansion Supplement, which are mixed together prior to use.
  • the CTSTM OpTmizerTM T- cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific).
  • SR Immune Cell Serum Replacement
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), along with 2-mercaptoethanol at 55mM. In some embodiments, the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and the final concentration of 2-mercaptoethanol in the media is 55 ⁇ M.
  • SR Immune Cell Serum Replacement
  • the defined medium is CTSTM OpTmizerTM T-cell Expansion SFM (ThermoFisher Scientific). Any formulation of CTSTM OpTmizerTM is useful in the present invention.
  • CTSTM OpTmizerTM T-cell Expansion SFM is a combination of IL CTSTM OpTmizerTM T-cell Expansion Basal Medium and 26 mL CTSTM OpTmizerTM T-Cell Expansion Supplement, which are mixed together prior to use.
  • the CTSTM OpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), along with 2-mercaptoethanol at 55mM.
  • the CTSTMOpTmizerTM T- cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2- mercaptoethanol, and 2mM of L-glutamine, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine, and further comprises about 3000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific), 55mM of 2-mercaptoethanol, and 2mM of L-glutamine, and further comprises about 6000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2-mercaptoethanol, and further comprises about 1000 lU/mL to about 8000 lU/mL of IL-2.
  • the CTSTMOpTmizerTM T-cell Expansion SFM is supplemented with about 3% of the CTSTM Immune Cell Serum Replacement (SR) (ThermoFisher Scientific) and 55mM of 2-mercaptoethanol, and further comprises about 3000 lU/mL of IL-2.
  • SR Immune Cell Serum Replacement

Abstract

La présente invention concerne des méthodes et des processus améliorés et/ou abrégés pour préparer des TIL afin de préparer des populations thérapeutiques de TIL avec une efficacité thérapeutique accrue pour le traitement du carcinome pulmonaire non à petites cellules (CPNPC), le CPNPCétant réfractaire au traitement avec un anticorps anti-PD-1 et/ou un anticorps anti-PD-Ll et/ou un inhibiteur de VEGF, ou le CPNPC ayant un score de proportion tumorale (TPS) prédéterminé.
PCT/US2021/053841 2020-10-06 2021-10-06 Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs WO2022076606A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2023521133A JP2023546359A (ja) 2020-10-06 2021-10-06 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
CA3195019A CA3195019A1 (fr) 2020-10-06 2021-10-06 Traitement de patients souffrant de cpnpc avec des therapies de lymphocytes infiltrant les tumeurs
EP21802087.3A EP4225330A1 (fr) 2020-10-06 2021-10-06 Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
US18/247,877 US20230372397A1 (en) 2020-10-06 2021-10-06 Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023521067A JP2023544199A (ja) 2020-12-17 2021-10-15 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
US18/247,878 US20230374453A1 (en) 2020-10-06 2021-10-15 Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3195023A CA3195023A1 (fr) 2020-12-17 2021-10-15 Traitement de patients souffrant de cpnpc avec des therapies lymphocytaires infiltrant les tumeurs
PCT/US2021/055304 WO2022076952A1 (fr) 2020-10-06 2021-10-15 Traitement de patients souffrant de cpnpc avec des thérapies lymphocytaires infiltrant les tumeurs
EP21805781.8A EP4225331A1 (fr) 2020-10-06 2021-10-15 Traitement de patients souffrant de cpnpc avec des thérapies lymphocytaires infiltrant les tumeurs

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063088282P 2020-10-06 2020-10-06
US63/088,282 2020-10-06
US202063127027P 2020-12-17 2020-12-17
US63/127,027 2020-12-17
US202163146402P 2021-02-05 2021-02-05
US63/146,402 2021-02-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/247,878 Continuation US20230374453A1 (en) 2020-10-06 2021-10-15 Treatment of nsclc patients with tumor infiltrating lymphocyte therapies

Publications (1)

Publication Number Publication Date
WO2022076606A1 true WO2022076606A1 (fr) 2022-04-14

Family

ID=78500739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/053841 WO2022076606A1 (fr) 2020-10-06 2021-10-06 Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs

Country Status (1)

Country Link
WO (1) WO2022076606A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618877B2 (en) 2017-01-13 2023-04-04 Instil Bio (Uk) Limited Aseptic tissue processing method, kit and device
US11767510B2 (en) 2019-12-20 2023-09-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2023201369A1 (fr) * 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti

Citations (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316A2 (fr) 1984-03-06 1985-09-11 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5019034A (en) 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5128257A (en) 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US5137817A (en) 1990-10-05 1992-08-11 Amoco Corporation Apparatus and method for electroporation
US5173158A (en) 1991-07-22 1992-12-22 Schmukler Robert E Apparatus and methods for electroporation and electrofusion
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5232856A (en) 1990-06-25 1993-08-03 Firth Kevin L Electroporation device
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
WO1995012673A1 (fr) 1993-11-03 1995-05-11 The Board Of Trustees Of The Leland Stanford Junior University Recepteur situe sur la surface de lymphocytes t actives, appele act-4
WO1995021925A1 (fr) 1994-02-14 1995-08-17 American Cyanamid Company Recepteurs heterologues couples a des proteines g et exprimes dans la levure, leur fusion avec des proteines g et leur utilisation dans des dosages biologiques
EP0672141A1 (fr) 1992-10-23 1995-09-20 Immunex Corporation Procede de preparation de proteines oligomeres solubles
US5459127A (en) 1990-04-19 1995-10-17 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1996014339A1 (fr) 1994-11-05 1996-05-17 The Wellcome Foundation Limited Anticorps
US5593875A (en) 1994-09-08 1997-01-14 Genentech, Inc. Methods for calcium phosphate transfection
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1998005787A1 (fr) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US5766902A (en) 1993-08-20 1998-06-16 Therexsys Limited Transfection process
WO1998030679A1 (fr) 1997-01-10 1998-07-16 Life Technologies, Inc. Substitut de serum pour cellules souches embryonnaires
US5834250A (en) 1988-10-28 1998-11-10 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5928893A (en) 1995-04-08 1999-07-27 Lg Chemical Ltd. Monoclonal antibody specific for human 4-1BB and cell line producing same
US5955365A (en) 1992-04-03 1999-09-21 Regents Of The University Of California Self-assembling polynucleotide delivery system
WO1999051642A1 (fr) 1998-04-02 1999-10-14 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1999058572A1 (fr) 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Molecules de liaison derivees d'immunoglobulines ne declenchant pas de lyse dependante du complement
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6025337A (en) 1994-06-27 2000-02-15 Johns Hopkins University Solid microparticles for gene delivery
WO2000009560A2 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
US6056938A (en) 1995-02-21 2000-05-02 Imarx Pharaceutical Corp. Cationic lipids and the use thereof
WO2000032767A1 (fr) 1998-12-03 2000-06-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RECEPTEURS SOLUBLES DE RECOMBINAISON DU Fc
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6210669B1 (en) 1996-10-11 2001-04-03 Bristol-Myers Squibb Co. Methods and compositions for immunomodulation
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
EP1176195A1 (fr) 1999-04-09 2002-01-30 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
WO2002044215A2 (fr) 2000-12-01 2002-06-06 Cockbain, Julian Produit
WO2002060919A2 (fr) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules a demi-vies longues, compositions et utilisations de celles-ci
US6475994B2 (en) 1998-01-07 2002-11-05 Donald A. Tomalia Method and articles for transfection of genetic material
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6534484B1 (en) 1995-06-07 2003-03-18 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
WO2003074569A2 (fr) 2002-03-01 2003-09-12 Immunomedics, Inc. Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
WO2004016750A2 (fr) 2002-08-14 2004-02-26 Macrogenics, Inc. Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps
US6706289B2 (en) 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
WO2004029207A2 (fr) 2002-09-27 2004-04-08 Xencor Inc. Variants fc optimises et methodes destinees a leur generation
WO2004035752A2 (fr) 2002-10-15 2004-04-29 Protein Design Labs, Inc. Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6746838B1 (en) 1997-05-23 2004-06-08 Gendaq Limited Nucleic acid binding proteins
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
WO2004063351A2 (fr) 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
WO2004074455A2 (fr) 2003-02-20 2004-09-02 Applied Molecular Evolution Variants de la region fc
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
WO2004099249A2 (fr) 2003-05-02 2004-11-18 Xencor, Inc. Variants fc optimises et leurs procedes de generation
US6887673B2 (en) 2002-07-30 2005-05-03 Bristol-Myers Squibb Company Humanized antibodies against human 4-1BB
US20050095244A1 (en) 2003-10-10 2005-05-05 Maria Jure-Kunkel Fully human antibodies against human 4-1BB
WO2005040217A2 (fr) 2003-10-17 2005-05-06 Cambridge University Technical Services Limited Polypeptides comprenant des regions constantes modifiees
US20050106717A1 (en) 2003-10-08 2005-05-19 Wilson John R. Cell culture methods and devices utilizing gas permeable materials
WO2005070963A1 (fr) 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Variants de la region fc
WO2005077981A2 (fr) 2003-12-22 2005-08-25 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
WO2005092925A2 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2006019447A1 (fr) 2004-07-15 2006-02-23 Xencor, Inc. Variantes genetiques de fc optimisees
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
WO2006121810A2 (fr) 2005-05-06 2006-11-16 Providence Health System Proteine de fusion trimere immunoglobulinique ox-40 et procedes d'utilisation
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
WO2008025516A2 (fr) 2006-08-28 2008-03-06 Apogenix Gmbh Protéines de fusion de superfamille
WO2009007120A2 (fr) 2007-07-10 2009-01-15 Apogenix Gmbh Protéines de fusion collectines de la superfamille des tnf
US20090131360A1 (en) 2007-10-02 2009-05-21 Rxi Pharmaceuticals, Corp. Tripartite RNAi constructs
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
WO2010003766A2 (fr) 2008-06-17 2010-01-14 Apogenix Gmbh Récepteurs multimériques tnf
WO2010010051A1 (fr) 2008-07-21 2010-01-28 Apogenix Gmbh Molécules à une seule chaîne
US7687070B2 (en) 1994-02-11 2010-03-30 Life Technologies Corporation Reagents for intracellular delivery of macromolecules
US7696175B2 (en) 2004-10-29 2010-04-13 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2010078966A1 (fr) 2009-01-09 2010-07-15 Apogenix Gmbh Protéines de fusion formant des trimères
US20110039914A1 (en) 2008-02-11 2011-02-17 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
US20110136228A1 (en) 2009-12-08 2011-06-09 Vera Juan F Methods of cell culture for adoptive cell therapy
US7961515B2 (en) 2006-07-14 2011-06-14 Semiconductor Energy Laboratory Co., Ltd. Nonvolatile memory
US7960515B2 (en) 2007-12-14 2011-06-14 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
US20110201118A1 (en) 2010-06-14 2011-08-18 Iowa State University Research Foundation, Inc. Nuclease activity of tal effector and foki fusion protein
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2012027328A2 (fr) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
WO2012032433A1 (fr) 2010-09-09 2012-03-15 Pfizer Inc. Molécules de liaison 4-1bb
WO2012065086A1 (fr) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugués d'une fraction il-2 et d'un polymère
WO2012129201A1 (fr) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz
WO2012177788A1 (fr) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulateurs de 4-1bb et réponses immunitaires
WO2013028231A1 (fr) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
WO2013038191A2 (fr) 2011-09-16 2013-03-21 Bioceros B.V. Anticorps anti-cd134 (ox40) et leurs utilisations
US20130102075A1 (en) 2009-12-08 2013-04-25 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US20130117869A1 (en) 2011-04-05 2013-05-09 Cellectis S.A. Method for the generation of compact tale-nucleases and uses thereof
US20130131141A1 (en) 2010-03-24 2013-05-23 Anastasia Khvorova Reduced size self-delivering rnai compounds
US20130131142A1 (en) 2010-03-24 2013-05-23 Lyn Libertine Rna interference in ocular indications
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2013173835A1 (fr) 2012-05-18 2013-11-21 Wilson Wolf Manufacturing Corporation Procédés de culture cellulaire améliorés pour thérapie cellulaire adoptive
US20130315884A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2013188427A1 (fr) 2012-06-11 2013-12-19 Wilson Wolf Manufacturing Corporation Procédés améliorés de culture cellulaire pour une thérapie cellulaire adoptive
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US8795965B2 (en) 2012-12-12 2014-08-05 The Broad Institute, Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US20140227237A1 (en) 2011-09-16 2014-08-14 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
WO2014148895A1 (fr) 2013-03-18 2014-09-25 Biocerox Products B.V. Anticorps anti-cd134 (ox40) humanisés et leurs utilisations
US20140295426A1 (en) 2011-07-28 2014-10-02 Veridex Llc Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids
US8865406B2 (en) 2012-12-12 2014-10-21 The Broad Institute Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8889356B2 (en) 2012-12-12 2014-11-18 The Broad Institute Inc. CRISPR-Cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8906616B2 (en) 2012-12-12 2014-12-09 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20140377739A1 (en) 2013-06-24 2014-12-25 Wilson Wolf Manufacturing Closed system device and methods for gas permeable cell culture process
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US20150203871A1 (en) 2012-06-05 2015-07-23 Cellectis Transcription Activator-Like Effector (TALE) Fusion Protein
WO2015119923A1 (fr) 2014-02-04 2015-08-13 Pfizer Inc. Combinaison d'un antagoniste de pd -1 et d'un agoniste de 4-1bb pour le traitement du cancer
WO2015189356A1 (fr) 2014-06-11 2015-12-17 Polybiocept Ab Multiplication de lymphocytes avec une composition de cytokines pour une immunothérapie cellulaire active
US20160010058A1 (en) 2013-03-01 2016-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of producing enriched populations of tumor-reactive t cells from tumor
US20160120906A1 (en) 2013-05-13 2016-05-05 Cellectis Methods for engineering highly active t cell for immunotheraphy
US20160304873A1 (en) 2013-12-02 2016-10-20 Mirimmune Inc. Immunotherapy of Cancer
WO2017008019A1 (fr) * 2015-07-08 2017-01-12 The Johns Hopkins University Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2018081473A1 (fr) 2016-10-26 2018-05-03 Iovance Biotherapeutics, Inc. Re-stimulation de lymphocytes infiltrant les tumeurs cryoconservés
US20180201889A1 (en) 2015-07-09 2018-07-19 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
WO2018132496A1 (fr) 2017-01-10 2018-07-19 Nektar Therapeutics Conjugués polymères à bras multiples de composés agonistes de tlr et méthodes de traitement immunothérapeutiques associées
US10087464B2 (en) 2011-02-15 2018-10-02 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
US20180282694A1 (en) 2017-03-29 2018-10-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2018209115A1 (fr) * 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
US10155945B2 (en) 2011-11-04 2018-12-18 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US20190017072A1 (en) 2016-01-12 2019-01-17 Sqz Biotechnologies Company Intracellular delivery of complexes
US10183979B2 (en) 2012-06-08 2019-01-22 Alkermes, Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
US20190048341A1 (en) 2015-10-19 2019-02-14 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
US20190093073A1 (en) 2011-10-17 2019-03-28 Massachusetts Institute Of Technology Intracellular delivery
US20190211337A1 (en) 2008-09-22 2019-07-11 Phio Pharmaceuticals Corp. Neutral nanotransporters
US20190275133A1 (en) 2016-11-10 2019-09-12 Nektar Therapeutics Immunotherapeutic tumor treatment method
US20190307796A1 (en) 2016-06-03 2019-10-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (pgc1alpha) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (tils)
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2020096986A2 (fr) * 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Sélection de lymphocytes t réactifs à une tumeur améliorés
WO2020096988A2 (fr) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
US20200181220A1 (en) 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
US20200270334A1 (en) 2017-05-24 2020-08-27 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US20200330601A1 (en) 2019-02-06 2020-10-22 Synthorx, Inc. IL-2 Conjugates and Methods of Use Thereof
US10913948B2 (en) 2010-03-24 2021-02-09 Phio Pharmaceuticals Corp. RNA interference in dermal and fibrotic indications
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy

Patent Citations (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316A2 (fr) 1984-03-06 1985-09-11 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5128257A (en) 1987-08-31 1992-07-07 Baer Bradford W Electroporation apparatus and process
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5019034B1 (en) 1988-01-21 1995-08-15 Massachusetts Inst Technology Control of transport of molecules across tissue using electroporation
US5019034A (en) 1988-01-21 1991-05-28 Massachusetts Institute Of Technology Control of transport of molecules across tissue using electroporation
US5834250A (en) 1988-10-28 1998-11-10 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6905685B2 (en) 1988-11-07 2005-06-14 Byoung S. Kwon Methods of using antibodies to human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6974863B2 (en) 1988-11-07 2005-12-13 Indiana University Research And Technology Corporation Antibody for 4-1BB
US5824778A (en) 1988-12-22 1998-10-20 Kirin-Amgen, Inc. Chemically-modified G-CSF
EP0401384A1 (fr) 1988-12-22 1990-12-12 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5459127A (en) 1990-04-19 1995-10-17 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5232856A (en) 1990-06-25 1993-08-03 Firth Kevin L Electroporation device
US5137817A (en) 1990-10-05 1992-08-11 Amoco Corporation Apparatus and method for electroporation
US5173158A (en) 1991-07-22 1992-12-22 Schmukler Robert E Apparatus and methods for electroporation and electrofusion
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US6350861B1 (en) 1992-03-09 2002-02-26 Protein Design Labs, Inc. Antibodies with increased binding affinity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5955365A (en) 1992-04-03 1999-09-21 Regents Of The University Of California Self-assembling polynucleotide delivery system
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
EP0672141A1 (fr) 1992-10-23 1995-09-20 Immunex Corporation Procede de preparation de proteines oligomeres solubles
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5766902A (en) 1993-08-20 1998-06-16 Therexsys Limited Transfection process
WO1995012673A1 (fr) 1993-11-03 1995-05-11 The Board Of Trustees Of The Leland Stanford Junior University Recepteur situe sur la surface de lymphocytes t actives, appele act-4
US7687070B2 (en) 1994-02-11 2010-03-30 Life Technologies Corporation Reagents for intracellular delivery of macromolecules
WO1995021925A1 (fr) 1994-02-14 1995-08-17 American Cyanamid Company Recepteurs heterologues couples a des proteines g et exprimes dans la levure, leur fusion avec des proteines g et leur utilisation dans des dosages biologiques
US6025337A (en) 1994-06-27 2000-02-15 Johns Hopkins University Solid microparticles for gene delivery
US6410517B1 (en) 1994-06-27 2002-06-25 Johns Hopkins University Targeted gene delivery system
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US6110490A (en) 1994-08-05 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Liposomal delivery system for biologically active agents
US5593875A (en) 1994-09-08 1997-01-14 Genentech, Inc. Methods for calcium phosphate transfection
WO1996014339A1 (fr) 1994-11-05 1996-05-17 The Wellcome Foundation Limited Anticorps
US6056938A (en) 1995-02-21 2000-05-02 Imarx Pharaceutical Corp. Cationic lipids and the use thereof
US6569997B1 (en) 1995-03-23 2003-05-27 Advanced Research And Technology Institute, Inc. Antibody specific for H4-1BB
US5928893A (en) 1995-04-08 1999-07-27 Lg Chemical Ltd. Monoclonal antibody specific for human 4-1BB and cell line producing same
US6998253B1 (en) 1995-04-14 2006-02-14 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6534484B1 (en) 1995-06-07 2003-03-18 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6078490A (en) 1995-12-08 2000-06-20 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1998005787A1 (fr) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6210669B1 (en) 1996-10-11 2001-04-03 Bristol-Myers Squibb Co. Methods and compositions for immunomodulation
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US20020076747A1 (en) 1997-01-10 2002-06-20 Paul J. Price Method for expanding embryonic stem cells in serum-free culture
WO1998030679A1 (fr) 1997-01-10 1998-07-16 Life Technologies, Inc. Substitut de serum pour cellules souches embryonnaires
US6821505B2 (en) 1997-03-03 2004-11-23 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
US7241574B2 (en) 1997-05-23 2007-07-10 Gendaq Ltd. Nucleic acid binding proteins
US6866997B1 (en) 1997-05-23 2005-03-15 Gendaq Limited Nucleic acid binding proteins
US6746838B1 (en) 1997-05-23 2004-06-08 Gendaq Limited Nucleic acid binding proteins
US7241573B2 (en) 1997-05-23 2007-07-10 Gendaq Ltd. Nucleic acid binding proteins
US6475994B2 (en) 1998-01-07 2002-11-05 Donald A. Tomalia Method and articles for transfection of genetic material
US7504101B2 (en) 1998-02-24 2009-03-17 Sisters Of Providence In Oregon Methods for enhancing antigen-specific immune response using antibodies that bind OX-40
US7622444B2 (en) 1998-02-24 2009-11-24 Sisters Of Providence In Oregon Methods for using OX-40 ligand to enhance an antigen specific immune response
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7595376B2 (en) 1998-03-02 2009-09-29 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6903185B2 (en) 1998-03-02 2005-06-07 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
WO1999051642A1 (fr) 1998-04-02 1999-10-14 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6538124B1 (en) 1998-04-02 2003-03-25 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
WO1999058572A1 (fr) 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Molecules de liaison derivees d'immunoglobulines ne declenchant pas de lyse dependante du complement
WO2000009560A2 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
WO2000032767A1 (fr) 1998-12-03 2000-06-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RECEPTEURS SOLUBLES DE RECOMBINAISON DU Fc
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6933113B2 (en) 1999-01-12 2005-08-23 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7220719B2 (en) 1999-01-12 2007-05-22 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US6979539B2 (en) 1999-01-12 2005-12-27 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6607882B1 (en) 1999-01-12 2003-08-19 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6824978B1 (en) 1999-01-12 2004-11-30 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7585849B2 (en) 1999-03-24 2009-09-08 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
EP1176195A1 (fr) 1999-04-09 2002-01-30 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US6706289B2 (en) 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
WO2002044215A2 (fr) 2000-12-01 2002-06-06 Cockbain, Julian Produit
WO2002060919A2 (fr) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules a demi-vies longues, compositions et utilisations de celles-ci
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
WO2003074569A2 (fr) 2002-03-01 2003-09-12 Immunomedics, Inc. Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
US8133983B2 (en) 2002-06-13 2012-03-13 Crucell Holland B.V. Agonistic binding molecules to the human OX40 receptor
US7214493B2 (en) 2002-07-30 2007-05-08 Bristol-Myers Squibb Company Polynucleotides encoding humanized antibodies against human 4-1BB
US6887673B2 (en) 2002-07-30 2005-05-03 Bristol-Myers Squibb Company Humanized antibodies against human 4-1BB
WO2004016750A2 (fr) 2002-08-14 2004-02-26 Macrogenics, Inc. Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps
WO2004029207A2 (fr) 2002-09-27 2004-04-08 Xencor Inc. Variants fc optimises et methodes destinees a leur generation
WO2004035752A2 (fr) 2002-10-15 2004-04-29 Protein Design Labs, Inc. Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
WO2004063351A2 (fr) 2003-01-09 2004-07-29 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
WO2004074455A2 (fr) 2003-02-20 2004-09-02 Applied Molecular Evolution Variants de la region fc
WO2004099249A2 (fr) 2003-05-02 2004-11-18 Xencor, Inc. Variants fc optimises et leurs procedes de generation
US20050106717A1 (en) 2003-10-08 2005-05-19 Wilson John R. Cell culture methods and devices utilizing gas permeable materials
US20050095244A1 (en) 2003-10-10 2005-05-05 Maria Jure-Kunkel Fully human antibodies against human 4-1BB
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005040217A2 (fr) 2003-10-17 2005-05-06 Cambridge University Technical Services Limited Polypeptides comprenant des regions constantes modifiees
WO2005077981A2 (fr) 2003-12-22 2005-08-25 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
WO2005070963A1 (fr) 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Variants de la region fc
WO2005092925A2 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
WO2006019447A1 (fr) 2004-07-15 2006-02-23 Xencor, Inc. Variantes genetiques de fc optimisees
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
US7696175B2 (en) 2004-10-29 2010-04-13 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
WO2006121810A2 (fr) 2005-05-06 2006-11-16 Providence Health System Proteine de fusion trimere immunoglobulinique ox-40 et procedes d'utilisation
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7961515B2 (en) 2006-07-14 2011-06-14 Semiconductor Energy Laboratory Co., Ltd. Nonvolatile memory
WO2008025516A2 (fr) 2006-08-28 2008-03-06 Apogenix Gmbh Protéines de fusion de superfamille
US20110027218A1 (en) 2006-08-28 2011-02-03 Apogenix Gmbh Tnf superfamily fusion proteins
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20150126709A1 (en) 2007-07-10 2015-05-07 Apogenix Gmbh Trail collectin fusion proteins
WO2009007120A2 (fr) 2007-07-10 2009-01-15 Apogenix Gmbh Protéines de fusion collectines de la superfamille des tnf
US20090131360A1 (en) 2007-10-02 2009-05-21 Rxi Pharmaceuticals, Corp. Tripartite RNAi constructs
US9028824B2 (en) 2007-12-14 2015-05-12 Pfizer Inc. Binding molecules to the human OX40 receptor
US8236930B2 (en) 2007-12-14 2012-08-07 Pfizer Inc. Binding molecules to the human OX40 receptor
US7960515B2 (en) 2007-12-14 2011-06-14 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
US10633654B2 (en) 2008-02-11 2020-04-28 Phio Pharmaceuticals Corp. Modified RNAi polynucleotides and uses thereof
US20110039914A1 (en) 2008-02-11 2011-02-17 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
WO2010003766A2 (fr) 2008-06-17 2010-01-14 Apogenix Gmbh Récepteurs multimériques tnf
US20110111494A1 (en) 2008-06-17 2011-05-12 Oliver Hill Multimeric tnf receptors
US8921519B2 (en) 2008-07-21 2014-12-30 Apogenix Gmbh Single chain fusion polypeptides comprising soluble light cytokine domains
US9359420B2 (en) 2008-07-21 2016-06-07 Apogenix Ag Single chain trail fusion polypeptides and encoding nucleic acids
US9340599B2 (en) 2008-07-21 2016-05-17 Apogenix Ag Single chain CD40L fusion polypeptides
US20150110734A1 (en) 2008-07-21 2015-04-23 Apogenix Gmbh Trail single chain molecules
US8450460B2 (en) 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
WO2010010051A1 (fr) 2008-07-21 2010-01-28 Apogenix Gmbh Molécules à une seule chaîne
US20190211337A1 (en) 2008-09-22 2019-07-11 Phio Pharmaceuticals Corp. Neutral nanotransporters
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
WO2010078966A1 (fr) 2009-01-09 2010-07-15 Apogenix Gmbh Protéines de fusion formant des trimères
US20150126710A1 (en) 2009-01-09 2015-05-07 Apogenix Gmbh Fusion proteins forming trimers
US8809050B2 (en) 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
US20150175966A1 (en) 2009-12-08 2015-06-25 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130102075A1 (en) 2009-12-08 2013-04-25 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US20110136228A1 (en) 2009-12-08 2011-06-09 Vera Juan F Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20160208216A1 (en) 2009-12-08 2016-07-21 Juan F. Vera Methods of cell culture for adoptive cell therapy
WO2011072088A2 (fr) 2009-12-08 2011-06-16 Wilson Wolf Manufacturing Corporation Procédés améliorés de culture cellulaire pour thérapie cellulaire adoptive
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
US20130131141A1 (en) 2010-03-24 2013-05-23 Anastasia Khvorova Reduced size self-delivering rnai compounds
US20130131142A1 (en) 2010-03-24 2013-05-23 Lyn Libertine Rna interference in ocular indications
US10913948B2 (en) 2010-03-24 2021-02-09 Phio Pharmaceuticals Corp. RNA interference in dermal and fibrotic indications
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US20110201118A1 (en) 2010-06-14 2011-08-18 Iowa State University Research Foundation, Inc. Nuclease activity of tal effector and foki fusion protein
US9006399B2 (en) 2010-08-23 2015-04-14 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
US9163085B2 (en) 2010-08-23 2015-10-20 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of treating cancer
WO2012027328A2 (fr) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
WO2012032433A1 (fr) 2010-09-09 2012-03-15 Pfizer Inc. Molécules de liaison 4-1bb
US8337850B2 (en) 2010-09-09 2012-12-25 Pfizer Inc. 4-1BB binding molecules
US8821867B2 (en) 2010-09-09 2014-09-02 Pfizer Inc 4-1BB binding molecules
US9468678B2 (en) 2010-09-09 2016-10-18 Pfizer Inc. Method of producing 4-1BB binding molecules and associated nucleic acids
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2012065086A1 (fr) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugués d'une fraction il-2 et d'un polymère
US20140328791A1 (en) 2010-11-12 2014-11-06 Nektar Therapeutics Conjugates of an IL-2 Moiety and a Polymer
US10087464B2 (en) 2011-02-15 2018-10-02 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2012129201A1 (fr) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz
US20130117869A1 (en) 2011-04-05 2013-05-09 Cellectis S.A. Method for the generation of compact tale-nucleases and uses thereof
WO2012177788A1 (fr) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulateurs de 4-1bb et réponses immunitaires
US20140295426A1 (en) 2011-07-28 2014-10-02 Veridex Llc Methods for Diagnosing Cancer by Characterization of Tumor Cells Associated with Pleural or Serous Fluids
WO2013028231A1 (fr) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
US20150132288A1 (en) 2011-09-16 2015-05-14 Biocerox Products B.V. Anti-cd134 (ox40) antibodies and uses thereof
WO2013038191A2 (fr) 2011-09-16 2013-03-21 Bioceros B.V. Anticorps anti-cd134 (ox40) et leurs utilisations
US20140227237A1 (en) 2011-09-16 2014-08-14 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
US20190093073A1 (en) 2011-10-17 2019-03-28 Massachusetts Institute Of Technology Intracellular delivery
US10155945B2 (en) 2011-11-04 2018-12-18 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013173835A1 (fr) 2012-05-18 2013-11-21 Wilson Wolf Manufacturing Corporation Procédés de culture cellulaire améliorés pour thérapie cellulaire adoptive
US20130315884A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150203871A1 (en) 2012-06-05 2015-07-23 Cellectis Transcription Activator-Like Effector (TALE) Fusion Protein
US10183979B2 (en) 2012-06-08 2019-01-22 Alkermes, Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
WO2013188427A1 (fr) 2012-06-11 2013-12-19 Wilson Wolf Manufacturing Corporation Procédés améliorés de culture cellulaire pour une thérapie cellulaire adoptive
US8871445B2 (en) 2012-12-12 2014-10-28 The Broad Institute Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US8889356B2 (en) 2012-12-12 2014-11-18 The Broad Institute Inc. CRISPR-Cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US8945839B2 (en) 2012-12-12 2015-02-03 The Broad Institute Inc. CRISPR-Cas systems and methods for altering expression of gene products
US8932814B2 (en) 2012-12-12 2015-01-13 The Broad Institute Inc. CRISPR-Cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8771945B1 (en) 2012-12-12 2014-07-08 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US8795965B2 (en) 2012-12-12 2014-08-05 The Broad Institute, Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US8865406B2 (en) 2012-12-12 2014-10-21 The Broad Institute Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8999641B2 (en) 2012-12-12 2015-04-07 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US8895308B1 (en) 2012-12-12 2014-11-25 The Broad Institute Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8906616B2 (en) 2012-12-12 2014-12-09 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US20160010058A1 (en) 2013-03-01 2016-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of producing enriched populations of tumor-reactive t cells from tumor
US20140377284A1 (en) 2013-03-18 2014-12-25 Janssen Pharmaceuticals, Inc. Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2014148895A1 (fr) 2013-03-18 2014-09-25 Biocerox Products B.V. Anticorps anti-cd134 (ox40) humanisés et leurs utilisations
US20160120906A1 (en) 2013-05-13 2016-05-05 Cellectis Methods for engineering highly active t cell for immunotheraphy
US20140377739A1 (en) 2013-06-24 2014-12-25 Wilson Wolf Manufacturing Closed system device and methods for gas permeable cell culture process
WO2014210036A1 (fr) 2013-06-24 2014-12-31 Wilson Wolf Manufacturing Corporation Dispositif à système clos et procédés de processus de culture de cellules perméable aux gaz
US20160304873A1 (en) 2013-12-02 2016-10-20 Mirimmune Inc. Immunotherapy of Cancer
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2015119923A1 (fr) 2014-02-04 2015-08-13 Pfizer Inc. Combinaison d'un antagoniste de pd -1 et d'un agoniste de 4-1bb pour le traitement du cancer
WO2015189356A1 (fr) 2014-06-11 2015-12-17 Polybiocept Ab Multiplication de lymphocytes avec une composition de cytokines pour une immunothérapie cellulaire active
WO2015189357A1 (fr) 2014-06-11 2015-12-17 Polybiocept Ab Expansion de lymphocytes avec une composition de cytokine pour immunothérapie cellulaire active
US20170107490A1 (en) 2014-06-11 2017-04-20 Polybiocept Ab Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2017008019A1 (fr) * 2015-07-08 2017-01-12 The Johns Hopkins University Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
US20180201889A1 (en) 2015-07-09 2018-07-19 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
US20190048341A1 (en) 2015-10-19 2019-02-14 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
US20190017072A1 (en) 2016-01-12 2019-01-17 Sqz Biotechnologies Company Intracellular delivery of complexes
US20190307796A1 (en) 2016-06-03 2019-10-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (pgc1alpha) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (tils)
US20200299644A1 (en) 2016-10-26 2020-09-24 Iovance Biotherapeutics, Inc. Restimulation of cryopreserved tumor infiltrating lymphocytes
WO2018081473A1 (fr) 2016-10-26 2018-05-03 Iovance Biotherapeutics, Inc. Re-stimulation de lymphocytes infiltrant les tumeurs cryoconservés
US20190275133A1 (en) 2016-11-10 2019-09-12 Nektar Therapeutics Immunotherapeutic tumor treatment method
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018132496A1 (fr) 2017-01-10 2018-07-19 Nektar Therapeutics Conjugués polymères à bras multiples de composés agonistes de tlr et méthodes de traitement immunothérapeutiques associées
US10925900B2 (en) 2017-03-29 2021-02-23 lovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20180280436A1 (en) 2017-03-29 2018-10-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20180282694A1 (en) 2017-03-29 2018-10-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20200347350A1 (en) 2017-05-10 2020-11-05 Iovance Biotherapeutics, Inc. Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood
WO2018209115A1 (fr) * 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
US20200270334A1 (en) 2017-05-24 2020-08-27 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US20200181220A1 (en) 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2020096988A2 (fr) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
WO2020096986A2 (fr) * 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Sélection de lymphocytes t réactifs à une tumeur améliorés
US20200330601A1 (en) 2019-02-06 2020-10-22 Synthorx, Inc. IL-2 Conjugates and Methods of Use Thereof
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy

Non-Patent Citations (95)

* Cited by examiner, † Cited by third party
Title
AHMAD ET AL., CLIN. & DEV. IMMUNOL., 2012, pages 980250
AMERATUNGA MALAKA ET AL: "PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC", PLOS ONE, vol. 11, no. 4, 22 January 2016 (2016-01-22), pages e0153954, XP055881984, DOI: 10.1371/journal.pone.0153954 *
ANONYMOUS: "Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov", 6 January 2017 (2017-01-06), XP055881643, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03215810> [retrieved on 20220120] *
ANONYMOUS: "Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) >=50% enrolled in KEYNOTE-024. | Journal of Clinical Oncology", 20 May 2017 (2017-05-20), XP055882983, Retrieved from the Internet <URL:https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.9000> [retrieved on 20220124] *
ANONYMOUS: "T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov", 12 July 2017 (2017-07-12), XP055881795, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02133196> [retrieved on 20220120] *
AUGUSTYNS ET AL., NUCL. ACIDS. RES., vol. 18, 1992, pages 4711
BEANE ET AL., MOL. THERAPY, vol. 23, 2015, pages 1380 - 1390
BERGAN ET AL., NUCL. ACIDS RES., vol. 21, 1993, pages 3567
BESSER ET AL., CLIN. CANCER RES., vol. 19, 2013, pages OF1 - OF9
BESSER ET AL., J IMMUNOTHER, vol. 182, 2009, pages 1481 - 423
BESSER ET AL., J IMMUNOTHER., vol. 32, 2009, pages 415 - 423
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BLACK ROBERT C ET AL: "UPDATES IN ONCOLOGY: PART 1 NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance", 1 January 2015 (2015-01-01), XP055883015, Retrieved from the Internet <URL:http://rimed.org/rimedicaljournal/2015/10/2015-10-25-onc-black.pdf> [retrieved on 20220124] *
BOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
BYRNE ET AL., J OCUL. PHARMACOL. THER., vol. 29, 2013, pages 855 - 864
BYRNE ET AL., J. OCULAR PHARMACOL. THERAPEUT., vol. 29, 2013, pages 855 - 864
CAS , no. 60-24-2
CEPKOPEAR, CUR. PROT. MOL. BIOL., 1996
CHEN JUSTIN A ET AL: "Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations", CURRENT TREATMENT OPTIONS IN ONCOLOGY, SPRINGER US, NEW YORK, vol. 21, no. 7, 25 June 2020 (2020-06-25), XP037178672, ISSN: 1527-2729, [retrieved on 20200625], DOI: 10.1007/S11864-020-00750-Y *
CHEN JUSTIN A ET AL: "Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations", CURRENT TREATMENT OPTIONS IN ONCOLOGY, SPRINGER US, NEW YORK, vol. 21, no. 7, 25 June 2020 (2020-06-25), XP037185986, ISSN: 1527-2729, [retrieved on 20200625], DOI: 10.1007/S11864-020-00750-Y *
CHENOKAYAREA, MOL. CELL. BIOL., vol. 7, 1987, pages 2745 - 2752
COX ET AL., NATURE MEDICINE, vol. 21, no. 2, 2015
CURTI ET AL., CANCER RES., vol. 73, 2013, pages 7189 - 98
DE MARCO, MICROBIAL CELL FACTORIES, vol. 10, 2011, pages 44
DE MELLO RAMON ANDRADE BEZERRA ET AL: "Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives", CANCERS, vol. 14, no. 1, 1 January 2022 (2022-01-01), CH, pages 122, XP055883010, ISSN: 2072-6694, DOI: 10.3390/cancers14010122 *
DONIA ET AL., SCAND. J. IMMUNOL., vol. 75, 2012, pages 157 - 167
DUDLEY ET AL., CLIN. CANCER RES., vol. 16, 2010, pages 6122 - 6131
DUDLEY ET AL., J IMMUNOTHER, vol. 26, 2003, pages 332 - 42
DUDLEY ET AL., JLMMUNOTHER, vol. 26, 2003, pages 332 - 342
DULL ET AL., J VIROLOGY, vol. 72, 1998, pages 8463 - 71
FEHNIGERCALIGIURI, BLOOD, vol. 97, 2001, pages 14 - 32
FELGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7417
FISHER ET AL., CANCER IMMUNOLOG. & IMMUNOTHER, vol. 61, 2012, pages 1721 - 33
FRYMACKALL, BLOOD, vol. 99, 2002, pages 3892 - 904
GANDHI LEENA ET AL., N ENGL J MED, vol. 378, no. 22, 2018, pages 2078 - 2092
GIEFFERS ET AL., MOL. CANCER THERAPEUTICS, vol. 12, 2013, pages 2735 - 47
GRAHAMVAN DER EB, VIROLOGY, vol. 52, 1973, pages 456 - 467
HACKETT ET AL., MOL. THERAPY, vol. 18, 2010, pages 674 - 83
HELLMANN ET AL., NEW ENGL J MED, vol. 381, 2019, pages 2020 - 31
HUANG ET AL., J IMMUNOTHER., vol. 28, 2005, pages 258 - 267
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
JAEGERNAGEL, SCIENCE, vol. 255, 1992, pages 1523 - 3
JIN ET AL., J IMMUNOTHERAPY, vol. 35, 2012, pages 283 - 292
JIN, J. IMMUNOTHER., vol. 35, 2012, pages 283 - 292
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KHVOROVAWATTS, NAT. BIOTECHNOL., vol. 35, 2017, pages 238 - 248
LEE ET AL., PLOS ONE, vol. 8, 2013, pages e69677
LEVINE ET AL., PROC. NAT 'I ACAD. SCI., vol. 103, 2006, pages 17372 - 77
LIGTENBERG ET AL., MOL. THERAPY, vol. 26, 2018, pages 1482 - 93
MOK T. S. K. ET AL., LANCET, vol. 393, no. 10183, 2019, pages 1819 - 1830
MOLINA JRYANG PCASSIVI SDSCHILD SEADJEI AA., MAYO CLIN PROC., vol. 83, no. 5, 2008, pages 584 - 94
MONNIER ET AL., ANTIBODIES, vol. 2, 2013, pages 193 - 208
MORGENSZTERN D., JTHORAC DIS, vol. 11, 2019, pages S1963 - S1965
MUSIN, RUSS. MATH. SURV., vol. 58, 2003, pages 794 - 795
NOSAKI K. ET AL., LUNG CANCER, vol. 135, 2019, pages 188 - 195
PAZ-ARES L. ET AL., NENGL J MED, vol. 379, no. 21, 2018, pages 2040 - 2051
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
R. E. BIRDB. W. WALKER: "Single Chain Antibody Variable Regions", TIBTECH, vol. 9, 1991, pages 132 - 137
R. RAAGM. WHITLOW: "Single Chain Fvs", FASEB, vol. 9, 1995, pages 73 - 80
RECK M. ET AL., NENGL J MED, vol. 375, no. 19, 2016, pages 1823 - 1833
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ROBBINS ET AL., J. IMMUNOL., vol. 173, 2004, pages 7125 - 7130
ROSE ET AL., BIOTECHNIQUES, vol. 10, 1991, pages 520 - 525
ROSENBERG ET AL., NEW ENG. J. OF MED., vol. 319, 1988, pages 1676
SADEGHI ET AL., ACTA ONCOLOGICA, vol. 52, 2013, pages 978 - 986
SCHILLER J. H. ET AL., NENGL J MED, vol. 346, no. 2, 2002, pages 92 - 8
SEGAL ET AL., CLIN. CANCER RES., 2016, Retrieved from the Internet <URL:http:/dx.doi.org/10.1158/1078-0432.CCR-16-1272>
SHEN ET AL., J IMMUNOTHER., vol. 30, 2007, pages 123 - 129
SHEN ET AL., J. IMMUNOTHER., vol. 30, 2007, pages 123 - 129
SHIELDS ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740
SIEGEL RL, CA CANCER J CLIN, vol. 65, no. 1, 2015, pages 5 - 29
SMITH ET AL., CLIN TRANSL IMMUNOLOGY, vol. 4, no. 1
SMITH ET AL., CLIN TRANSL IMMUNOLOGY, vol. 4, no. 1, 2015
SOCINSKI MA ET AL., NEW ENGL J MED, vol. 378, 2018, pages 2288 - 301
SPOLSKILEONARD, NAT. REV. DRUG. DISC., vol. 13, 2014, pages 379 - 95
STEINKEBORISH, RESPIR. RES., vol. 2, 2001, pages 66 - 70
SWARTZ ET AL., CANCER RES., vol. 72, 2012, pages 2473
TARENTINO ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 5523
TEIXIDÓ CRISTINA ET AL: "PD-L1 expression testing in non-small cell lung cancer", THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol. 10, 1 January 2018 (2018-01-01), XP055882989, ISSN: 1758-8359, Retrieved from the Internet <URL:http://journals.sagepub.com/doi/full-xml/10.1177/1758835918763493> DOI: 10.1177/1758835918763493 *
TRAN ET AL., J IMMUNOTHER, vol. 31, 2008, pages 742 - 51
TRAN ET AL., J IMMUNOTHER., vol. 31, 2008, pages 742 - 751
TRAN ET AL., J. IMMUNOTHER., vol. 31, 2008, pages 742 - 751
TRAN ET AL., J1MMUNOTHER., vol. 31, 2008, pages 742 - 751
TSONG, BIOPHYS. J., vol. 60, 1991, pages 297 - 306
TSOUKAS ET AL., J. IMMUNOL., vol. 135, 1985, pages 1719
UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180
VITERI S. ET AL., TRANSL LUNG CANCER RES, vol. 9, no. 1, 2020, pages 148 - 153
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WEINBERG ET AL., J IMMUNOTHER, vol. 29, 2006, pages 575 - 585
WEINBERG ET AL., J. IMMUNOTHER., vol. 29, 2006, pages 575 - 585
WIGLER ET AL., PROC. NATL. ACAD. SCI., vol. 76, 1979, pages 1373 - 1376
WIGLER, SCI., vol. 76, 1979, pages 1373 - 1376
YAMANE-OHNUKI ET AL., BIOTECHNOL. BIOENG., vol. 87, 2004, pages 614 - 622
ZHOU ET AL., J. IMMUNOTHER., vol. 28, 2005, pages 53 - 62
ZUFFEREY ET AL., NAT. BIOTECHNOL., vol. 15, 1997, pages 871 - 75

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618877B2 (en) 2017-01-13 2023-04-04 Instil Bio (Uk) Limited Aseptic tissue processing method, kit and device
US11618878B2 (en) 2017-01-13 2023-04-04 Instil Bio (Uk) Limited Aseptic tissue processing method, kit and device
US11767510B2 (en) 2019-12-20 2023-09-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2023201369A1 (fr) * 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti

Similar Documents

Publication Publication Date Title
WO2022165260A9 (fr) Procédés de fabrication de lymphocytes infiltrant les tumeurs modifiés et leur utilisation dans la thérapie cellulaire adoptive
EP3876957A1 (fr) Traitement de patients souffrant de nsclc réfractaires à un anticorps anti-pd-1
WO2021226061A1 (fr) Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
US20230372397A1 (en) Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (fr) Traitement de patients souffrant de cpnpc avec des thérapies de lymphocytes infiltrant les tumeurs
EP4262811A1 (fr) Traitement avec des thérapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de ctla-4 et de pd-1
EP4262827A1 (fr) Traitement de cancers à l&#39;aide de lymphocytes infiltrant les tumeurs
JP2024510505A (ja) Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法
WO2022125941A1 (fr) Traitement de patients atteints de cancer par des thérapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de braf et/ou des inhibiteurs de mek
WO2023009716A1 (fr) Traitement de patients atteints d&#39;un cancer avec des thérapies de lymphocytes infiltrant les tumeurs en combinaison avec des inhibiteurs de kras
EP4326287A2 (fr) Récepteurs costimulateurs chimériques, récepteurs de chimiokines et leur utilisation dans des immunothérapies cellulaires
WO2022187741A2 (fr) Stockage de tumeur et compositions de culture cellulaire
CA3195023A1 (fr) Traitement de patients souffrant de cpnpc avec des therapies lymphocytaires infiltrant les tumeurs
WO2023196877A1 (fr) Traitement de patients souffrant de cpnpc avec des thérapies lymphocytaires infiltrant les tumeurs
WO2024030758A1 (fr) Récepteurs de costimulation chimériques, récepteurs de chimiokines et leur utilisation dans des immunothérapies cellulaires
WO2023049862A1 (fr) Processus d&#39;expansion et agents pour lymphocytes infiltrant la tumeur
WO2023086803A1 (fr) Procédés de traitement de multiplication utilisant des lymphocytes infiltrant les tumeurs cd8
WO2023004074A2 (fr) Procédé de cryoconservation de fragments de tumeur solide
WO2023039488A1 (fr) Procédés de production de produits til par inactivation de pd-1 avec talen
WO2023220608A1 (fr) Traitement de patients atteints d&#39;un cancer avec des thérapies lymphocytaires infiltrant les tumeurs en combinaison avec un agoniste d&#39;il-15r

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21802087

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023521133

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3195019

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021802087

Country of ref document: EP

Effective date: 20230508